Section |
Name |
Details |
09.06.07 |
Renavit® |
For initation by Renal team only.
ACBS Indications Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis |
11.04.01 |
Minims®Dexamethasone drops 0.1% |
Preservative free |
03.01.05 |
Vortex® Spacer |
First line spacer option.
Not at RBCH |
13.06 |
10 mg (1%) clindamycin (as clindamycin phosphate) and 0.25 mg (0.025%) tretinoin Treclin ® |
|
13.08.01 |
5-aminolevulinic acid hydrochloride Ameluz® |
Poole
Treatment of actinic keratosis (AK) of mild to moderate severity on the face and scalp (Olsen grade 1 to 2) and of field cancerization in adults.
Treatment of superficial and/or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. |
13.05.03 |
5-methoxypsoralen |
Unlicensed product - hospital use only Take tablets 2-3 hours before PUVA treatment.
DCHFT: Consultant use only. |
13.05.03 |
8-methoxypsoralen |
Unlicensed product - hospital use only
Apply gel 30 minutes before PUVA treatment
DCHFT: Consultant use only. |
13.05.03 |
8-methoxypsoralen |
Unlicensed product - hospital use only
Take tablets 2-3 hours before PUVA treatment
DCHFT: Consultant use only. |
05.03.01 |
Abacavir Ziagen® |
See commissioning and funding guidance from NHS England. |
05.03.01 |
Abacavir and Lamivudine generic brands |
Generic product should be used where possible. Kivexa® is non-formulary
Commissioned by NHS England (for HIV in combination with anti-retroviral drugs). See BHIVA Guidelines. |
05.03.01 |
Abacavir and Lamivudine and Zidovudine Trizivir® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs). As per BHIVA Guidelines. |
05.03.01 |
Abacavir with Lamivudine and Dolutegravir Triumeq® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs. |
10.01.03 |
Abatacept Orencia® |
Commissioned by NHS England for:
- Juvenile idiopathic arthritis in line with NICE TA373.
- Paediatric indications where an adult NICE TA is available.
Commissioned by CCG for the treatment of rheumatoid arthritis in line with NICE TA195 and TA375.
|
02.09 |
Abciximab ReoPro® |
Injection / infusion.
Cardiology consultant use only. |
08.01.05 |
Abemaciclib Verzenios® |
Commissioned by CDF in line with NICE TA563 and TA579 and CDF criteria. |
09.06.07 |
Abidec® |
For paediatrics, to be initiated in hospital |
08.03.04.02 |
Abiraterone acetate Zytiga ® |
For use in accordance with NICE TA259 and TA387 reccomendations. |
08.01.05 |
Acalabrutinib Calquence® |
Commissioned within the CDF as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: • they have a 17p deletion or TP53 mutation
Commissioned within the CDF as a second-line option for treating CLL in adults where: • ibrutinib is their only suitable treatment option
Commissioning will transfer to NHSE 90 days following NICE publication |
04.10.01 |
Acamprosate |
EC tablets.
For maintenance of abstinence in alcohol dependent patients in accordance with local shared care guideline. |
06.01.02.03 |
Acarbose Glucobay® |
Consider acarbose for a person unable to use other oral glucose lowering medications |
06.01.01.03 |
Accu-Chek ® FastClix |
|
06.01.06 |
Accu-chek ® Performa Test Strips |
|
06.01.06 |
Accu-chek®Mobile Cassette |
|
02.08.02 |
Acenocoumarol Sinthrome® |
Tablets.
Specialist initiation in patients intolerant of warfarin (where other oral agents are not indicated).
|
01.05 |
Acetarsol Suppositories Arsenic Suppositories |
  RBCH only: Consultant Gastroenterologist prescription only to treat severe refractory proctitis |
11.06 |
Acetazolamide Diamox® |
Tablets 250mg
|
11.06 |
Acetazolamide Diamox® SR |
Capsules 250mg
|
11.06 |
Acetazolamide injection 500mg |
|
11.08.02 |
Acetylcholine Chloride solution Miochol-E® |
|
03.07 |
Acetylcysteine |
Injection.
RBCH: Injection used for nebulisation in Critical Care and Respiratory in-patients (off-label):
Mix 1mL injection with 4mL sodium chloride 0.9%
DCHFT: Injection used for nebulisation in Critical Care (off-label). Regimen / dose depends on individual patient. |
16.01 |
Acetylcysteine 600mg tablets |
Unlicensed For prevention of contrast-induced nephropathy |
11.08.01 |
Acetylcysteine drops 5% Ilube® |
Preserved |
18 |
Acetylcysteine IV Parvolex |
See BNF for treatment graph and acetylcysteine treatment protocols for paracetamol overdose. |
13.10.03 |
Aciclovir |
Cream, aciclovir 5%
Self Care Medicine for primary care for 2g pack size
|
05.03.02.01 |
Aciclovir IV |
|
05.03.02.01 |
Aciclovir oral |
NOTE: aciclovir 400mg TDS is approved for use in pregnancy by the Royal College of Obstetricians & Gynaecologists - use from 36 weeks until delivery as per RCOG/BASHH guideline. |
13.05.02 |
Acitretin Neotigason® |
Hospital use only - not recommended in women of child bearing age.
Pregnancy Prevention Scheme applies if prescribed in women of child bearing age.
DCHFT: Consultant use only. |
03.01.02 |
Aclidinium (Eklira Genuair®) |
Inhaler.
Long acting option
Use with caution in patients with history of myocardial infarction within last 6 months, unstable angina, newly diagnosed arrhythmia within last 3 months, hospitalisation with moderate or severe heart failure within last 12 months.
Use second line |
03.01.04 |
Aclidinium bromide/Formoterol fumarate dihydrate Duaklir Genuair ® |
|
13.06.01 |
Acnecide® |
Gel, benzoyl peroxide 5% in an aqueous gel basis Excipients include propylene glycol
For use within acne guideline when required in combination with antibiotics Not RBCH
Self Care Medicine
|
A5.08.06 |
Actico Cohesive ® |
10cm x 6m only: Seek specialist advice for when to use other widths
Available as a latex free option |
13.08.01 |
Actikerall® |
Solution, fluorouracil 0.5%, salicylic acid 10% Not stocked at RBCH |
18 |
Activated charcoal |
For reduction of absorption of poisons in the gastro-intestinal system. Useful for many oral poisons (but see Toxbase or NPIS for advice on use). |
A5.02.01 |
ActivHeal Hydrogel |
Available as 8g or 15g
ActivHeal® Hydrogel is used as a primary dressing indicated for use on dry and sloughy wounds with nil to low exudate:
- Pressure ulcers
- Cavity wounds
- Leg ulcers
- Graft and Donor sites
- Diabetic ulcers
- Post op surgical wounds
- Lacerations and abrasions
|
01.05.03 |
Adalimumab Humira® |
|
10.01.03 |
Adalimumab Humira® |
For rheumatoid arthritis in accordance with NICE TA 375.
Paediatric indications (where adult TA available) - commissioned by NHS England.
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis in accordannce with NICE TA373. |
11.04.02 |
Adalimumab Humira® |
Commissioned by NHS England for non-infectious uveitis in line with NICE TA460 at specialist centres only.
Specialist centres in the South region:
- University Hospital Southampton NHS Foundation Trust
- Oxford University Hospitals NHS Foundation Trust
- University Hospital Bristol NHS Foundation Trust
|
13.05.03 |
Adalimumab Humira® |
Commissioned by CCG for psoriasis in accordance with NICE TA146. Commissioned by NHS England via specialist centres only for treating moderate to severe hidradenitis suppurativa in accordance with NICE TA392. |
19.07 |
Adapt barrier ring |
Hollister Ltd Product size:48mm. Product reference code:7805 Pack size 10 Product size:98mm. Product reference code:7806 Pack size 10 |
19.07 |
Adapt CeraRing Hollister Ltd |
Product size: 48mm x 4.45mm Code: 8805
Pack size: 10
Product size 48mm x 2.3mm Code: 8815
Pack size: 10 |
19.01 |
Adapt No-Sting medical adhesive remover aerosol |
Hollister Ltd Product reference code 7737 Approved pack size 50ml |
19.07 |
Adapt slim barrier ring |
Hollister Ltd Product size:48mm. Product reference code:7815 Pack size 10 |
19.10 |
Adapt stoma powder™ |
Hollister Ltd Product reference code 7906 Approved pack size 28.3g
AMBER – only to be initiated by stoma nurse; Protective powder for broken skin or Mucocutaneous Separation. |
09.06.04 |
Adcal-D3® |
Colecalciferol with calcium Alternative preparations are available subject to patient preference |
09.03 |
Addiphos® |
|
09.03 |
Additrace® |
|
02.03.02 |
Adenosine |
Injection. |
23.08 |
Adhesive Remover |
Company |
Product Codes |
Price Per Unit |
Comments |
Clinimed Appeel no sting medical adhesive remover |
Sterile Adhesive remover aerosol 100ml 1x1 code: 3500
Sterile Wipes 1x30 pack of single use wipes code:3505
|
16.50
15.82
|
These adhesive removal products can be used to help remove sheaths |
|
23.04 |
Adjustable leg bags (for sheath user) |
Company |
Code |
Price |
Comment |
Coloplast Simpla Plus non-sterile leg bag
|
Adjustable bag 500mls Code – 21583
|
£3.04 (Box of 10)
|
For sheath use only. Safety lock tap and anti-kink tubing.
|
|
02.07.03 |
Adrenaline / Epinephrine |
Injection.
The algorithm for cardiopulmonary resuscitation can be found at http://www.resus.org.uk/
See Section 3.4.3 for management of anaphylaxis.
|
03.04.03 |
Adrenaline / Epinephrine IM/SC |
Pre-filled syringe - various brands available. Injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should normally prescribe by brand.
|
03.04.03 |
Adrenaline / Epinephrine IV |
Intravenous route should only be used by specialists where there is doubt about the adequacy of circulation and absorption of IM adrenaline/epinephrine.
Ensure that the correct strength of adrenaline injection is used. |
03.01.05 |
AeroChamber Plus Flo-Vu® |
First line spacer option. |
03.01.05 |
AeroChamber Plus® |
First line spacer option. |
08.01.05 |
Afatinib Giotrif® |
Commissioned by NHS England in line with NICE TA310. |
11.08.02 |
Aflibercept Eylea® |
PbR excluded: Commissioned by CCG in accordance with NICE guidance - refer to Commissioning Statements. |
09.08.01 |
Agalsidase Alfa |
Commissioned by NHS England - For initiation by specialist centres only. |
09.08.01 |
Agalsidase Beta |
Commissioned by NHS England - For initiation by specialist centres only |
06.01.01.03 |
AgaMatrix® Ultra-Thin Lancets |
|
16.01 |
Ajmaline |
Unlicensed
For diagnosis of Brugada’s syndrome |
13.07 |
Aldara® |
Hospital use only for anogenital warts
Cream, imiquimod 5%
Excipients include benzyl alcohol, cetyl alcohol, hydroxybenzoates (parabens), polysorbate 60, stearyl alcohol
May damage latex condoms and diaphragms
DCHFT: Consultant only. |
13.08.01 |
Aldara® |
Cream, imiquimod 5% |
08.02.04 |
Aldesleukin Proleukin® |
Commissioned by NHS England for cancer, but not routinely. |
08.01.05 |
Alectinib Alecensa® |
Commissioned by NHSE in line with NICE TA536 recommendations. |
08.02.03 |
Alemtuzumab Lemtrada® |
This is no longer licensed but is available through a patient access programme for oncological and transplant indications. Refer to the medicines management team for commissioning arrangements. NHS England commissioned for MS (TA312). Also commissioned by NHS England for CLL and pre-transplant immunosuppression (islet transplantation) only if provided at zero drug cost. |
08.02.04 |
Alemtuzumab Lemtrada® |
Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA312.
3rd treatment cycles may only be given following MDT approval and completion of additional Blueteq form in accrodance with NHSE commissioning policy 170075P |
06.06.02 |
Alendronic Acid |
For use in osteoporosis
Binosto® 70mg effervescent tablets are non-formulary - see below |
09.06.04 |
Alfacalcidol |
|
A2.03.01 |
Alfamino® |
On advice of dietitian or hospital specialist, for cow's milk protein allergy and other ACBS indications |
15.01.04.03 |
Alfentanil Rapifen® |
Injection. |
04.07.02 |
Alfentanil Buccal/Nasal Spray |
Unlicensed
RBCH: Palliative care only for in-patient use - see policy.
DCHFT: Palliative care consultant only for Joseph Weld Hospice or inpatient use only. |
07.04.01 |
Alfuzosin |
including MR formulations (Besavar® XL, Vasran® XL, Xatral® XL)
|
09.08.01 |
Alglucosidase Alfa Myozyme® |
Commissioned by NHS England: For initiation by specialist centres only |
02.12 |
Alirocumab Praluent® |
RED, Initiation by lipid specialist – this can be by written or verbal approval to other secondary care consultant clinicians. A copy of any letters should be forwarded to the patient’s GP.
Commissioned by CCG in accordance with NICE TA 393 for primary non-familial hypercholesterolaemia or mixed dyslipidaemia and primary heterozygous familial hypercholesterolaemia. Commissioned by NHS England via specialist centres only for homozygous familial hypercholesterolaemia. |
02.05.05.03 |
Aliskiren Rasilez® |
|
13.05.01 |
Alitretinoin Toctino® |
PbR excluded: Commissioned by CCG
Treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids. Use within the criteria defined by NICE TA177 and its licensed indication. Criteria for discontinuation of Alitretinoin treatment are also specified by NICE. |
10.01.04 |
Allopurinol |
|
06.01.02.03 |
Alogliptin Vipidia® |
- Dosing adjustment required in renal impairment, see SPC.
- The SPC says: "Experience of alogliptin use in clinical trials in patients with congestive heart failure (NYHA functional class III and IV) is limited and caution is warranted in these patients.
- If patients and their clinicians consider one of the gliptins to be a suitable treatment then the least expensive should be chosen, all other things being equal.
|
09.06.05 |
Alpha Tocopheryl Acetate |
|
07.04.05 |
Alprostadil injection |
Not prescribable on the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ’SLS’. DCHFT: Consultant only. |
02.10.02 |
Alteplase Actilyse® |
Injection / infusion.
Use in accordance with NICE TA 52.Also use in accordance with NICE TA 264.
|
A2.03.01 |
Althera® |
Alternative option for cow’s milk protein allergy |
A2.01.02.03 |
Altraplen® Compact |
NICE CG32 (Feb 2006) Nutrition support in adults
This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume |
A2.01.02.03 |
Altraplen® Protein |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency |
A2.04.01.02 |
Altrashot |
|
01.01.01 |
Aluminium Hydroxide |
Specialist use only. |
09.05.02.02 |
Aluminium Hydroxide |
Alu-Cap® discontinued
Unlicensed products available |
04.09.01 |
Amantadine |
Tablets, syrup.
For dyskinesia in advanced Parkinson's Disease.
See shared care guideline for amantadine. |
02.05.01 |
Ambrisentan Volibris® |
Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension. |
05.01.04 |
Amikacin |
For microbiology use only.
DCHFT: Consultant only.
Amikacin liposomal commissioned by NHS England in CF but not routinely. |
11.03.01 |
Amikacin Intravitreal injection |
Unlicensed
DCHFT: Not routinely stocked. |
02.02.03 |
Amiloride Hydrochloride |
Tablets. |
03.01.03 |
Aminophylline IV |
Hospital only. |
03.01.03 |
Aminophylline modified release |
Phyllocontin discontinued Feb 21
Further information and advice in CAS alert: CAS-ViewAlert (mhra.gov.uk) and linked supply disruption alert. |
02.03.02 |
Amiodarone |
Tablets, (Injection - secondary care only). Hospital initiation. |
04.02.01 |
Amisulpride |
Hospital or specialist initiation.
In accordance with NICE CG178 recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia and local shared care guideline.
See guidance on the use of antipsychotics in conditions other than schizophrenia (NICE CG 82). |
04.03.01 |
Amitriptyline |
Not first line with regard to depression, as per the Dorset Primary Care Protocol for Depression (see link above) |
04.07.03 |
Amitriptyline |
Tablets, syrup.
unlicensed |
02.06.02 |
Amlodipine |
Tablets.
1st Line Choice
Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate. |
05.01.01.03 |
Amoxicillin |
|
05.01.01.03 |
Amoxicillin IV |
|
05.02.03 |
Amphotericin Fungizone® |
Must be prescribed by brand. RBCH: for ocular injection or intravesical administration only |
11.03.02 |
Amphotericin drops 0.15% |
Preservative free
unlicensed
DCHFT: On formulary but not stocked. |
05.02.03 |
Amphotericin Liposomal AmBisome® |
Must be prescribed by brand. For neutropenic sepsis or on advice of microbiology |
08.01.05 |
Amsacrine |
|
13.10.01.02 |
Anabact® |
Gel, metronidazole 0.75%
Excipients include hydroxybenzoates (parabens), propylene glycol
For malodourous fungating tumours and ulcers |
09.01.04 |
Anagrelide |
When used in combination with hydroxycarbamide or outside licensed indications. |
09.01.04 |
Anagrelide |
For treatment of essential thrombocythaemia in accordance with local shared care guideline. |
10.01.03 |
Anakinra Kineret® |
Commissioned by NHS England for the treatment of Adult-Onset Still’s Disease refractory to second-line therapy in line with clinical commissioning policy 170056P via specilaist centres only.
Commissioned by NHSE for treating Adult-onset Still's disease with moderate to high disease activity, or continued disease activity after disease that has responded inadequately to 2 or more conventional disease‑modifying antirheumatic drugs (DMARDs), in line with NICE TA685.
Commissioned by NHSE for treating systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD, in line with NICE TA685.
Commissioned by NHS England in Cryopyrin Assoicated Periodic Syndrome via specilaist centres only in line with highly specialised criteria. |
08.03.04.01 |
Anastrozole |
For early breast cancer.
Also for advanced disease in postmenopausal women who are oestrogen-receptor positive or responsive to tamoxifen |
13.12 |
Anhydrol Forte® |
Restrict to patients in exceptional circumstances, this is a Self Care Medicine
Solution (= application), aluminium chloride hexahydrate 20% in an alcoholic basis
|
05.02.04 |
Anidulafungin Ecalta® |
Commissioned by NHS England according to agreed Trust Guidelines for fungal infections. DCHFT: Not routinely stocked. |
01.01.01 |
Antacid and oxetacaine |
Restricted use at PHT, RBCH and DCHFT : Specialist use only. |
11.04.02 |
Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® |
First choice for
Self Care Medicine for primary care.
|
13.08.01 |
Anthelios XL® |
Anthelios® XL SPF 50+ Melt-in cream is a borderline substance and regarded as a drug when prescribed for skin protection against ultraviolet radiation and/or visible light in abnormal cutaneous photosensitivity causing severe cutaneous reactions in genetic disorders (including xeroderma pigmentosum and porphyrias), severe photodermatoses (both idiopathic and acquired) and in those with increased risk of ultraviolet radiation causing severe adverse effects due to chronic disease (such as haematological malignancies), medical therapies and/or procedures . Preparations with SPF less than 30 should not normally be prescribed.
Self Care Medicine for primary care
|
A5.03.01 |
Antibacterial Medical Honey, honey (medical grade, Leptospermum sp.), Medihoney® |
Antibacterial Medical Honey, honey (medical grade, Leptospermum sp.), Antibacterial Wound Gel, honey (medical grade, Leptospermum sp.), 80% in natural waxes and oils, |
02.11 |
Antihaemophilic Factor/von Willebrand Factor Complex |
Non pharmacy item please contact blood bank for details and availability.
Recombinant Von Willebrand Factor not routinely commissioned by NHS England. As per IFR approval. |
09.01.03 |
Anti-Human Thrombocyte Globulin (horse) Inj 100 mg in 5mL |
RBCH: Aplastic anaemia - See guidelines |
09.01.03 |
Antilymphocyte immunoglobulin |
Commissioned by NHS England in accordance with BCSH guidelines |
02.11 |
Antithrombin III |
Non pharmacy item please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines. |
08.02.02 |
Antithymocyte immunoglobulin (rabbit) Thymoglobuline® |
Commissioned by NHS England as per British Committee for Standards in Haemotology (BCSH) Guidelines.
Not recommended as initial treatments to prevent organ rejection in patients having a kidney transplant as per NICE TA481 and TA482. |
01.07.01 |
Anusol® Ointment, cream, suppositories. |
Self Care Medicine for primary care.
Red for in-patient use as unable to purchase OTC.
|
01.07.02 |
Anusol-HC® |
Ointment, suppositories
On formulary at DCHFT.
Self Care Medicine for primary care.
|
02.08.02 |
Apixaban Eliquis® |
Tablets.
- For prevention of stroke or systemic embolism in patients with AF within NICE TA275 and local guidance, as per licensed indications.
|
02.08.02 |
Apixaban Eliquis® |
Tablets.
In accordance with NICE TA245 for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.RBCH: 1st line option is dalteparin.DCHFT: 1st line option is enoxaparin.
|
02.08.02 |
Apixaban Eliquis® |
For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE technology appraisal 341 |
02.08.02 |
Apixaban Eliquis® |

- In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
- Note routine 1st line option at RBCH and DCH is LMWH

- For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
- For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA.
|
02.08.02 |
Apixaban Eliquis® |
Prophylaxis in Superficial Thrombophlebitis - refer to Anticoagulation policy. 6 week course Unlicensed |
04.09.01 |
Apomorphine injection |
Hospital only.
Treatment is managed by the Parkinson's Disease speciality nurses. |
11.08.02 |
Apraclonidine drops 0.5% Iopidine® |
DCHFT: 0.5% and 1% stocked. The two strengths have different licensed indications. |
10.01.03 |
Apremilast Otezla® |
|
13.05.03 |
Apremilast Otezla® |
In accordance with NICE guidance. |
04.06 |
Aprepitant Emend® |
Capsules.
Hospital use only.
In accordance with locally agreed criteria as an adjunct to dexamethasone and 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy. |
13.02.01 |
AproDerm Colloidal Oat Cream® |
Prescribe by BRAND The AproDerm® range is suitable from birth for those suffering from:
Eczema Psoriasis and Other Dry Skin Conditions as well as for those requiring a daily moisturiser or pre-bathing emollient
Paraffin free
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
A2.03.01 |
Aptamil Pepti 1® |
Alternative option for cow's milk protein allergy in infants under 6 months of age |
A2.03.01 |
Aptamil Pepti 2® |
Alternative option for cow’s milk protein allergy in infants over 6 months of age |
A2.03.01 |
Aptamil Pepti Junior® |
Alternative option for cow's milk protein allergy |
13.02.01 |
Aquadrate® |
Cream, urea 10% DCHFT: Not routinely stocked.
Self Care Medicine for primary care.
|
13.02.01.01 |
Aqueous Cream, BP |
Cream, emulsifying ointment 30%, (1)phenoxyethanol 1% in freshly boiled and cooled purified water
Excipients include cetostearyl alcohol
Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.
Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required
Self Care Medicine for primary care.
|
06.02.02 |
Aqueous iodine oral solution Lugol's solution |
Hospital only |
01.06.03 |
Arachis Oil |
Enema.
- Contains peanut oil. DO NOT give to patients with PEANUT ALLERGY.
Self Care Medicine for primary care.
|
02.08.01 |
Argatroban Exembol® |
For treatment of Heparin-Induced Thrombocytopaenia (HIT)in critically unwell patients or those with severe renal impairment on advice of Consultant Haematologist. |
04.02.01 |
Aripiprazole (oral) Abilify® |
Tablets, Orodispersible tablets. Use in accordance with NICE CG178 recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia and local shared care guidelines. See guidance on the use of antipsychotics in conditions other than schizophrenia Solution shouldn't be used routinely as is very expensive (30mg = ~£600 per month) Option based on NICE guidance and licence. |
04.02.01 |
Aripiprazole (oral) Abilify® |
Red when used in children with neuro-developmental disorders. Use in accordance with NICE TA292 in moderate to severe manic episodes in adolescents with bipolar 1 disorder. |
04.02.02 |
Aripiprazole intramuscular injection Abilify Maintena® |
For the maintenance of adult patients with schizophrenia who have responded to oral aripiprazole but who are non-compliant.
see guidelines for the use of aripiprazole long acting injections |
08.01.05 |
Arsenic Trioxide Trisenox® |
Commissioned by NHSE in line NICE TA526 recommendations. |
05.04.01 |
Artemether with lumefantrine Riamet® |
"Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel" |
09.06.03 |
Ascorbic Acid 200 mg, 500mg, 1g effervescent strengths only |
This has been re-categorised as "red" for Scurvy only as per DMAG November 2017. 200mg twice a day is the most cost-effective dose.
Approved as Red at RBCH:
- Acute Corneal conditions 500mg twice a day for 6 week course (Eye Consultant only)
- Palliative Care consultant only: Tongue "descaling" where other options insufficient (1/4 x 1g tablet per dose)
|
A5.03.03 |
Askina® Calgitrol® Ag Silver Paste Dressing |
Indicated for the management of exuding partial to full thickness wounds, stage I -IV pressure sores, venous ulcers, second degree burns and donor sites. It is indicated for external use only and may be used in the management of infected wounds under medical supervision at the discretion of the physician.
Sterile dressing consisting of two layers:
- an absorbent polyurethane foam layer which provides for the absorption of wound exudate.
- an ionic silver alginate matrix which provides for broad anti-microbial effectiveness and helps prevent contamination from external bacteria.
|
02.09 |
Aspirin |
Self Care Medicine for primary care.
|
04.07.01 |
Aspirin |
Tablets, suppositories.
Dispersible tablets are considered 2nd Line
Self Care Medicine for primary care.
|
02.09 |
Aspirin Intravenous |
Approved at RBCH for patients requiring urgent PCI and are unable to have NG sited for enteral administration. |
05.03.01 |
Atazanavir Reyataz® |
Commissioned by NHS England as per BHIVA Guidelines. |
02.04 |
Atenolol |
Tablet, Liquid, (Injection - secondary care only). |
08.01.05 |
Atezolizumab Tecentriq® |
Commissioned by CDF in line with CDF criteria and NICE TA492 recommendations at a dose of 1200mg every 3 weeks (Specialist Sevices Circular 2096 Dec 19). Other licensed dose schedules are not funded.
Commissioned by NHSE in line with NICE TA520,TA525 and and TA584 recommendations. For NICE TA 520 and 525 the dose must be 1200mg every 3 weeks (Specialist Sevices Circular 2096 Dec 19). Other licensed dose schedules are not funded.
Use in combination with bevacizumab, paclitaxel and carboplatin, for the treatment of adult patients with EGFR activating mutations or ALK positive tumour mutations metastatic non-squamous non-small cell lung cancer (NSCLC) after failure of appropriate targeted therapies via MHRA Early Access to Medicines Scheme (EAMS). For eligible patients, clinicians can request an application form for registration with Roche by sending an email to welwyn.atezolizumabEAMS@roche.com. Off-label indication.
Use in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >1% and who have not received prior chemotherapy for metastatic disease, as per NICE TA639. • Patients previously started for this indication via the MHRA Early Access to Medicines Scheme (EAMS) who do not meet the new criteria should continue to receive the drug from the manufacturer.
Use in combination with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults with an ECOG score of 0 or 1, as per NICE TA638. • Patients previously started for this indication via the MHRA Early Access to Medicines Scheme (EAMS) who do not meet the new criteria should continue to receive the drug from the manufacturer.
Atezolizumab plus Bevacizumab is commissioned by NHSE as an option for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE TA666, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Note (July 2018): The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. |
04.04 |
Atomoxetine Strattera® |
Capsules.
For use in ADHD in accordance with recommendations made by NICE (TA98) and locally agreed treatment algorithm and shared care guideline.
DCHFT: Consultant psychiatrist only. |
02.12 |
Atorvastatin |
Tablets. |
07.01.03 |
Atosiban |
Not at RBCH |
05.04.08 |
Atovaquone Wellvone® suspension |
|
15.01.05 |
Atracurium Besilate Tracrium® |
Injection. |
A5.01.01 |
Atrauman |
Non-adherent knitted polyester primary dressing impregnated with neutral triglycerides |
15.01.03 |
Atropine |
Injection. |
18 |
Atropine injection |
For bradycardia and organophosphate or carbamate insecticide poisoning. |
11.05 |
Atropine Sulfate drops 1% |
DCHFT: Unlicensed 1% eye ointment also on local formulary. |
12.02.01 |
Avamys® |
Fluticasone furoate 27.5micrograms/dose nasal spray |
09.01.04 |
Avatrombopag Doptelet® |
In line with NICE TA626 |
13.02.01 |
Aveeno® |
Cream, colloidal oatmeal in emollient basis Excipients include benzyl alcohol, cetyl alcohol, isopropyl palmitate RBCH: Dermatology only
Only to be used under ACBS specified conditions as follows:
Endogenous and exogenous eczema, xeroderma, ichthyosis and senile pruritus associated with dry skin.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
08.01.05 |
Avelumab Bavencio® |
Commissioned by NHSE for the treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma in line with NICE TA517.
Available via CDF managed access agreement for the treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma - see link below.
Commissioned by the CDF in combination with Axitinib for untreated advanced renal cell carcinoma in adults as per NICE TA645 and NHSE commissioning statement SSC 2170.
Available via an EAMS scheme for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy. |
08.01.05 |
Axicabtagene ciloleucel YESCARTA® |
Commissioned by CDF in line with CDF criteria and NICE TA559 at commissioned CAR-T treatment centres only.
Commissioned centres include:
- University College London Hospital NHS Foundation Trust
- King’s College Hospital NHS Foundation Trust
- University Hospitals Bristol NHS Trust
|
08.01.05 |
Axitinib Inlyta® |
Commissioned by NHS England in line with NICE TA333. |
10.03.02 |
Axsain® |
Capsaicin 0.075% cream Specialist initiation
|
A2.02.01.02 |
AYMES Shake Milkshake style and Juice shakes |
Calorie content is based on a sachet being made up with 200ml of full cream milk and contains approx. 385 Kcals.
If patient likes milky drinks, prescribe as a supplement to diet 1-2 servings/day.
Not suitable for patient with cow's milk intolerence or galactosaemia.
Not nutritionally complete.
If patient dislikes milky drinks choose from the juice style supplements instead. |
A2.02.01.02 |
Aymes® Complete |
NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds |
08.01.03 |
Azacitidine Vidaza® |
Commissioned by NHS England in line with NICE TA218. Azacitadine is not recommended for treating acute myeloid leukaemia with more than 30% bone marrow blasts as per NICE TA399. |
01.05.03 |
Azathioprine |
Tablets, suspension (unlicensed special).
Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults Unlicensed for these indications but in line with national guidelines.There are a number of different indications for azathioprine. Please see here for other indications. Unlicensed suspension 50mg/5mL (expensive) may be available as a special. At RBCH, suspension is Consultant Gastroenterologist for Crohn's disease in conjunction with allopurinol only. |
08.02.01 |
Azathioprine |
Commissioned by NHS England (for transplant immunosuppression only) in new patients only until formal repatriation agreed. As per Trust Guidelines. Hospital initiation. |
10.01.03 |
Azathioprine |
|
13.05.03 |
Azathioprine |
Hospital use only - unlicensed For severe refractory eczema Unlicensed use: 0.5-3mg/kg daily dependent on TPMT activity |
05.01.05 |
Azithromycin |
for Sexual Health indications in Primary Care - see Sexual Health Dorset Guidelines below. Liquid preparation is green for use in children who are allergic to penicillin.
For patients with COPD and bronchiectasis, in line with local shared care guideline
For other indications.
|
11.03.01 |
Azithromycin dihydrate drops 1.5% |
|
05.01.02.03 |
Aztreonam Azactam® |
Consultant microbiologist or specialist use only. |
05.01.02.03 |
Aztreonam Lysine nebuliser solution Cayston® |
Commissioned by NHS England for use in CF as per policy A01/P/b.
Adult patients: specialist centre only (University Hospital Southampton)
Paediatric patients: PHFT use in line with network arrangements with UHS.
Not at DCH or RBCH. |
10.02.02 |
Baclofen |
Withdraw slowly as abrupt cessation may precipitate seizures |
13.02.01.01 |
Balneum Plus® bath oil |
Reserved for patients with severe eczema and infants under the age of 1 year.
Bath oil,soya oil 82.95%, mixed lauromacrogols 15%
Excipients include butylated hydroxytoluene, propylene glycol, fragrance
Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.
Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required
Self Care Medicine for primary care.
|
13.02.01 |
Balneum® |
Cream, urea 5%, ceramide 0.1%
Excipients include cetostearyl alcohol, polysorbates, propylene glycol Not RBCH
Self Care Medicine for primary care.
|
13.02.01.01 |
Balneum® bath oil |
Reserved for patients with severe eczema and infants under the age of 1 year.
Bath oil, soya oil 84.75% Excipients include butylated hydroxytoluene, propylene glycol, fragrance
Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.
Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required
Self Care Medicine for primary care.
|
10.01.03 |
Baricitinib Olumiant® |
|
08.02.02 |
Basiliximab Simulect® |
Commissioned by NHS England at specialist centres only in line with NICE TA recommendations. |
08.02.04 |
BCG bladder instillation OncoTICE® |
1st line at RBCH |
08.02.04 |
BCG bladder instillation ImmuCyst® |
Bacillus Calmette-Guérin
|
14.04 |
BCG vaccine diagnostic agent |
Tuberculin PPD (Mantoux test) - named patient. |
14.04 |
BCG vaccine Intradermal |
Bacillus Calmette-Guérin Vaccine
BCG Vaccine, Dried/Tub/BCG
This vaccine is not available at NHS expense in Dorset for Overseas Travel : See Dorset Guidance on Prescribing for Overseas Travel
|
22.01 |
BD Viva |
Size: 4mm/32g Size: 5mm/31g Pack Size : 90
|
03.02.01 |
Beclometasone (Beclomethasone) |
Inhalers.
Prescribe by brand
MHRA/CHM advice (July 2008):
Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Clenil® and QVAR®)are not interchangeable and should be prescribed by brand name; QVAR® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil® |
03.02.03 |
Beclometasone 100 micrograms/Formoterol 6 micrograms Fostair® |
Inhaler (MDI and NEXThaler)
MHRA/CHM advice (July 2008):
Fostair® has extra-fine particles and is more potent than traditional beclometasone dipropionate CFC-free inhalers.
When switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, Fostair® 100/6 can be prescribed for patients already using beclometasone dipropionate 250 micrograms in another CFC-free inhaler; the dose of Fostair® should be adjusted according to response
|
03.02.03 |
Beclometasone 200mcg / Formoterol 6mcg Fostair® 200/6 |
|
12.02.01 |
Beclometasone dipropionate 50micrograms/dose nasal spray |
Self Care Medicine for primary care.
|
01.05.02 |
Beclometasone tablets Clipper® |
M/R tablets.
Not at DCHFT |
03.02.03 |
Beclomethasone / Formoterol / Glycopyrronium Trimbow® |
For use within its licensed indication for COPD |
10.01.03 |
Belimumab Benlysta® |
|
08.01.01 |
Bendamustine Levact® |
Commissioned by NHS England in line with TA216 and NHSE clinical commissioning policies (see below).
NOT commissioned for the treatment of relapsed multiple myeloma from 3rd September 2020 in line with new NHSE commissioning statement SSC 2161. • Existing patients registered with BlueTeq prior to this date may continue to receive Bendamustine for this indication providing the patient continues to meet the treatment criteria. |
02.02.01 |
Bendroflumethiazide |
Tablets. |
03.04.02 |
Benralizumab Fasenra ® |
Commissioned by NHS England in accordance with NICE TA565 at specialist centres only. |
05.01.01.01 |
Benzathine benzylpenicillin |
For GUM |
10.01.04 |
Benzbromarone |
Approved at RBCH and PHT for the long-term managment of chronic gout where:
- previous intolerance/failure of allopurinol and/or febuxostat
- renal impairment precludes use of allopurinol and/or febuxostat
|
12.03.01 |
Benzydamine hydrochloride mouthwash 0.15% |
Self Care Medicine for primary care.
|
12.03.01 |
Benzydamine hydrochloride oralmucosal spray 0.15% |
Self Care Medicine for primary care.
|
11.03.01 |
Benzylpenicillin intravitreal injection |
Unlicensed
DCHFT: Not routinely stocked. |
05.01.01.01 |
Benzylpenicillin IV Crystapen® |
|
03.05.02 |
Beractant Survanta® |
Hospital only.
Commissioned by NHS England for Respiratory Distress Syndrome in neonates - use in line with Trust guidelines |
13.04 |
Betacap® |
Scalp application, betamethasone (as valerate) 0.1% in a water-miscible basis containing coconut oil derivative Potency: potent
|
09.06.01 |
Beta-Carotene |
|
04.06 |
Betahistine Dihydrochloride |
Tablets.
For Ménière's disease |
09.08.01 |
Betaine Cystadane® |
Commissioned by NHS England for Homocystinuria according to service specification only via specialised metabolic centres or via outreach netwroks. |
06.03.02 |
Betamethasone |
RBCH: 500microgram tablets used in preference to Dexamethasone 500microgram tablets (apart from Dexamethasone suppression testing) |
13.04 |
Betamethasone and clioquinol Non-proprietary |
Cream, betamethasone (as valerate) 0.1%, clioquinol 3% Potency: potent
Excipients may include cetostearyl alcohol, chlorocresol
Note Stains clothing
Ointment, betamethasone (as valerate) 0.1%, clioquinol 3%
Potency: potent
Note Stains clothing
|
13.04 |
Betamethasone and neomycin Non-proprietary |
Cream, betamethasone (as valerate) 0.1%, neomycin sulfate 0.5% Potency: potent Excipients may include cetostearyl alcohol, chlorocresol Ointment, betamethasone (as valerate) 0.1%, neomycin sulfate 0.5% Potency: potent
Only to be used on the advice of a specialist |
11.04.01 |
Betamethasone drops 0.1% |
|
11.04.01 |
Betamethasone drops 0.1% with Neomycin 0.5% Betnesol N® |
Not DCHFT. |
11.04.01 |
Betamethasone ointment 0.1% |
|
12.01.01 |
Betamethasone Sodium Phosphate drops 0.1% Betnesol®, Vistamethasone® |
|
12.02.01 |
Betamethasone sodium phosphate drops 0.1% Betnesol®, Vistamethasone® |
|
12.01.01 |
Betamethasone sodium phosphate drops 0.1% and neomycin sulfate 0.5% Betnesol-N® |
|
12.02.03 |
Betamethasone sodium phosphate drops 0.1% with neomycin sulfate 0.5% Betnesol-N® |
|
11.06 |
Betaxolol Betoptic® |
Drops 0.25% and 0.5% |
11.06 |
Betaxolol Unit dose eye drop suspension 0.25% Betoptic® |
Preservative-free.
DCHFT: Not routinely stocked. |
13.04 |
Betnovate® |
Scalp application, betamethasone (as valerate) 0.1% in a water-miscible basis Potency: potent |
13.04 |
Betnovate® |
Cream, betamethasone (as valerate) 0.1% in a water-miscible basis
Potency: potent
Excipients include cetostearyl alcohol, chlorocresol
Ointment, betamethasone (as valerate) 0.1% in an anhydrous paraffin basis
Potency: potent |
13.04 |
Betnovate-RD® cream |
Cream, betamethasone (as valerate) 0.025% in a water-miscible basis (1 in 4 dilution of Betnovate® cream)
Potency: moderate
Excipients include cetostearyl alcohol, chlorocresol |
13.04 |
Betnovate-RD® ointment |
Ointment, betamethasone (as valerate) 0.025% in an anhydrous paraffin basis (1 in 4 dilution of Betnovate® ointment)
Potency: moderate |
08.01.05 |
Bevacizumab Avastin® |

For use in line with CDF criteria. Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only.

Not recommended as per NICE TA560 with carboplatin, gemcitabine and paclitaxel for treating the first occurence of platinum-sensitive advanced ovarian cancer. |
11.08.02 |
Bevacizumab 1.25mg/0.05ml syringe for intravitreal injection |
Unlicensed
RBCH: Approved for Eye specialist use in the following indications where there is no licensed product available:
- Iris/drainage angle neovascularization - single injection
- Pre-operative use to reduce the risk of vitreous hemorrhage during vitreoretinal surgery - single injection
- Treatment of choroidal neovascularisation non-age related macular degeneration (AMD) or myopic CNV causes - repeated injection up to maximum frequency of monthly according to condition.
- Treatment of choroidal neovascularisation due to age related macular degeneration where clinical benefit is present but patient falls outside the criteria for licensed drug treatment i.e. better than 6/12
|
08.01.05 |
Bexarotene Targretin® |
When approved for an individual patient |
02.12 |
Bezafibrate |
Tablets, modified release tablets. |
A5.02.05 |
Biatain Silicone ® |
A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border. |
A5.02.05 |
Biatain Silicone Lite Dressings |
All sizes
Biatain® Silicone Lite is a thin and ultra flexible foam dressing with gentle silicone adhesive. It can be used on a wide range of exuding wounds and is to be used whenever a thin foam dressing is needed. Biatain® Silicone Lite combines superior absorption and increased mobility. |
08.03.04.02 |
Bicalutamide |
50mg - for use in advanced/metastatic disease. 150mg - for locally advanced disease as an alternative to LHRH and also as neo-adjuvant/adjuvant treatment prior to and after radiotherapy in accordance with locally agreed criteria and shared care guideline.
|
11.06 |
Bimatoprost drops 0.01% Lumigan® |
0.01% is only strength on formulary |
11.06 |
Bimatoprost drops 300micrograms/ml with timolol 5mg/ml Ganfort® |
Includes preservative-free option where appropriate.
DCHFT: Preservative free option - Consultant only and in patients with proven intolerance to preserved eye drops. |
08.01.05 |
Binimetinib Mektovi® |
Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination encorafenib). |
12.03.05 |
BioXtra® |
Gel, lactoperoxidase, lactoferrin, lysozyme, whey colostrum, xylitol and other ingredients
Self Care Medicine for primary care.
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
Humalog®Mix25
Humalog®Mix50 |
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
|
01.06.02 |
Bisacodyl |
Tablets, suppositories. Tablets most cost effective option as at Feb'2015
- Alternative prescribing option.
Self Care Medicine for primary care.
|
01.03.03 |
Bismuth subsalicylate Pepto-Bismol® |
As part of Helicobacter pylori eradication quadruple therapy in resistant cases ( unlicensed).
The recommended dose of 525mg QDS is equivalent to:
- Pepto-bismol SUSPENSION 30ml QDS (this is blacklisted in primary care)
- Pepto-bismol TABLETS 2 tabs QDS
Self Care Medicine for primary care.
|
02.04 |
Bisoprolol |
Tablets. |
02.08.01 |
Bivalirudin Angiox® |
Injection.
Cardiology use only in accordance with NICE TA230.
See commissioning statement for bivalirudin.
DCHFT: Consultant use only, in accordance with NICE TA230 (ST elevated myocardial infarction) or for anticoagulant patients who develop heparin induced thrombocytopeania (HIT).
|
08.01.02 |
Bleomycin |
In addition to licensed indications, approved at RBCH for treatment of venous malformations by Interventional Radiology unlicensed |
08.02.03 |
Blinatumomab Blincyto® |
In accordance with NICE TA450 and NICE TA589. |
12.03.01 |
Bonjela® |
Choline salicylate dental gel
Self Care Medicine for primary care.
|
08.01.05 |
Bortezomib Velcade® |
In accordance with NICE TA (TA129, TA228, TA311) or CDF policy. |
02.05.01 |
Bosentan Tracleer® |
Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension. |
08.01.05 |
Bosutinib Bosulif® |
Commissioned by NHS England in line with NICE TA401. |
04.07.04.02 |
Botulinum Toxin Type A |
|
04.09.03 |
Botulinum Toxin Type A |
For all commissioned indications, use in accordance with the Interim Criteria Based Access Protocol and the access protocol for overactive bladder. When used for migraine also in accordance with recommendations of NICE TA 260. Preparations are not interchangeable and should be used under specialist supervision. Commissioned by NHS England for use in focal spasticity in children according to agreed Trust Guidelines, but not routinely commissioned for intravesical use in spinal cord injury in new patients.
Xeomin® may be used for chronic sialorrhoea associated with chronic neurological conditions in line with licences and with NICE TA605 |
13.12 |
Botulinum toxin type A Botox® |
For severe axillary hyperhidrosis that has not responded to topical therapy in accordance with local guidelines |
14.04 |
Botulism antitoxin |
Specialist clinics only
DCHFT: Not routinely stocked. |
08.01.05 |
Brentuximab vedotin Adcetris® |
Commissioned by NHSE in line with NICE TA478, TA524 and TA577 recommendations.
Commissioned by NHSE in line with NICE TA641 in combination with Cyclophosphamide, Doxorubicin and Prednisone (CHP) for untreated systemic anaplastic large cell lymphoma in adults. |
13.06.01 |
Brevoxyl® |
Cream, benzoyl peroxide 4% in an aqueous basis Excipients include cetyl alcohol, fragrance, stearyl alcohol
For use within acne guideline when required in combination with antibioticsFor use within acne guideline when required in combination with antibiotics
Self Care Medicine Not RBCH
|
08.01.05 |
Brigatinib Alunbrig® |
Commissioned by NHSE in line with NICE TA571 as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer previously treated with crizotinib.
Commissioned by NHSE in line with NICE TA670 as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) that has not been previously treated with an ALK inhibitor in adults. • This indication is funded by CDF until 27th April 2021 |
13.06.03 |
Brimonidine Tartrate Mirvaso® |
A routine European review has identified post-marketing reports of systemic cardiovascular effects including bradycardia, hypotension and dizziness. Warn patients not to apply the gel to irritated or damaged skin, including after laser therapy. For more information refer to MHRA link below. |
11.06 |
Brimonidine tartrate drops 0.2% |
|
11.06 |
Brinzolamide 10mg / Brimonidine 2mg Eye Drops Simbrinza® |
For recommendation by Glaucoma specialists only as a precursor or to avoid a Trabeculectomy. |
11.06 |
Brinzolamide drops 10mg with timolol 5mg/ml Azarga® |
Consultant ophthalmologist |
11.06 |
Brinzolamide drops 10mg/ml Azopt® |
|
13.05.03 |
Brodalumab Kyntheum® 210 mg Solution for Injection |
|
11.08.02 |
Brolucizumab Beovu® ,Novartis |
|
06.07.01 |
Bromocriptine |
1st line use in pregnancy |
03.02.01 |
Budesonide Inhaled /Nebulised) |
Alternative prescribing option. |
03.02.03 |
Budesonide / Formoterol Fobumix® |
For use within its licensed indications for asthma and COPD |
01.05.02 |
Budesonide capsules Budenofalk® |
Capsules containing EC granules - standard release (thrice daily administration).Prescribe by brand name.
For patients with active Crohn's disease who are at high risk of corticosteroid side effects with, or intolerant of conventional steroids (e.g. prednisolone). |
01.05.02 |
Budesonide CR capsules Entocort® |
- MR Capsules - once daily administration.
- Prescribe by brand name.
For patients with active Crohn's disease who are at high risk of corticosteroid side effects with, or intolerant of conventional steroids (e.g. prednisolone).
|
01.05.02 |
Budesonide orodispersible Jorveza® |
UHD
Adults: For eosinophilic esophagitis (EoE)
Paediatrics: 14 years and older, for treatment of eosinophilic esophagitis (EoE) under the care of Dr. Tighe for the period January 21-January 22. |
03.02.03 |
Budesonide/Formoterol Symbicort® |
Inhalers.
200/6 metered dose inhaler, licensed for COPD only.
200/6 and 400/12 turbohalers are licensed for COPD and asthma. 100/6 turbohaler, licensed for asthma only. *prescribe by brand to ensure the patient receives the same inhaler at each dispensing*
For generic prescription - patients should be supplied with the combination inhaler they have been using or trained in. |
03.02.03 |
Budesonide/Formoterol DuoResp Spiromax® |
*prescribe by brand to ensure the patient receives the same inhaler at each dispensing*
If generic prescription - patients should be supplied with the combination inhaler they have been using or trained in
March 2018: Non Formulary for new initiations |
02.02.02 |
Bumetanide |
Tablets. |
15.02 |
Bupivacaine and Adrenaline |
Bupivacaine 0.25% + Adrenaline 1 in 200,000 Injection.
Bupivacaine 0.5% + Adrenaline 1 in 200,000 Injection. |
15.02 |
Bupivacaine hydrochloride Marcain® |
0.25% and 0.5% injections.
DCHFT: 0.5% injection only.RBCH also: Bupivacaine 0.15% in Sodium Chloride 0.9% Epidural Infusion. |
15.02 |
Bupivacaine Hydrochloride with Glucose Marcain Heavy® |
0.5% Injection. |
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
|
04.07.02 |
Buprenorphine Patches Butrans® |
5mcg/hr, 10mcg/hr and 20mcg patches
Only for patients with genuine swallowing difficulties who don't require a daily morphine dose exceeding 60mg. |
04.10.03 |
Buprenorphine prolonged-release solution for injection Buvidal® |
For Substance misuse as per DMAG November 2020 |
04.10.03 |
Buprenorphine Sublingual tablets Subutex® |
For substance misuse as per DMAG March 2018 |
04.10.02 |
Bupropion |
Tablets.
As an adjunct to smoking cessation in combination with motivational support in accordance with NICE recommendations (PH45). |
06.07.02 |
Buserelin Suprefact® Suprecur® |
Nasal spray and injection for in vitro fertilisation |
08.03.04.02 |
Buserelin Suprefact® |
|
08.01.01 |
Busulfan Myleran®, Busilvex® |
|
03.04.03 |
C1 esterase inhibitor Berinert®, Cinryze® |
Injection.
Acute Treatment or Short-term prophylaxis prior to planned procedures for Hereditary Angioedema and Acquired Angioedema
In accordance with NHS England commissioning policy
May only be initiated by (or on advice of) Specialist Centres - locally this centre is University Hospitals of Southampton
Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
Prophylactic treatment of hereditary angioedema (HAE) types I and II
In accordance with NHS England commissioning policy in patients who fail, are intolerant or have contra-indications to oral prophylactic therapies.
May only be initiated by Specialist Centres (local centre is University Hospital of Southampton)
Prior approval must be given via Blueteq system
|
08.01.05 |
Cabazitaxel Jevtana® |
Commissioned in accordance with NICE guidance. |
06.07.01 |
Cabergoline |
|
08.01 |
Cabozantinib Cometriq® |
Commissioned by CDF (for cancer) as per CDF policy. |
08.01.05 |
Cabozantinib Cometriq®, Cabometyx® |
Cabometyx®:
- Commissioned by NHSE in accordance with NICE TA463 and TA542 for the treatment of previously treated advanced renal cell carcinoma and untreated locally advanced or metastatic renal cell carcinoma respectively.
- Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.
Cometriq®:
- Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.
|
03.05.01 |
Caffeine citrate |
Infusion.
NICU/SCBU only. |
13.05.02 |
Calcipotriol Non-proprietary |
Ointment, calcipotriol 50 micrograms/g
Note Not licensed for use in children under 18 years |
13.05.02 |
Calcipotriol Non-proprietary |
Scalp solution, calcipotriol 50 micrograms/mL |
13.05.02 |
Calcipotriol and Betamethasone cutaneous foam Enstilar ® |
One gram of cutaneous foam contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).
Not stocked at RBCH |
13.05.02 |
Calcipotriol and betamethasone dipropionate ointment Dovobet® |
In accordance with the local guideline for prescribing in stable plaque psoriasis in adults.
Ointment, betamethasone 0.05%, calcipotriol (as monohydrate) 50 micrograms/g. Excipients include butylated hydroxytoluene.
Gel; betamethasone 0.05%, calcipotriol (as monohydrate) 50 micrograms/g.
RBCH: Gel and Ointment not stocked
DCHFT: Ointment only. |
09.05.01.02 |
Calcitonin Miacalcic® |
Calcitonin can be used for the treatment of hypercalcaemia associated with malignancy DCHFT: Renal consultant only. |
06.06.01 |
Calcitonin (salmon) / Salcatonin Miacalcic® |
 For prevention of acute bone loss due to sudden immobility
 For hypercalcaemia of malignancy
|
09.06.04 |
Calcitriol |
Injection = Red |
09.06.04 |
Calcium 1000mg and colecalciferol 880iu chewable tablets Theical D3 |
|
09.05.01.01 |
Calcium 5.1mmol / 10ml syrup Alliance Calcium Syrup® |
Replaces Calcium Sandoz syrup |
09.05.02.02 |
Calcium Acetate Phosex® |
In accordance with the phosphate binders shared care guideline for the management of Hyperphosphataemia in patients with chronic kidney disease |
09.05.02.02 |
Calcium Acetate 435mg/Magnesium Carbonate Heavy 235mg Osvaren® |
In accordance with the phosphate binders shared care guideline for the management of Hyperphosphataemia in patients with chronic kidney disease. |
09.06.04 |
Calcium and Ergocalciferol |
DCHFT: Local formulary states that there is insufficient calcium for prevention of osteoporosis. |
09.05.01.01 |
Calcium carbonate Adcal® |
|
09.05.02.02 |
Calcium Carbonate |
In accordance with the phosphate binders shared care guideline for the management of Hyperphosphataemia in patients with chronic kidney disease. |
09.06.04 |
Calcium carbonate and colecalciferol Calceos® |
2nd line option at RBCH for patients intolerat of Adcal D3 |
09.06.04 |
Calcium Carbonate with Colecalciferol Cacit® D3 |
Not at DCHFT and RBCH |
09.05.01.01 |
Calcium Chloride |
IV injection/infusion |
18 |
Calcium chloride injection |
For calcium channel blocker overdose and systemic effects of hydrofluoric acid. |
08.01 |
Calcium Folinate |
DCHFT: 15mg and 350mg injections and 15mg tablets available. |
18 |
Calcium folinate |
For methotrexate overdose or poisoning and methanol or formic acid poisoning. |
18 |
Calcium gluconate |
Injection (by local infiltration) and gel (topically) for hydrofluoric acid burns.
RBCH: Gel kept in ED Resus |
09.05.01.01 |
Calcium Gluconate injection |
|
09.05.01.01 |
Calcium lactate |
Not DCHFT and RBCH. |
09.05.01.01 |
Calcium-Sandoz® liquid |
Now discontinued. Use Alliance Calcium Syrup |
A2.04.01.02 |
Calogen Extra® |
Energy supplement.
To be used under direction of dietitian only.
Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. |
A2.04.01.02 |
Calogen Extra® shots |
Energy supplement.
Calogen and Calogen extra contain some vitamins & minerals
To be used under direction of dietitian only.
Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. |
A2.04.01.02 |
Calogen® |
Energy supplement.
Calogen and Calogen extra contain some vitamins & minerals
To be used under direction of dietitian only.
Dilute before use in child under the age of 5. |
A2.04.01.02 |
Calshake® |
Generally use as a second choice to 1.5kcal/ml sip feeds as not nutritionally complete. However these supplements do provide more calories per ml approx. 600kcal in 250ml so useful for those with very high calorie needs (when reconstituted with whole milk) e.g. CF Patients |
09.05.01.01 |
Calvive® |
Tablets Calvive® 1000 (Formerly Sandocal®1000) only at RBCH |
06.01.02.03 |
Canagliflozin Invokana® |
When used as monotherapy or with oral hypoglycaemics in patients with Type 2 Diabetes When used in combination with insulin
|
08.02.04 |
Canakinumab Ilaris® |
Commissioned by NHS England as per Cryopyrin Associated Periodic Syndrome service specification.
Commissioned by NHSE via specialist centres for the treatment of periodic fever syndrome (all ages) under the NHSE policy. NOTE: Does not apply to any hospitals in Dorset Not routinely commissioned by NHS England for juvenile arthritis - see NICE TA302. |
02.05.05.02 |
Candesartan |
|
13.04 |
Canesten HC® |
Cream, hydrocortisone 1%, clotrimazole 1% Potency: mild Excipients include benzyl alcohol, cetostearyl alcohol
Self Care Medicine for primary care (15g tube).
|
02.09 |
Cangrelor Kengrexal® |
Approved at RBCH for patients requiring urgent PCI who are unable to have NG sited to administer enteral antiplatelets. |
04.08.01 |
Cannabidiol Epidyolex® |
Commissioned by NHS England for use with Clobazam in Specialist Centres Only as per criteria laid out in NICE TA614 and TA615. |
10.02.02 |
Cannabis extract oromucosal spray Sativex® |
For patients with MS who have not responded to alternative anti-spasticity medications in accordance with NICE NG144 |
13.09 |
Capasal® |
Restrict to where moderate to severe skin condition requires it (not for cradle cap)
Shampoo, coal tar 1%, coconut oil 1%, salicylic acid 0.5%
Self Care Medicine
|
08.01.03 |
Capecitabine |
|
12.03.01 |
Caphosol |
Paediatrics only Only at PHFT and DCHFT.
DCHFT: Paediatric patients undergoing intensive mucositis inducing chemotherapy.
Mouth Rinse. Caphosol comprises two
separately packaged aqueous solutions, (Caphosol A) and (Caphosol B) which when combined, forms a solution supersaturated with calcium and phosphate ions.
Ingredients : Dibasic Sodium Phosphate 0.032, Monobasic Sodium Phosphate 0.009, Calcium Chloride 0.052, Sodium Chloride 0.569, Purified water qs (%w/w)
|
10.03.02 |
Capsaicin 179mg cutaneous patch Qutenza® |
|
02.05.05.01 |
Captopril |
Tablets, liquid.
Restricted for paediatric or diagnostic use only. |
04.02.03 |
Carbamazepine |
Carbagen® IR tablets and PR tablets have been discontinued (Sept 2020).
Please see the SPS information here for further details. |
04.07.03 |
Carbamazepine |
Tablets, chewable tablets, modified release tablets, liquid, suppositories. For trigeminal neuralgia.
Carbagen® IR tablets and PR tablets have been discontinued (Sept 2020).
Please see the SPS information here for further details. |
04.08.01 |
Carbamazepine |
Tablets, modified release tablets, liquid, suppositories. Options based on licence.
Category 1: ensure patient is maintained on a specific manufacturer's product.
Tegretol Chewtabs discontinuation: 100mg tablet was depleted by the end of October 2014 and 200mg tablet expected to be depleted by May 2015.
|
07.01.01 |
Carbetocin Pabel® |
PHFT - for prevention of post-partum haemorrhage following caesarean section. |
06.02.02 |
Carbimazole |
|
03.07 |
Carbocisteine |
Capsules, liquid.
DCHFT: Initiation restricted to consultant respiratory specialist only. |
11.08.01 |
Carbomer 980 Gel |
RBCH: Viscotears®
Self Care Medicine for primary care.
|
08.01.05 |
Carboplatin |
|
07.01.01 |
Carboprost |
|
08.01.05 |
Carfilzomib Kyprolis® |
Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults who have had only 1 previous therapy in accordance with NICE TA657. |
09.08.01 |
Carglumic Acid Carbaglu® |
Commissioned by NHS England in urea cycle disorders. For initiation by specialist centres only as per NHS England Service Specification. |
11.08.01 |
Carmellose drops 0.5% or 1% Celluvisc® |
Preservative free NOT RBCH - if admitted and patient supply not available convert to sodium hyaluronate 0.15% preservative-free whilst in-patient.
Self Care Medicine for primary care.
|
12.03.01 |
Carmellose Sodium Orabase® |
|
08.01.01 |
Carmustine Gliadel® |
Carmustine implants recommended as a possible treatment for people with newly diagnosed high-grade glioma only if 90% or more of their tumour has been removed.
Carmustine implants are not recommended for people with newly diagnosed high-grade glioma if less than 90% of their tumour has been removed.
|
A2.05.02 |
Carobel, Instant® |
|
02.04 |
Carvedilol |
Tablets.
Specialist initiation.
DCHFT: Restricted as adjunct for treatment of patients with heart failure. Not for routine post-acute myocardial infarction use.
|
05.02.04 |
Caspofungin Generic, Cancidas® |
Generic drug should be used where possible For microbiology or haematology use only. Commissioned by NHS England for fungal infection according to agreed Trust Guidelines. |
23.16 |
Catheter Bags and Sleeves |
Company |
Product codes and sizes |
Price per unit |
Comments |
Optium
Ugo Fix
|
- Small - 3005 (24-39cm)
- Medium - 3006 (26-55cm)
- Large - 3007 (40-70cm)
- Extra Large - 3008 (65-90cm)
|
£1.83 |
Good instructions with product. Comes with wash bag. Good size variety. |
Clinisupplies |
- Small - PLS3881 (24-40cm)
- Medium - PLS3904 (36-50cm)
- Large - PLS3928 (40-65cm)
|
£1.88 |
Soft to touch.
Washable
|
|
23.12 |
Catheter leg bags and night bags |
Company |
Product Codes |
Price per unit |
Comments |
Convatec / Unomedical |
Day Bags:
Available in short & long tubes, 500ml
T-tap 500ml
- 45-05-SVCG - Short
- 45-06-LVCG - Long
Lever tap 500ml
- 46-05 SVCG - Short
- 46-06 LVCG - Long
Night Bags:
- 47-60-LBH (single use)
- 46-20-IDCG (drainable)
|
£2.54 (Box of 10)
£0.33
£1.18 (Box of 10)
|
Supplied by local hospitals to patients on discharge.
Easy use taps, good instructions and sample port.
Variety of taps and gloves with sterile bags.
Good for Care Homes
|
Qufora |
Day Bags:
500ml bags are available in lever tap and T-tap, short and long tubes. Codes:
Lever Tap
500ml
- 12161804 Short
- 12161504 Long
T-tap
500ml
- 12151804 Short
- 12151504 Long
Night Bags (S4)
- 14851204 (drainable)
- 13800101 (single use)
|
2.24 (Box of 10)
0.97
0.49
|
Bed clip, tap and good instructions.
3 litre bag also abailable in the range
|
Clinnisupplies
Prosys
|
Day Bags:
Size 500ml bags are are available in lever tap and t-tap, Short and long tubes/
Codes:
T-Tap
500mls - P500S Short
P500L Long
Lever-Tap
500mls - P500S-LT Short
P500L-LT Long
Night bags
Codes:
Drainable P2000-LT
Single Use PSU2
|
£2.56 (Box of 10)
£1.20
£0.31
|
There are hospital to home discharge packs available which contain one leg bag and 7 single use night bags.
Gloves in all packs and taps twist to face leg.
Literature available.
|
|
23.07 |
Catheter Maintenance Solutions |
Company |
Product |
Price Per Unit |
Comments |
B Braun
FB99849
9746609
9746625
|
Uro-Tainer NaCl 0.9% 50ml
Uro-Tainer Twin Suby G 2x30ml code: 9746609
Uro-Tainer Twin Solution R 2x30ml code: 9746625
|
£3.57
£4.98
£4.98
|
Preferred product as solution needs to drip into catheter.
For Suby G and R solutions, catheters need to be inspected for encrustation by cutting down the length of the catheter after removal.
|
Linc Medical
MCI/701
|
Bladder Infusion Kit MCI/701 |
2.00 (Box of 10 (19.90) |
These are for administrating catheter maintenance solutions if used more than once a week. The solution can be administered via the sample port rather than removing the bag every time and reducing the need to use more than one bag per week. |
|
23.15 |
Catheter Valves |
Company |
Product Codes |
Price per unit |
Comments |
Qufora |
21104204 |
1.70 |
Box of 5 |
Linc Medical Care-Flo |
CF1 |
1.50 |
Box of 5 |
|
23.10 |
Catheterisation packs - Cath-it (including catheter removal pack) |
Company |
Product Codes |
Price per unit |
Comments |
Richardson Health |
Sizes:
Small-Medium Gloves 908410
Medicum-Large Gloves 908420
|
£2,08each |
Contains 3 pairs of gloves |
|
13.09 |
Ceanel Concentrate® |
Restrict to where moderate to severe skin condition requires it
Shampoo, cetrimide 10%, undecenoic acid 1%
Self Care Medicine
|
05.01.02.01 |
Cefalexin |
|
05.01.02.01 |
Cefixime Suprax® |
For paediatrics and GUM indications only.
DCHFT: 2nd line in GUM for women who are needle phobic. |
05.01.02.01 |
Cefotaxime IV |
Not at RBCH.
DCHFT: For use in paediatrics only. |
11.03.01 |
Ceftazidime 5% drops |
Preservative-free
unlicensed
Not DCHFT. |
05.01.02.01 |
Ceftazidime Injection |
RBCH: On microbiology advice only |
05.01.02.01 |
Ceftazidime with Avibactam Zavicefta® |
Approved at RBCH and PHT only when recommended by a Consultant Microbiologist |
05.01.02.01 |
Ceftriaxone IV |
RBCH: 1st line for suspected meningitis |
05.01.02.01 |
Cefuroxime Zinacef® |
RBCH: Oral formulations not available - use cefalexin
DCHFT: Oral formulations not available - use cefalexin |
11.03.01 |
Cefuroxime drops 5% |
Preservative-free
unlicensed
RBCH: Store in freezer until required for use.
DCHFT: Consultant use only. Unlicensed cefuroxime 5% kits available. Unlicensed frozen storage product not routinely stocked. |
05.01.02.01 |
Cefuroxime IV Zinacef® |
|
10.01.01 |
Celecoxib Celebrex® |
There is no good evidence to support the use of coxibs alone instead of NSAIDs co-prescribed with a PPI. Coxibs also have a higher CV risk than ibuprofen 1200mg/day or naproxen 1000mg/day (MeReC Extra no.30, Nov 2007). |
08.01.05 |
Cemiplimab Libtayo® |
Commissioned in accordance with CDF policy and NICE TA592. |
08.02.03 |
Ceredase® Alglucerase |
Trusts are responsible for making the necessary arrangements for patients to receive intravenous treatment. |
08.01.05 |
Ceritinib Zykadia® |
Commissioned by NHS England in line with NICE TA395 and TA500. |
09.03 |
Cernevit® |
Not DCHFT. |
10.01.03 |
Certolizumab Pegol Cimzia® |
Use in accordance with NICE guidance and local pathways for RA, AS or PSA. Not routinely commissioned by NHS England for paediatric indications - see NHS England drugs list. |
13.05.03 |
Certolizumab pegol Cimzia® |
For treatment of plaque psoriasis as per NICE TA 574 |
03.04.01 |
Cetirizine |
Tablets, syrup.
Self Care Medicine for primary care.
|
13.02.01 |
Cetomacrogol A cream |
For use in genital areas |
13.02.01 |
Cetraben® |
Emollient cream; white soft paraffin 13.2%, light liquid paraffin 10.5% Excipients include cetostearyl alcohol Hydroxybenzoates (parabens) are no longer included as an excipient as per up to date SPC from manufacturer - BNF in the process of being updated.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
13.02.01.01 |
Cetraben® |
Reserved for patients with severe eczema and infants under the age of 1 year.
Emollient bath additive, light liquid paraffin 82.8%
Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.
Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required
|
08.01.05 |
Cetuximab Erbitux® |
For use in line with NICE TA recommendations. |
08.01 |
Chemotherapy drugs |
Commissioned by NHS England/CDF as per Trust Guidelines, NICE/CDF policy. |
04.01.01 |
Chloral Hydrate |
PGH: For use as part of the paediatric sedation guideline only. |
04.01.01 |
Chloral Hydrate |
|
04.01.01 |
Chloral Hydrate 500mg in 5mL |
|
08.01.01 |
Chlorambucil Leukeran® |
|
11.03.01 |
Chloramphenicol drops 0.5% |
|
11.03.01 |
Chloramphenicol ointment 1% |
|
05.01.07 |
Chloramphenicol oral or IV |
PHT: For microbiology use only.
RBCH: IV in accordance with local policy; Oral on microbiology advice only.
DCHFT: IV in accordance with local policy (e.g. as per meningitis guideline). Otherwise, on microbiology advice only.
|
04.01.02 |
Chlordiazepoxide |
For alcohol withdrawal. |
13.11.02 |
Chlorhexidine |
Various preparations available - see BNF |
13.11.02 |
Chlorhexidine 0.015% with Cetrimide 0.15% Tisept®; Travasept100® |
|
07.04.04 |
Chlorhexidine 0.02% |
|
13.11.02 |
Chlorhexidine 2% in Isopropyl Alcohol 70% ChloraPrep® |
Not DCHFT. |
11.03.01 |
Chlorhexidine Digluconate 0.03% drops |
Unlicensed
Not DCHFT. |
12.03.04 |
Chlorhexidine gluconate dental gel 1% |
Also used as part of oral hygiene protocols for ventilated patients in Critical Care to prevent VAP Unlicensed
Self Care Medicine for primary care.
|
12.03.04 |
Chlorhexidine gluconate mouthwash 0.2% |
Self Care Medicine for primary care.
|
15.02 |
Chloroprocaine Ampres® |
Injection.
DCHFT: Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes. |
05.04.01 |
Chloroquine |
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel |
02.02.01 |
Chlorothiazide |
Suspension.
Unlicensed
Suspension 250mg/5ml for paediatric use only. Available as an unlicensed import.
|
03.04.01 |
Chlorphenamine (Chlorpheniramine) |
Tablets, syrup. Sedating option
Self Care Medicine for primary care.
|
03.04.01 |
Chlorphenamine IV |
Sedating option |
04.02.01 |
Chlorpromazine |
Hospital or specialist initiation.
Option based on NICE guidance and licence.
Tablet, Oral solution, Suppository.
Use of intramuscular chlorpromazine is not recommended - can cause marked postural hypotension.
|
04.06 |
Chlorpromazine Hydrochloride |
Tablets, syrup, elixir,.
Palliative care. |
04.06 |
Chlorpromazine Hydrochloride Injection |
|
06.05.01 |
Chorionic gonadotrophin Choragon®, Pregnyl® |
|
03.02.01 |
Ciclesonide Alvesco® |
Inhaler. |
01.05.03 |
Ciclosporin |
Capsules, injection.
MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands.There are a number of different indications for ciclosporin. Please see
here for other indications.
Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults Unlicensed for these indications but in line with national guidelines. |
08.02.02 |
Ciclosporin |
Commissioned by NHS England (for transplant immunosuppression only) for new patients only until formal repatriation of existing patients to specialist centres agreed, timescales to achieve this are variable. As per Trust Guidelines. Hospital initiation. |
10.01.03 |
Ciclosporin |
For rheumatoid arthritis in accordance with NICE recommendations (CG79). |
13.05.03 |
Ciclosporin |
Hospital use only For severe psoriasis or severe eczema DCHFT: Ciclosporin prescribing should be brand specific. Currently DCHFT does not stock Capimune®. Neoral® is currently the brand of choice at DCHFT. Consultant use only. |
11.08.01 |
Ciclosporin 0.1% eye drops Ikervis® |
In accordance with NICE TA369 and Dorset Dry Eye Pathway for severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes. Preservative-free RBCH: Consultant initiation |
05.03.02.02 |
Cidofovir Vistide® |
Commissioned by NHS England (for cytomegalovirus) according to agreed Trust Guidelines. |
01.03.01 |
Cimetidine |
Specialist use only - Dermatology and Palliative Care (both 'off-label' use).
During the shortage of ranitidine, you can supply cimetidine, nizatidine or famotidine as a last resort
|
09.05.01.02 |
Cinacalcet Mimpara® |
Commissioned by NHS England for refractory secondary hyperparathyroidism in patients with end-stage renal disease in accordance with criteria in NICE TA 117
DCHFT - renal consultant only |
09.05.01.02 |
Cinacalcet |
Commissioned by NHS England (for complex primary hyperparathyroidism) for specialist centres.
|
01.07.02 |
Cinchocaine with hydrocortisone |
Ointment, suppositories
Brands include Proctosedyl® and Uniroid HC® |
01.07.02 |
Cinchocaine with prednisolone |
Ointment, suppositories.
Brands include: Scheriproct® |
04.06 |
Cinnarizine |
Tablets. Antihistamine option.
Self Care Medicine for primary care.
|
12.01.01 |
Ciprofloxacin ear drops (single use) 2mg/ml Cetraxal® |
As Second line choice only in Primary Care, based on sensitivities |
12.01.01 |
Ciprofloxacin eye 0.3% Drops Ciloxan® |
ENT use only: Treatent of ear infection
1st line - use licensed ear drops 1st line in ear.
2nd line - use eye drops in the ear - Off label use (UNLICENSED ROUTE) |
05.01.12 |
Ciprofloxacin IV |
RBCH: Strictly on microbiology advice only or in accordance with neutropenic sepsis policy
Excellent oral bioavailability - use oral route where possible |
05.01.12 |
Ciprofloxacin oral |
RBCH: Strictly on microbiology advice only or in accordance with neutropenic sepsis policy
DCHFT: As per antibiotic treatment guidelines only. |
15.01.05 |
Cisatracurium Nimbex® |
Not RBCH.DCHFT: Only stocked to cover vecuronium shortages. Used as alternative non-depolarising neuromuscular blocker with low potential for histamine release for use in those patients who are allergic/intolerant to the other more commonly used agents such as atracurium and rocuronium.
|
08.01.05 |
Cisplatin |
|
04.03.03 |
Citalopram |
|
01.06.05 |
CitraFleet® |
Oral powder.
- Choice to be determined by Trust.
- DCHFT: Picolax® oral powder used as alternative.
|
08.01.03 |
Cladribine Leustat®, Litak® |
|
08.02.04 |
Cladribine Mavenclad® |
Commissioned by NHS England for treatment of highly active relapsing multiple sclerosis at approved centres in accordance with NICE TA616. |
05.01.05 |
Clarithromycin IV |
|
05.01.05 |
Clarithromycin oral |
|
A5.02.02 |
Clearfilm® |
All sizes are on the formulary |
19.15 |
Clearway Bridge |
Opus Healthcare Product reference code 7700 Approved pack size 30 AMBER – Used to help prevent leaks caused by pancaking of stool when problem not solved by simple measures |
19.15 |
Clearway Bridge Mini |
Opus Healthcare Product reference code 8800 Approved pack size 30 AMBER – Used to help prevent leaks caused by pancaking of stool when problem not solved by simple measures |
05.01.06 |
Clindamycin |
|
13.06.01 |
Clindamycin 1% |
Topical solution, clindamycin 1% (as phosphate), in an aqueous alcoholic basis
Excipients include propylene glycol
Lotion, clindamycin 1% (as phosphate) in an aqueous basis
Excipients include cetostearyl alcohol, hydroxybenzoates (parabens |
07.02.02 |
Clindamycin 2% Cream Dalacin® |
Excipients include benzyl alcohol, cetostearyl alcohol, polysorbates, propylene glycol May damage latex condoms and diaphragms
|
05.01.06 |
Clindamycin IV |
|
A5.08.03 |
Clinifast |
Tubular bandage for fixation/retention and wet and dry wrapping
Red Line 3.5cm x 1m
Green Line 5cm x 1m / 3m / 5m
Blue Line 7.5cm x 1m / 3m / 5m
Yellow Line 10.75 x 1m / 3m / 5m
Beige Line 17.5cm x 1m |
A5.07.03 |
Clinipore Surgical Adhesive Tape |
Permeable Non-Woven Synthetic Adhesive Tape BP 1988
Hypoallergenic and strictly conforms to Drug Tariff specifications
Clinipore is gentle on the skin, leaving minimal adhesive residue upon removal
Available as 1.25cm x 5m / 2.5cm x 5m / 2.5cm x 10cm and 5cm x 5m |
A5.02.08 |
Clinisorb |
Odour control via activated charcoal
CliniSorb is indicated for the management of malodorous wounds. It can be used on fungating wounds and a variety of other chronic wounds with good results.
- CliniSorb can be cut to size if necessary
- CliniSorb can be applied either side down
- A secondary dressing can be applied on top of CliniSorb if appropriate
- CliniSorb can be secured in place using adhesive tape or in a manner appropriate for the indication
- Change when necessary
|
04.08.01 |
Clobazam |
Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.
|
13.04 |
Clobetasol with neomycin and nystatin Non-proprietary |
Cream, clobetasol propionate 0.05%, neomycin sulfate 0.5%, nystatin 100 000 units/g Potency: very potent Ointment, clobetasol propionate 0.05%, neomycin sulfate 0.5%, nystatin 100 000 units/g Potency: very potent
Not DCHFT. |
08.01.03 |
Clofarabine Evoltra® |
Commissioned by CDF for the treatment of relapsed/refractory acute lymphoblastic leukaemia in line with CDF criteria. |
04.01.01 |
Clomethiazole |
See .
|
06.05.01 |
Clomifene Citrate |
Prescribing should fall within NICE CG156:
• Do not offer oral ovarian stimulation agents(such as
clomifene citrate, anastrozole or letrozole) to women
with unexplained infertility, and
• For women who are taking clomifene citrate, do not
continue treatment for longer than 6 months.
In accordance with the product SPC, 3 courses should constitute an adequate trial.
Due to the limited length of time it is used and that patients are likely to be receiving ongoing care in a specialist setting the number of requests to pick up this prescribing in primary care should be minimal.
|
04.03.01 |
Clomipramine |
|
04.08.01 |
Clonazepam |
Tablets.
Options based on licence.
Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
04.08.02 |
Clonazepam IV |
|
02.05.02 |
Clonidine injection Catapres® Ampoules |
Injection.
DCHFT: Tablets on formulary. Awaiting CCG advice on traffic light categorisation (Nov 2014). |
02.09 |
Clopidogrel |
Tablets.
- In accordance with NICE recommendations for the use of clopidogrel in the treatment of non-ST-segment-elevation in ACS (TA80), clopidogrel should be used for up to 12 months.
- Post stent insertion (unless follows acute coronary syndrome, see above):
- clopidogrel should be used for 1 month following insertion of non-drug eluting stent. - clopidogrel should be used for 12 months following insertion of a drug-eluting stent.
- Update from the Cardiology Working Group July 2020 : The interaction of omeprazole on the antiplatelet efficacy of clopidogrel is no longer considered clinically significant.
|
07.02.02 |
Clotrimazole |
Self Care Medicine for primary care.
|
13.10.02 |
Clotrimazole |
Cream, clotrimazole 1%
Self Care Medicine for primary care.
|
11.03.02 |
Clotrimazole drops 1% |
Preservative free
unlicensed
Not RBCH
DCHFT: On formulary but not stocked. |
12.01.01 |
Clotrimazole topical solution 1% Canesten® |
Solution, clotrimazole 1% in polyethylene glycol 400 (macrogol 400).
Self Care Medicine for primary care.
|
04.02.01 |
Clozapine tablets Clozaril |
To be initiated by consultant psychiatrist only. For treatment-resistant schizophrenia. Clozaril is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed. 24 hour helpline number for CPMS 08457 698269. Use in accordance with NICE recommendations for the treatment and management of psychosis and schizophrenia in adults (CG178 which replaces CG82) and local shared care guideline. (Amber in original pilot sites.)
|
02.08.02 |
CoaguChek® |
Testing strips
Added March 2020
Review September 2020 |
13.05.02 |
Coal tar strong in emulsifying ointment |
Extemporaneous product. unlicensed |
13.05.02 |
Coal tar strong with betamethasone |
Extemporaneous product Unlicensed
Not RBCH: prescribe coal tar and steroids separately |
05.01.01.03 |
Co-Amoxiclav |
|
05.01.01.03 |
Co-Amoxiclav IV Augmentin® |
RBCH: On microbiology advice |
04.09.01 |
Co-Beneldopa |
Capsules, dispersible tablets, modified release capsules.
= Benserazide/Levodopa. |
05.03.01 |
Cobicistat Tybost® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs).
|
15.02 |
Cocaine |
DCHFT Only: 10% sterile nasal solution. Unlicensed. |
11.07 |
Cocaine 4% Eye Drops |
Unlicensed
For diagnosis of Horner's syndrome
DCHFT: Not routinely stocked. |
04.09.01 |
Co-Careldopa |
Tablets, modified release tablets.
= Carbidopa/levodopa. |
04.09.01 |
Co-Careldopa and Entacapone Stalevo® |
Tablets.
In accordance with local guidance on drug treatment of Parkinson's disease and shared care guidance. |
04.09.01 |
Co-Careldopa Intestinal gel Duodopa® |
Hospital only. Use following individual patient funding approval. For use with enteral tube. Commissioned by NHS England (for PD) but not routinely. |
04.07.01 |
Co-Codamol |
Preferred formulation - tablets
Co-Codamol Soluble are considered 2nd Line
Self Care Medicine for primary care.
|
13.06.02 |
Co-Cyprindiol 2000/35 |
Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms (equiv. Dianette®). |
01.06.02 |
Co-danthramer |
Suspension.
For relief of constipation in palliative care.
|
01.06.02 |
Co-danthrusate |
Capsules.
For relief of constipation in palliative care. |
01.04.02 |
Codeine phosphate |
Tablets.
Alternative prescribing option. |
04.07.02 |
Codeine Phosphate |
Tablets.
|
04.07.01 |
Co-dydramol |
Tablets.
Updated Information February 2018: Previously co-dydramol (dihydrocodeine/paracetamol) was available only in the ratio 1:50 (co-dydramol 10/500 mg). Two additional products are now available with a higher strength of dihydrocodeine (codydramol 20/500 mg and 30/500 mg tablets). It is therefore important that co-dydramol products are prescribed and dispensed by strength to minimise dispensing errors and the risk of accidental opioid overdose. |
19.04 |
Cohesive Paste® |
Pelican Healthcare Ltd Product reference code 839010 Approved pack size 60g |
10.01.04 |
Colchicine |
|
09.06.04 |
Colecalciferol 20,000 units |
In accordance with local guidance for the management of vitamin D deficiency and insufficiency in adults. Note dose is WEEKLY. Prescribers should use a LICENSED brand (e.g.Fultium D3®; Aviticol®;Plenachol®).
Many other 20,000unit preparations are available(e.g.Pro D3®, Dekristol®). These do not have a marketing authorisation as they are marketed as nutritional supplements. unlicensed
|
09.06.04 |
Colecalciferol 800 units |
Prescribers should use a LICENSED product (e.g. Fultium D3®, Invita D3®;Desunin®)
In accordance with local guidance for the management of vitamin D deficiency and insufficiency in adults. |
09.06.04 |
Colecalciferol and Calcium Carbonate Calcichew-D3® |
Not at DCHFT and RBCH. |
09.06.04 |
Colecalciferol and Calcium Carbonate Calcichew-D3® Forte |
Not at DCHFT and RBCH. |
09.06.04 |
Colecalciferol oral drops 2740 units/ml Fultium D3®, |
|
01.09.02 |
Colesevelam Cholestagel® |
For Bile Acid Malabsorption as a second line option where colestyramine has been found to be not effective or not tolerated. |
01.09.02 |
Colestyramine |
Powder. |
02.12 |
Colestyramine |
Sachets. |
05.01.07 |
Colistimethate for nebulisation Colomycin®, Colistin®, Promixin® |
Commissioned by NHS England for use in CF as per policy A01/P/b.
- If provided by primary care for Cystic Fibrosis prior to April 2013 as per shared care guidelines.
- For non-cystic fibrosis bronchiectasis as per shared care guidelines (Colomycin brand only).
For CF patients initiated after April 2013:
- Adult patients: specilaist centres only.
- Paediatric patients: PHFT use in line with network arrangements with UHS.
|
05.01.07 |
Colistimethate inhaler Colobreathe® |
Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA276.
Adult patients: specialist centre only (University Hospital Southampton)
Paediatric patients: DCH & PHFT use in line with network arrangements with UHS.
Not at RBCH. |
10.03.01 |
Collagenase |
For use in Dupuytren's Contracture in line with the existing criteria for access to treatment within the policy for common hand conditions.
Xiapex® has now been discontinued |
07.03.01 |
Combined Hormonal Contraceptives Evra® |
Transdermal combined contraceptive patch, which contains norelgestromin and ethinyloestradiol.
Refer to local guidance.
DCHFT: On local formulary. |
A5.02.04 |
Comfeel Plus Transparent Dressing |
Comfeel Plus Transparent is a thin and flexible hydrocolloid dressing.
Key benefits:
- Transparency for wound inspection
- Flexibilty to dress any part of the body
|
A2.02.02.03 |
Complan® Shake |
The calories are based on a sachet made up with 200ml of full cream milk and contain approx. 385 kcals.
If your patient likes milky drinks prescribe as a supplement to diet 1-2 servings/day.
Not suitable for patient with cow’s milk intolerance or galactosaemia. Not nutritionally complete.
If your patient dislikes milky drinks choose from the juice style supplements instead. |
09.02.02.01 |
Compound Sodium Lactate Intravenous Infusion Compound Hartmann's Solution for Injection |
RBCH: 1st line for fluid resuscitation
DCHFT: Rarely used |
13.07 |
Condyline® |
Hospital use only
Solution, podophyllotoxin 0.5% in alcoholic basis |
03.04.03 |
Conestat Alfa Ruconest® |
Commissioned by NHS England for Hereditary Angioedema (acute treatment only) and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy B09/P/b.
May only be initiated by (or on advice of) Specialist Centres where:
there is a contraindication to the use of C1 esterase inhibitor derived from blood products(for obstetric, religious or medical reasons)
the specialist determines that it will be more cost effective or clinically effective than the alternatives
Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre |
07.04.05 |
Constrictor rings for erectile dysfunction |
Hospital initiation only.
DCHFT: Not Pharmacy. |
06.01.06 |
Contour® Test Strips |
|
05.01.08 |
Co-trimoxazole IV Septrin® |
|
05.01.08 |
Co-trimoxazole oral Septrin® |
|
08.01.05 |
Crisantaspase |
|
08.01.05 |
Crizotinib Xalkori® |
Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422. |
13.02.02 |
Cutimed Protect Cream® |
- Protects wound margins and peri-wound skin from external factors including wound exudate, incontinence and friction, caused by urinary and/or faecal incontinence
- Preserves and maintains intact or irritated skin by building a moisture barrier with good permeability to oxygen and water vapour
- Prevention of incontinence dermatitis
- Prevents maceration by providing up to 96 hours of moisture barrier action
- Effective adjunctive skin therapy during treatment of chronic wounds e.g. venous or arterial, diabetic foot or pressure ulcers, or whenever skin requires a protective shield
|
13.02.02 |
Cutimed Protect Foam Applicators® |
|
13.02.02 |
Cutimed Protect Spray® |
Enables easy, even application over a wide area to protect peri-wound and irritated skin.
Alcohol and irritant free, non-stinging solution
|
A5.03 |
Cutimed Sorbact Gel Dressings |
Cutimed Sorbact gel dressings reduce bacterial load in a wound by combining Cutimed Sorbact swab with an amorphous hydrogel to support moist wound healing in lower exuding or sloughy wounds.
Available as 7.5cm x 15cm and 7.5cm x 7.5cm
|
A5.03 |
Cutimed Sorbact Ribbon |
Cutimed Sorbact can be used for all contaminated, colonised and infected, exuding wounds such as pressure, diabetic foot and venous leg ulcers. Also suitable for traumatic and post-operative wounds.
Available as 5cm x 200cm and 2cm x 50cm |
A5.03 |
Cutimed Sorbact Swabs |
All sizes approved for addition to the Joint Wound Formulary April 2018 |
09.01.02 |
Cyanocobalamin |
Cyanocobalamin is considered less suitable to prescribe in the BNF, hydroxocobalamin is now the preferred preparation.
As per Dorset guidline on "Investigation and Treatment of Adult Vitamin B12 (Cobalamin) Deficiency in Primary Care": Cyanocobalamin 50microgram tablets are Green on the formulary but are expensive on NHS so patients should be encouraged to purchase cheaper OTC supplements.
Prescribing should follow NHS England OTC guidance for vitamins i.e. proven deficiency due to chronic medical condition or surgery resulting in malabsorption |
04.06 |
Cyclizine |
Tablets. Antihistamine option.
Self Care Medicine for primary care.
|
21 |
Cyclizine |
|
04.06 |
Cyclizine Injection |
Formulary status does not apply for palliative care indications. |
11.05 |
Cyclopentolate Hydrochloride drops 0.5% |
Not RBCH |
11.05 |
Cyclopentolate Hydrochloride drops 1% |
|
08.01.01 |
Cyclophosphamide |
|
10.01.03 |
Cyclophosphamide |
IV and oral |
18 |
Cyproheptadine Periactin® |
Anticholinergic (antimuscarinic) antihistamine used in serotonin syndrome.
RBCH: kept in EDC and pharmacy |
06.04.02 |
Cyproterone Acetate |
|
08.03.04.02 |
Cyproterone Acetate |
|
08.01.03 |
Cytarabine |
|
02.08.02 |
Dabigatran Pradaxa® |
Capsules.
For prevention of stroke or systemic embolism in patients with AF within NICE TA249 and local guidance, as per licensed indications.
|
02.08.02 |
Dabigatran Pradaxa® |
Capsules.
For the prevention of venous thromboembolism after hip or knee replacement surgery in adults, in accordance with NICE TA157.RBCH:1st line option is dalteparin.DCHFT: 1st line option is enoxaparin.
|
02.08.02 |
Dabigatran Pradaxa ® |
For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA327
|
02.08.02 |
Dabigatran Pradaxa® |

- In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
- Note routine 1st line option at RBCH and DCH is LMWH

- For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
- For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA.
|
08.01.05 |
Dabrafenib Tafinlar® |
Commissioned by NHS England in line with NICE TA321, TA396 and TA544.
TA396 and TA544 require BlueTeq prior approval.
|
08.01.05 |
Dacarbazine |
|
05.03.03.02 |
Daclatasvir Daklinza® |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
08.01.05 |
Dacomitinib Vizimpro® |
In accordance with NICE TA595 |
08.01.02 |
Dactinomycin |
|
13.04 |
Daktacort® cream |
Cream, hydrocortisone 1%, miconazole nitrate 2% Potency: mild Excipients include butylated hydroxyanisole, disodium edetate
Self Care Medicine for primary care - Hydrocortisone 1% / Miconazole 2% cream 15g pack
|
13.04 |
Daktacort® ointment |
Ointment, hydrocortisone 1%, miconazole nitrate 2%
Potency: mild |
13.10.02 |
Daktarin® |
Cream, miconazole nitrate 2% Excipients include butylated hydroxyanisole
Self Care Medicine for primary care.
|
05.01.07 |
Dalbavancin |
PHFT only:
For treatment of cellulitis when approved by microbiology
For treatment of bone and joint infections (including spinal abscess, discitis, osteomyelitis and septic arthritis) when approved by microbiology and who are suitable for discharge and:
- Compliance with daily IV or oral antibiotics is likely to be an issue and are therefore at risk of treatment failure and readmission
- Discharge with an IV cannula is likely to be a risk e.g. IVDU
- Is likely to decline treatment / self-discharge and therefore likely to have repeated readmissions
- Are identified as suitable for early discharge in which oral antibiotics would not be appropriate and were not requiring any other medical/therapy interventions.
|
09.06.07 |
Dalivit® |
RBCH Tube-fed /Swallowing difficulites who would otherwise require Sanatogen A-Z |
02.08.01 |
Dalteparin Fragmin® |
for DVT in patients who are intravenous drug users.
Specialist initiation:
Please use in accordance with the relevant local shared care guidance.
for specialist indications, e.g. prevention of clotting in the extracorporeal circuit during haemodialysis, not listed above.
|
02.08.01 |
Danaparoid Orgaran® |
Injection.
For consultant use only on haematological advice. |
06.07.02 |
Danazol |
|
19.01 |
Dansac EasiSpray™ adhesive remover |
Dansac Ltd Product Reference Code 083-01 Approved Pack Size 50ml |
18 |
Dantrolene IV |
For malignant hyperthermia, neuroleptic malignant syndrome (NMS). Other drug related pyrexia seek NPIS advice.
RBCH: Kept in ITU and Theatres |
10.02.02 |
Dantrolene sodium |
Specialist use.
DCHFT: Specialist / Consultant use only. |
15.01.08 |
Dantrolene sodium Dantrium Intravenous® |
Injection. |
06.01.02.03 |
Dapagliflozin Forxiga® |
When used with oral hypoglycaemics in patients with Type 2 Diabetes
When used with insulin in patients with Type 2 Diabetes
When used in Type 1 diabetes in combination with insulin
|
05.01.10 |
Dapsone |
|
05.01.07 |
Daptomycin Cubicin® |
On microbiology advice only |
08.01.05 |
Daratumumab DARZALEX® |
Commissioned by CDF for use as monotherapy in line with NICE TA510 and CDF criteria.
Commissioned by CDF for use in combination with bortezomib and dexamethasone in line with NICE TA573 and CDF criteria. |
09.01.03 |
Darbepoetin Aranesp® |
Commissioned by NHS England (for dialysis-induced anaemia including via outpatients and only as per NICE CG114) and Trust Guidelines. |
08.03.04.02 |
Darolutamide Nubeqa® |
Commissioned by NHSE in combination with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer at high risk of developing metastatic disease as per NICE TA 660. |
05.03.01 |
Darunavir Prezista® |
Commissioned by NHS England for use in HIV in combination with other antiretrovirals as per BHIVA Guidelines. |
05.03.01 |
Darunavir & Cobicistat Rezolsta® |
Commissioned by NHS England (HIV in combination with other anti-retrovirals) |
05.03.01 |
Darunavir 800mg / Cobicistat 150mg / Emtricitabine 200mg / Tenofovir alafenamide 10mg Symtuza® |
Restricted for use according to NHSE Commissioning requirements and BHIVA guidelines. |
05.03.03.02 |
Dasabuvir Exviera® |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
08.01.05 |
Dasatinib Sprycel® |
Commissioned by NHS England in line with NICE TA425 and TA426. |
08.01.02 |
Daunorubicin |
DCHFT: Daunorubicin 20mg injection and daunorubicin lipid formulation (liposomal) DaunoXome® 50mg injection listed on formulary.
|
09.03 |
Decan® |
Not DCHFT. |
09.01.03 |
Deferasirox Exjade® |
Commissioned by NHS England for iron chelation in thalassaemia and sickle cell. |
09.01.03 |
Deferiprone Ferriprox® |
Commissioned by NHS England for iron chelation in thalassaemia and sickle cell. |
08.03.04.02 |
Degarelix Firmagon® |
Consultant urologist use for a SINGLE DOSE in naive prostate cancer that present with emergencies such as:
Spinal cord compression.
Severe uraemia due to malignant ureteric obstruction.
Impending long bone pathological fracture.
OR
in accordance with NICE TA404 |
09.06.07 |
DEKAs Essential/DEKAs Plus |
Fat-soluble vitamin supplements for use when recommended by specialist in patients with cystic fibrosis. Specialists to ensure preferred formulation and dose is clearly communicated to primary care prescribers |
06.05.02 |
Demeclocycline |
RBCH: Needs Endocrine CONSULTANT approval |
06.06.02 |
Denosumab 120mg XGEVA® |
In accordance with NICE TA265 for the prevention of skeletal-related events in patients with bone metastases from breast cancer and from solid tumours other than prostate. |
06.06.02 |
Denosumab 60mg Prolia® |
In accordance with NICE TA204 and local shared care guideline for the prevention of fragility fractures. |
13.08 |
DEPIGMENTING lotion 50ml |
unlicensed
Not DCHFT. |
07.03.02.02 |
Depo-Provera® |
Injection (aqueous suspension), medroxyprogesterone acetate 150 mg/mL
DCHFT: Family planning only. |
07.02.02 |
Dequalinium chloride 10mg vaginal tablets Fluomizin® |
Nov 18: Approved for use at RBCH as 2nd line agent |
13.10.04 |
Derbac-M® |
Liquid, malathion 0.5% in an aqueous basis Excipients include cetostearyl alcohol, fragrance, hydroxybenzoates (parabens)
Self Care Medicine for primary care.
|
13.02.01 |
Dermatonics Heel Balm® |
An alternative to Flexitol® with 25% Urea content
Self Care Medicine for primary care.
|
13.09 |
Dermax® |
Shampoo, benzalkonium chloride 0.5%
Self Care Medicine for primary care.
|
13.02.01.01 |
Dermol 200® |
Shower Emollient, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin 2.5%, isopropyl myristate 2.5% Excipients include cetostearyl alcohol
Self Care Medicine for primary care.
Age restriction of under one year or patients with severe conditions |
13.02.01.01 |
Dermol 600® |
Bath Emollient, benzalkonium chloride 0.5%, liquid paraffin 25%, isopropyl myristate 25% Excipients include polysorbate 60
Self Care Medicine for primary care.
Age restriction of under one year or patients with severe conditions |
13.02.01 |
Dermol® 500 |
Lotion, benzalkonium chloride 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin 2.5%, isopropyl myristate 2.5% Excipients include cetostearyl alcohol
Self Care Medicine for primary care.
|
13.04 |
Dermovate 60% and propylene glycol 40% |
Extemporaneous product Hospital only |
13.04 |
Dermovate® |
Cream, clobetasol propionate 0.05%
Potency: very potent
Excipients include beeswax (or beeswax substitute), cetostearyl alcohol, chlorocresol, propylene glycol
Ointment, clobetasol propionate 0.05%
Potency: very potent
Excipients include propylene glycol |
13.04 |
Dermovate® |
Scalp application, clobetasol propionate 0.05%, in a thickened alcoholic basis Potency: very potent |
18 |
Desferrioxamine |
For iron poisoning. RBCH: kept in ED resus and Pharmacy |
09.01.03 |
Desferrioxamine Mesilate |
Commissioned by NHS England for iron chelation in thalassaemia and sickle cell. |
15.01.02 |
Desflurane Suprane® |
Anaesthetic. |
06.05.02 |
Desmopressin acetate Injection DDAVP® or Octim® |
DDAVP® (4mcg/ml) injection and Octim® (15mcg/ml) injection are NOT interchangeable - see SPC/BNF for indications and doses.
|
06.05.02 |
Desmopressin oral/intranasal/sublingual |
Octim® nasal spray and Noqdirna® 25mcg/50mcg oral lyophilisates (for idiopathic nocturia in adults) are non-formulary.
|
07.03.02.01 |
Desogestrel 75 micrograms. Cerazette® |
DCHFT: Not stocked.
|
06.03.02 |
Dexamethasone |
For specific indications |
10.01.02.02 |
Dexamethasone |
|
21 |
Dexamethasone |
|
11.04.01 |
Dexamethasone drops 0.1% Maxidex® |
|
11.04.01 |
Dexamethasone for ocular injection |
Not DCHFT. |
11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
Commissioned by CCG for use in accordance with NICE TA229, TA 349 and TA460. |
04.04 |
Dexamfetamine |
Tablets.
For ADHD in children. Refer to local shared care guideline.
DCHFT: Consultant psychiatrist only. |
15.01.04.04 |
Dexmedetomidine Dexdor® |
RED - Critical care use only at PHT |
08.01 |
Dexrazoxane Cardioxane®, Savene® |
Commissioned by NHS England - use in accordance with agreed Trust Guidelines, for the treatment of anthracycline extravasation.
Commissioned by NHSE for preventing cardiotoxicity in children and young people (<25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer as per Commissioning Statement SSC 2137. Not routinely commissioned by NHS England for anthracycline cardiotoxicity outside the above indications. |
06.01.04 |
Dextrogel® |
Not at RBCH
Not at DCHFT |
04.07.02 |
Diamorphine |
Injections.
|
21 |
Diamorphine injection |
|
04.01.02 |
Diazepam |
See Primary care protocol for anxiety disorders. |
10.02.02 |
Diazepam |
|
15.01.04.01 |
Diazepam |
Tablet, oral solution, injection.
Red - when used as a premedication. See section 4.1.2 for other uses.
|
21 |
Diazepam injection |
|
04.08.02 |
Diazepam IV |
|
04.08.02 |
Diazepam rectal solution |
|
21 |
Diazepam rectal tubes |
|
06.01.04 |
Diazoxide Eudemine® |
Specialist initiation only |
11.03.01 |
Dibrompropamidine Isetionate ointment 0.15% Brolene® |
Acanthamoeba keratitis (unlicensed indication)
DCHFT: Consultant use only. Not routinely stocked. |
10.01.01 |
Diclofenac |
|
10.01.01 |
Diclofenac Injection Voltarol® |
|
11.08.02 |
Diclofenac Sodium unit dose drops 0.1% Voltarol® Ophtha |
|
21 |
Diclofenac suppositories |
|
18 |
Dicobalt edetate IV |
For severe cyanide poisoning.
RBCH: kept in Emergency Drug Cupboard |
01.02 |
Dicycloverine hydrochloride |
Tablets, syrup. |
05.03.01 |
Didanosine Videx® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines. |
08.03.01 |
Diethylstilbestrol |
Hospital initation |
13.06.01 |
Differin® |
Cream, adapalene 0.1%
Excipients include disodium edetate, hydroxybenzoates (parabens)
Gel, adapalene 0.1%
Excipients include disodium edetate, hydroxybenzoates (parabens), propylene glycol |
02.01.01 |
Digoxin |
Tablets, Elixir, (Injection - secondary care only) Bioavailabilities are approximately: Injection 100%, Liquid 80%, Tablets 70%.
July 2019: Amber for new heart failure patients in accordance with NICE Guidance NG106 |
02.01.01 |
Digoxin specific antibody fragments DigiFab ® |
Specific manufacturers - refer to www.toxbase.org |
18 |
Digoxin specific antibody fragments Digifab® |
For digoxin overdose - see Dorset-wide guideline. |
04.07.02 |
Dihydrocodeine |
Tablets, elixir.
Short-term use only. |
04.07.02 |
Dihydrocodeine Injection |
|
02.06.02 |
Diltiazem 60mg Tablets |
Although the means of formulation has called for the strict designation ‘modified-release’ the duration of action corresponds to that of tablets requiring administration 3 times daily. |
02.06.02 |
Diltiazem Extended Release |
Extended Release Capsules/tablets for once daily dosing
Slozem® products XL discontinued December 2019
- RBH + PHFT: use Viazem® XL
|
02.06.02 |
Diltiazem Modified Release |
Modified release capsules/tablets. for twice daily dosing
|
08.02.04 |
Dimethyl fumarate Tecfidera® |
Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA320. |
13.05.02 |
Dimethyl fumarate Skilarence® |
|
16.01 |
Dimethyl Sulfoxide 99% solution |
Used for management of extravasation of cytotoxic chemotherapy. |
07.04.04 |
Dimethyl sulfoxide Bladder Instillation 50% and 90% |
DCHFT: 50% only. |
13.07 |
Dinitrochlorobenzene (DNCB) |
Used at Poole Hospital NHS Foundation Trust |
07.01.01 |
Dinoprostone |
|
08.01.05 |
Dinumtuximab Qarziba® |
Commissioned by NHSE in line with NICE TA538 at or under shared care with a neuro-oncology centre. |
13.07 |
Diphenycyclopropenone (DCPN) |
Used at Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust In a variety of strengths ranging from 0.0010% to 7%
DCHFT: Some interest shown by Dermatologists in using. Awaiting formulary application (Dec 2014). Not currently stocked. |
13.02.01 |
Diprobase® |
Cream, cetomacrogol 2.25%, cetostearyl alcohol 7.2%, liquid paraffin 6%, white soft paraffin 15% Ointment, liquid paraffin 5%, white soft paraffin 95%, Excipients include cetostearyl alcohol, chlorocresol DCHFT: Ointment not stocked.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.Â
|
13.04 |
Diprosalic® |
Scalp application, betamethasone (as dipropionate) 0.05%, salicylic acid 2%, in an alcoholic basis, net price 100 mL = £10.10. Label: 28, counselling, application.
Potency: potent
Excipients include disodium edetate |
13.04 |
Diprosalic® |
Ointment, betamethasone (as dipropionate) 0.05%, salicylic acid 3%
Potency: potent |
02.09 |
Dipyridamole MR capsules Persantin® Retard |
Modified release capsule.
Specialist initiation.
Use in accordance with NICE TA210.
|
11.99.99.99 |
Disodium Edetate 0.37% |
Unlicensed
Preservative free |
06.06.02 |
Disodium Pamidronate |
For multiple myeloma and treatment of hypercalcaemia. |
02.03.02 |
Disopyramide |
Capsule, Tablet MR (Injection - secondary care only). Hospital initiation.
- DCHFT: Not routinely stocked.
|
04.10.01 |
Disulfiram |
Tablets. |
13.05.02 |
Dithranol in zinc and salicylic acid Lassar's paste |
Extemporaneous product - made to order unlicensed
0.1%, 0.2%, 0.5%, 1%, 3%, 4%, 5%
|
13.05.02 |
Dithrocream® |
Cream, dithranol 0.1%, 0.25%,0.5%,1% (P status), 2% (POM) Preparations not available for NHS prescription 2% Excipients include cetostearyl alcohol, chlorocresol DCHFT: 0.25% and 2% also stocked. |
02.07.01 |
Dobutamine |
Injection. |
08.01.05 |
Docetaxel |
|
01.06.02 |
Docusate sodium |
Capsules, syrup, paediatric syrup.
- Alternative prescribing option.
Self Care Medicine for primary care.
|
05.03.01 |
Dolutegravir Tivicay® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs).
|
04.06 |
Domperidone |
Tablets, suppositories, suspension.
Domperidone should only be used for the relief of the symptoms of nausea and vomiting (not conditions such as heartburn, bloating or relief of stomach discomfort)
The recommended dose in adults and adolescents over 12 years and over 35kg is 10 mg up to 3 times daily (it is no longer licensed in children under 12 or patients under 35kg).
Domperidone should be used at the lowest effective dose for the shortest possible duration (max. treatment duration should not normally exceed 1 week).
Domperidone is contra-indicated for use in conditions where cardiac conduction is, or could be impaired, or where there is underlying cardiac disease, when administered concomitantly with drugs that prolong the QT interval or potent CYP3A4 inhibitors, and in severe hepatic impairment
Note This advice does not apply to unlicensed uses of domperidone (e.g palliative care) |
04.11 |
Donepezil film-coated tablets |
Specialist initiation and use in accordance with NICE recommendations (TA217).
Refer to local shared care guideline (see below).
|
04.11 |
Donepezil orodispersible tablets |
Alternative prescribing option
|
02.07.01 |
Dopamine |
Injection. |
02.07.01 |
Dopexamine Dopacard® |
Injection. |
03.07 |
Dornase Alfa Pulmozyme® |
Commissioned by NHS England for Cystic Fibrosis in line with policy A01/P/b.
Amber if provided by primary care for Cystic Fibrosis prior to April 2013. For patients initiated after April 2013, Dornase Alfa is restricted to supply from secondary care.
- Adult patients: specialist centre only (University Hospital Southampton)
- Paediatric patients: PHFT use in line with network arrangements with UHS.
Not at DCH or RBCH. |
11.06 |
Dorzolomide 2% with timolol 0.5% Cosopt® |
Preservative free unit dose drops also amber |
11.06 |
Dorzolomide drops 2% Trusopt® |
|
11.06 |
Dorzolomide unit dose drops 2% Trusopt® |
Preservative free |
13.02.01 |
DoubleBase® |
Gel, isopropyl myristate 15%, liquid paraffin 15%
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.Â
|
13.05.02 |
Dovonex® |
Ointment, calcipotriol 50 micrograms/g
Excipients include disodium edetate, propylene glycol |
03.05.01 |
Doxapram |
Injection.
Hospital only. |
02.05.04 |
Doxazosin |
Tablets.
MR formulation is non formulary. |
07.04.01 |
Doxazosin |
|
13.03 |
Doxepin hydrochloride Xepin® |
Cream, doxepin hydrochloride 5%
Excipients include benzyl alcohol
Not at DCHFT. |
13.03 |
Doxepin hydrochloride Oral |
Unlicensed use of a licensed medicine |
08.01.02 |
Doxorubicin Hydrochloride |
|
08.01.02 |
Doxorubicin Hydrochloride Caelyx® |
In accordance with NICE TA91 or CDF policy. |
05.01.03 |
Doxycycline |
RBCH: Policy states to use higher doses than usual: 200mg stat then 100mg TWICE daily
|
13.06.02 |
Doxycycline |
|
13.12 |
Driclor® Aluminium salt |
Restrict to patients in exceptional circumstances, this is a Self Care Medicine
Application, aluminium chloride hexahydrate 20% in an alcoholic basis Not stocked at RBCH |
02.03.02 |
Dronedarone Multaq® |
Tablets.
In accordance with NICE TA197 and local shared care guideline.
Hospital initiation. |
04.06 |
Droperidol Xomolix® |
RBCH : Consultant Anaesthetist only in Recovery areas for Intractable PONV. |
13.06.01 |
Duac® Once Daily |
Gel, benzoyl peroxide 5%, clindamycin 1% (as phosphate) in an aqueous basis Excipients include disodium edetate
For use within acne guideline when required in combination with antibiotics
|
06.01.02.03 |
Dulaglutide Trulicity® |
When used with oral anti-hyperglycaemics in patients with Type 2 Diabetes
When used in combination with insulin in patients with Type 2 Diabetes
|
04.03.04 |
Duloxetine Cymbalta® |
For depression second choice after SSRIs, also for neuropathic pain in accordance with local guidelines.
|
04.07.03 |
Duloxetine Cymbalta® |
Capsules.
For neuropathic pain in accordance with local guideline.
Alternative prescribing option in diabetic neuropathic pain.
|
07.04.02 |
Duloxetine Yentreve® |
Choice should be based on selecting the most cost-effective option. |
13.08.01 |
Dundee reflective sun creams Dundee Block® |
When prescribed for skin protection against ultraviolet radiation and/or visible light in abnormal cutaneous photosensitivity causing severe cutaneous reactions in genetic disorders (including xeroderma pigmentosum and porphyrias), severe photodermatoses (both idiopathic and acquired) and in those with increased risk of ultraviolet radiation causing severe adverse effects due to chronic disease (such as haematological malignancies), medical therapies and/or procedures.
Self Care Medicine for primary care.
|
A2.04.01.02 |
Duocal® Super Soluble |
For paediatric patients. |
13.05.03 |
Dupilumab Dupixent® |
Commissioned by the CCG for treating Adults with moderate to severe atopic dermatitis, in accordance with NICE TA534 - BlueTeq not required for this indication in Adults!
Commissioned by NHSE in specialist paediatric dermatology centres for the treatment of adolescent patients aged 12 upto 18 years of age with severe atopic dermatitis who have responded inadequately to at least one systemic therapy or where the available systemic therapies are not recommended or are not tolerated who meet criteria set out within NICE TA 534 for adults as per NHS England SSC 2082.
Available via EAMS in specialist paediatric dermatology centres for children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy and where existing systemic therapies are not advisable. |
08.01.05 |
Durvalumab Imfinzi® |
Commissioned by CDF in line with NICE TA578 and CDF criteria. |
06.04.02 |
Dutasteride Avodart® |
|
11.03.02 |
Econazole drops 1% |
Preservative free
unlicensed
Not RBCH
DCHFT: On formulary but not stocked. |
07.02.02 |
Econazole nitrate pessaries/cream Gyno-Pevaryl |
|
09.01.03 |
Eculizumab Soliris® |

Commissioned by NHS England for aHUS as per NHS England Policy E03/PS(HSS)/a: On recommendation from Newcastle specialist centre only. Also commissioned by NHS England for paroxysmal nocturnal haemoglobinuria as per NHS National Specialised Commissioning Team (NSCT) Service Specification.
Not Recommended for treating refractory myasthenia gravis as per NICE TA636 |
02.08.02 |
Edoxaban Lixiana® |
As per NICE TA 354 |
02.08.02 |
Edoxaban Lixiana® |
Recommended as an option in accordance with NICE TA355 for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors, such as: •heart failure, high blood pressure or diabetes •had a stroke or transient ischaemic attack before •aged 75 years or older
|
02.08.02 |
Edoxaban Lixiana® |

- For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
- For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA.
|
05.03.01 |
Efavirenz Sustiva® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs as per BHIVA Guidelines. |
13.09 |
Eflornithine cream Vaniqa® |
Eflornithine 11.5% for facial hirsutism in women. Refer to local guideline. Excipients include cetostearyl alcohol, hydroxybenzoates, stearyl alcohol. |
05.03.03.02 |
Elbasvir with Grazoprevir Zepatier® |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
A2.03.01 |
EleCare® |
Alternative option for cow’s milk protein allergy |
A2.03.01 |
Elemental 028® Extra |
If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered
Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls
Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028
Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae. |
09.08.01 |
Eliglustat Cerdelga® |
To be prescribed by specialist metabolic centres only in accordance with NICE HSTG 5 and NHS England Commissioning criteria.
Approved specialist adult metabolic centres are: „h Addenbrookes „h University Hospital Birmingham „h Salford Royal „h UCLH „h Royal Free Hospital |
06.04.01.01 |
Elleste-Duet ® |
|
06.04.01.01 |
Elleste-Duet Conti ® |
|
06.04.01.01 |
Elleste-Solo® |
Estradiol only |
06.04.01.01 |
Elleste-Solo® MX |
Patches, self-adhesive, |
13.04 |
Elocon® |
Scalp lotion, mometasone furoate 0.1% in an aqueous isopropyl alcohol basis Potency: potent |
13.04 |
Elocon® |
Cream, mometasone furoate 0.1%
Potency: potent
Excipients include beeswax
Ointment, mometasone furoate 0.1%
Potency: potent
Excipients include beeswax, propylene glycol |
09.01.04 |
Eltrombopag Revolade® |
Commissioned by CCG: See commissioning statement
Use in accordance with NICE TA293 |
01.04.02 |
Eluxadoline Truberzi® |
In accordance with NICE TA |
02.11 |
Emicizumab Hemlibra® |
Commissioned by NHSE to prevent or reduce the frequency of bleeding episodes in people with haemophilia A who have factor VIII inhibitors in accordance with Clinical Commissioning Policy 170067/P via haemophilia comprehensive care centres only. |
06.01.02.03 |
Empagliflozin Jardiance® |
When used with oral hypoglycaemics in patients with Type 2 Diabetes When used with insulin in patients with Type 2 Diabetes
|
05.03.01 |
Emtricitabine Emtriva® |
Not routinely commissioned by NHS England for HIV in combination with other anti-retroviral drugs. Policy in progress. |
05.03.01 |
Emtricitabine & Tenofovir alafenamide fumarate Descovy® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines. |
05.03.01 |
Emtricitabine and tenofovir Generic, Truvada® |
Generic product should be used where possible.
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA guidelines. |
05.03.01 |
Emtricitabine, efavirenz and tenofovir Generic, Atripla® |
Generic product should be used where possible.
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines. |
05.03.01 |
Emtricitabine, Elvitegravir, Cobicistat, Tenofovir alafenamide fumarate Genvoya® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines. |
05.03.01 |
Emtricitabine, Rilpivirine hydrochloride & Tenofovir alafenamide fumarate Odefsey® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines. |
13.02.01.01 |
Emulsiderm® |
Liquid emulsion, benzalkonium chloride 0.5%, liquid paraffin 25%, isopropyl myristate 25% Excipients include polysorbate 60
Self Care Medicine for primary care.
Age restriction of under one year or patients with severe conditions |
13.02.01 |
Emulsifying Ointment BP |
Ointment, emulsifying wax 30%, white soft paraffin 50%, liquid paraffin 20% Excipients include cetostearyl alcohol
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
02.05.05.01 |
Enalapril |
Tablets.
Restricted for paediatric or diagnostic use only. |
08.01.05 |
Encorafenib Braftovi® |
Commissioned by CDF in line with NICE TA562 and CDF criteria (in combination binimetinib).
Commissioned by NHSE in combination with Cetuximab as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment in line with NICE TA668. • NOTE: Interim funding is via the CDF until April 6th 2021
|
A2.03.01 |
Enfamil AR® |
Pre-thickened feed for use in severe gastro-oesophageal reflux. |
A2.03.01 |
Enfamil® O-Lac |
For use in proven lactose intolerance (not suitable for use in cow's milk allergy).
If used for temporary lactose intolerance after a bout of gastroenteritis, it should only be used for 6-8 weeks before titrating back onto standard infant formula. |
05.03.01 |
Enfuvirtide Fuzeon® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
|
02.08.01 |
Enoxaparin Inhixa® (biosimilar) or Clexane® |
Two brands are available: Inhixa® and Clexane®.
Enoxaparin -Inhixa® is the preferred brand in Dorset.
Enoxaparin should be BRAND PRESCRIBED and patients should be maintained on the same brand where possible. If a need to switch arises (e.g during shortages) patients should be appropriately counselled on device differences.
for DVT in patients who are intravenous drug users.
for use in accordance with the relevant local shared care guidance.
for specialist indications, e.g. prevention of clotting in the extracorporeal circuit during haemodialysis, not listed above
|
A2.04.01.02 |
Enshake® |
Generally use as a second choice to 1.5kcal/ml sip feeds as not nutritionally complete. However these supplements do provide more calories per ml approx. 600kcal in 250ml so useful for those with very high calorie needs (when reconstituted with whole milk) e.g. CF Patients |
A2.01.02.03 |
Ensure Compact |
NICE CG32 (Feb 2006) Nutrition support in adults
This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume |
A2.02.02.01 |
Ensure Plus Savoury |
NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds |
A2.02.02.02 |
Ensure® Plus Crème |
NICE CG32 Nutrition support in adults
For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds |
A2.02.02.01 |
Ensure® Plus Fibre |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre. |
A2.02.01.02 |
Ensure® Plus Juce |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.
These are not suitable for those with an allergy to cow’s milk. |
A2.02.02.01 |
Ensure® Plus Milkshake style |
NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds |
A2.02.02.01 |
Ensure® Plus Yoghurt style |
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Useful for patients with taste changes e.g. as a side effect to cancer treatments |
A2.02.01.01 |
Ensure® Shake |
Calories are based on a sachet made up with 200ml of full cream milk and contains approx 385 kcals.
If patient likes milky drinks, prescribe as a supplement to diet 1-2 servings/day.
Not suitable for patients with cow's milk intolerance or galactosaemia.
Not nutritionally complete.
If patient dislikes milk drinks, choose from the juice style supplements instead.
|
A2.01.02.03 |
Ensure® TwoCal |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.
|
04.09.01 |
Entacapone |
Tablets. See shared care guideline for entacapone. Used as an adjunct to levodopa therapy in patients who cannot be stabilised, particularly those with 'end-of-dose' fluctuations. See local guidance on drug treatment of Parkinson's Disease and shared care guideline. |
05.03.03.01 |
Entecavir Generic, Baraclude® |
Generic product should be used where possible. |
15.01.02 |
Entonox® |
50% nitrous oxide, 50% oxygen. |
08.01.05 |
Entrectinib Rozlytrek® |
Commissioned by NHSE in line with NICE TA643 for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
Commissioned via the Cancer Drugs Fund (CDF) in line with NICE TA644 for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if: • the disease is locally advanced or metastatic or surgery could cause severe health problems and • they have not had an NTRK-inhibitor before and • they have no satisfactory treatment options. |
08.03.04.02 |
Enzalutamide Xtandi® |
In accordance with NICE TAs. NICE TA 316: for metastatic hormone‐relapsed prostate cancer previously treated with a docetaxel‐containing regimen. NICE TA 377: for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (from April 16) |
13.02.01 |
Epaderm® |
Cream, yellow soft paraffin 15%, liquid paraffin 10%, emulsifying wax 5% Excipients include cetostearyl alcohol, chlorocresol Ointment, emulsifying wax 30%, yellow soft paraffin 30%, liquid paraffin 40% Excipients include cetostearyl alcohol Not stocked at RBCH: use Hydromol ointment
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
02.07.02 |
Ephedrine |
Injection. |
12.02.02 |
Ephedrine |
Nasal drops 0.5% and 1%
Self Care Medicine for primary care.
|
13.06.01 |
Epiduo® |
Gel, adapalene 0.1%, benzoyl peroxide 2.5% Excipients include disodium edetate, polysorbate 80, propylene glyc
For use within acne guideline when required in combination with antibiotics
Not DCHFT and RBCH. |
08.01.02 |
Epirubicin hydrochloride |
|
02.02.03 |
Eplerenone Inspra® |
Tablets.
Restricted. Specialist initiation. |
02.08.01 |
Epoprostenol Flolan® |
Injection.
Commissioned by NHS England for PAH, as per NHS England policy A11/PS/b.
Used for anticoagulant in dialysis circuits and CVVH (included in tariff).
|
02.09 |
Eptifibatide Integrilin® |
Injection / infusion.
Cardiology consultant use only. |
09.06.04 |
Ergocalciferol injection |
|
07.01.01 |
Ergometrine Maleate |
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
|
08.01.05 |
Eribulin Halaven® |
Commissioned in accordance with NICE TA423 and TA515. |
08.01.05 |
Erlotinib Tarceva® |
Commissioned by NHS England for cancer, policy in progress. See NICE TA162 and TA374. |
05.01.02.02 |
Ertapenem Invanz® |
On microbiology advice only.
DCHFT: As per local guidelines or on microbiology advice only. |
06.01.02.03 |
Ertugliflozin Steglatro ® |
When used as monotherapy or with metformin in patients with Type 2 Diabetes
When used with metformin and dipeptidyl peptidase- 4 inhibitor for treating type 2 diabetes
NB: Not currently commissioned for use with insulin. |
13.06.02 |
Erythromycin |
|
05.01.05 |
Erythromycin IV |
Short-term as a prokinetic to improve gastric motility. |
05.01.05 |
Erythromycin oral |
For COPD or bronchiectasis and GUM
|
05.01.05 |
Erythromycin oral |
|
04.03.03 |
Escitalopram |
In the absence of a clinical rationale for a particular antidepressant the most cost-effective agent should be selected |
02.04 |
Esmolol IV Brevibloc® |
Injection. |
01.03.05 |
Esomeprazole |
Capsules.
- For use in Barrett's oesophagus only.
GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.
Such patients should be referred for specialist advice as per CKD NICE guidance i.e.
- eGFR less than 30 ml/min/1.73m2
- sustained decrease in eGFR of 25% or more within 12 months
- sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months
Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours. |
01.03.05 |
Esomeprazole IV |
DCHFT: Not available as non-formulary item. |
07.02.01 |
Estring® |
Vaginal ring, releasing estradiol approx. 7.5 micrograms/24 hours |
07.02.01 |
Estriol cream |
0.1% and 0.01% available.
0.01% Cream- contains arachis oil (peanut oil) and should not be applied by patients known to be allergic to peanuts. As there is a possible relationship between allergy to peanuts and allergy to soya, patients with soya allergy should also avoid. Contact between contraceptive diaphragms or condoms and the cream must be avoided since the rubber may be damaged by this preparation
DCHFT: 0.1% routinely stocked only.
|
10.01.03 |
Etanercept Benepali®, Enbrel® |
All products should be prescribed by brand. Biosimilar should be used where possible.
Commissioned by CCG for:
- Rheumatoid arthritis in accordance with NICE TA 375 and local pathway.
- Ankylosing spondylitis in accordance with NICE TA383 and local pathway
- Plaque psoriasis in accordance with NICE TA103
- Psoriatic arthritis in accordance with NICE TA199 and local pathway
Commissioned by NHS England for:
- Juvenile idiopathic arthritis in line with NICE TA373.
- Paediatric patients in line with adult NICE TAs.
|
13.05.03 |
Etanercept Benepali®, Enbrel® |
All products should be prescribed by brand. Biosimilar should be used where possible. |
09.05.01.02 |
Etelcalcetide Parsabiv® |
DCHFT renal consultants only. Commissioned by NHS England in line with NICE TA448 for treating secondary hyperparathyroidism via specialist centres only. Treatment must have prior approval on Blueteq®.
|
05.01.09 |
Ethambutol |
|
18 |
Ethanol (alcohol) injection |
Orally or by injection for ethylene glycol (antifreeze) and methanol (methyl alcohol) poisoning as alternative to fomepizole. |
11.08.02 |
Ethanol 20% Eye Solution |
Preservative-free
unlicensed |
02.13 |
Ethanolamine oleate |
Injection. |
08.03.01 |
Ethinylestradiol |
Hospital initiation |
07.03.01 |
Ethinylestradiol 20 mcg / norethisterone 1mg |
Ethinylestradiol 20 mcg / norethisterone 1mg
Prescribe by brand
Loestrin 20®
* 30th September 2019
The manufacturer advises that this product has been discontinued.
The Faculty of Sexual and Reproductive Healthcare recommend that a 30mcgEE/NET COC (Ovranette®/Microgynon®/Rigevidon®) can be considered first line CHC. If this is not tolerated, there is not clear evidence to inform a recommendation favouring any one 20/30mcg EE COC over any other based on progestogen content. |
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg |
Ethinylestradiol 20mcg / desogestrel 150mcg
Prescribe by brand
Mercilon® 150microgram/20microgram tablets
Bimizza® 150microgram/20microgram tablets
Gedarel® 20microgram/150microgram tablets
Munalea® 150microgram/20microgram tablets - this product has been discontinued |
07.03.01 |
Ethinylestradiol 30 micrograms/ Norethisterone acetate 1.5mg |
Ethinylestradiol 30 micrograms/ Norethisterone acetate 1.5mg
Prescribe by brand
Loestrin 30®
* 30th September 2019
The manufacturer advises that this product has been discontinued.
The Faculty of Sexual and Reproductive Healthcare recommend that a 30mcgEE/NET COC (Ovranette®/Microgynon®/Rigevidon®) can be considered first line CHC. If this is not tolerated, there is not clear evidence to inform a recommendation favouring any one 20/30mcg EE COC over any other based on progestogen content. |
07.03.01 |
Ethinylestradiol 30 micrograms/drospirenone 3 mg |
Ethinylestradiol 30 micrograms/drospirenone 3 mg. Use in accordance with locally agreed guideline. Not for first-line use.
Prescribe by brand
Yasmin®
Dretine® 0.03mg/3mg tablets
Lucette® 0.03mg/3mg tablets
Yacella® 0.03mg/3mg tablets
Yiznell® 0.03mg/3mg tablets |
07.03.01 |
Ethinylestradiol 30 micrograms/gestodene 75 micrograms |
Ethinylestradiol 30 micrograms/gestodene 75 micrograms
Prescribe by brand
Femodene® tablets
Aidulan® 30microgram/75microgram tablets - this has now been discontinued
Katya® 30/75 tablets
Millinette® 30microgram/75microgram tablets
Sofiperla® 75microgram/30microgram tablets - this has now been discontinued
|
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg |
Ethinylestradiol 30mcg / levonorgestrel 150mcg
Prescribe by brand
Microgynon 30® tablets
Elevin® 150microgram/30microgram
Leandra®30microgram/150microgram tablets - This has now been discontinued
Levest® 150/30 tablets
Maexeni® 150microgram/30microgram tablets
Ovranette® 150microgram/30microgram tablets
Rigevidon® tablets
|
07.03.01 |
Ethinylestradiol 35 micrograms/Norgestimate 250 micrograms |
Ethinylestradiol 35 micrograms/Norgestimate 250 micrograms
Prescribe by brand
Cilique® 250microgram/35microgram tablets
Lizinna® 250microgram/35microgram tablets
Cilest® - Now discontinued. |
04.08.01 |
Ethosuximide |
Capsules, liquid.
Options based on licence.
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
15.02 |
Ethyl Chloride Cryogesic® Spray |
Aerosol spray. |
10.01.01 |
Etodolac |
|
15.01.01 |
Etomidate Hypnomidate® |
Injection. |
08.01.04 |
Etoposide |
|
05.03.01 |
Etravirine Intelence® |
Commissioned by NHS England in HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
|
13.04 |
Etrivex® |
Shampoo, clobetasol propionate 0.05% Potency: very potent
Not at RBCH
Not at DCHFT |
13.02.01 |
Eucerin® Intensive |
Lotion, urea 10% Excipients include benzyl alcohol, isopropyl palmitate Not RBCH Not DCHFT Not stocked PGH
Self Care Medicine for primary care.
|
13.04 |
Eumovate® |
Cream, clobetasone butyrate 0.05% Potency: moderate Excipients include beeswax substitute, cetostearyl alcohol, chlorocresol Ointment, clobetasone butyrate 0.05% Potency: moderate
Self Care Medicine for primary care - Clobetasone 0.05% cream 15g pack
|
18 |
European Viper Venom Antivenom |
For European adder (Vipera berus) envenoming (bites).
DCH: Kept in ED Fridge & Emergency Drugs Fridge. |
08.01.05 |
Everolimus Afinitor® |
Commissioned by NHS England in line with NICE TA recommendations. |
16.01 |
Evicel® Fibrant sealant |
RBCH: For use in robotic partial nephrectomies |
02.12 |
Evolocumab Repatha® |
RED, Initiation by lipid specialist – this can be by written or verbal approval to other secondary care consultant clinicians. A copy of any letters should be forwarded to the patient’s GP.
Commissioned by CCG in accordance with NICE TA 394 for primary non-familial hypercholesterolaemia or mixed dyslipidaemia and primary heterozygous familial hypercholesterolaemia. Commissioned by NHS England via specialist centres only for homozygous familial hypercholesterolaemia. |
06.04.01.01 |
Evorel® |
Patches, self-adhesive,
RBCH: 50 microgram routinely stocked |
06.04.01.01 |
Evorel® Conti |
patches, self-adhesive |
06.04.01.01 |
Evorel® Sequi |
combination pack, self-adhesive patches |
08.03.04.01 |
Exemestane |
In accordance with NICE TA112 and local shared care guideline. Also for advanced disease in postmenopausal women in whom anti-oestrogen therapy has failed. |
06.01.02.03 |
Exenatide prolonged release Bydureon® |
Use in accordance with NICE NG28 and local shared care guideline. Once weekly preparation: 2mg once weekly, in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione.
When used with oral hypoglycaemics in patients with Type 2 Diabetes
When used with insulin in patients with Type 2 Diabetes DCHFT: Consultant diabetologist only. |
06.01.02.03 |
Exenatide standard release injection Byetta® |
Use with oral agents, in accordance with NICE NG28 recommendations for treatment of type 2 diabetes and local shared care guideline. Also when used as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults Give twice daily within 1 hour before 2 main meals (at least 6 hours apart)
 : When used with oral hypoglycaemics in patients with Type 2 Diabetes
 : When used with insulin in patients with Type 2 Diabetes DCHFT: Consultant diabetologist only. |
13.05.02 |
Exorex® |
Restrict to where moderate to severe skin condition requires it
Lotion, coal tar solution 5% in an emollient basis Excipients include hydroxybenzoates (parabens)
Self Care Medicine
|
02.12 |
Ezetimibe Ezetrol® |
Tablets.
Use of ezetimibe should only be considered for patients with primary hypercholesterolaemia, in line with licensed indications.Use in accordance with NICE TA385. |
02.12 |
Ezetimibe Ezetrol® |
For use in combination with a statin for the secondary prevention of cardiovascular disease. |
02.11 |
Factor IX Fraction, Dried |
Non pharmacy item please contact blood bank for details and availability.
Commissioned by NHS England, as per BCSH guidelines.
Available from CSL Behring (Mononine®), BPL (Replenine®-VF, Dried Factor IX Fraction), Grifols (AlphaNine®), Biotest UK (Haemonine®)
Note Preparation of recombinant coagulation factor IX (nonacog alfa) available from Pfizer (BeneFIX®)
|
02.11 |
Factor VII |
Non pharmacy item please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines.
|
02.11 |
Factor VIIa (Recombinant) - eptacog alfa (activated) NovoSeven® |
Non pharmacy item please contact blood bank for details and availability.
DCHFT: Currently held by Pharmacy (Nov 2014).
Commissioned by NHS England as per BCSH Guidelines.
|
02.11 |
Factor VIII Fc Fusion Protein |
Non-pharmacy item. Please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines.
|
02.11 |
Factor VIII Fraction, Dried |
Commissioned by NHS England as per BCSH Guidelines.
Available from Biotest UK (Haemoctin®), CSL Behring (Haemate® P), BPL (Optivate®, High Purity Factor VIII and von Willebrand factor concentrate; 8Y®), Grifols (Alphanate®; Fanhdi®), Octapharma (Octanate®; Wilate®); Haemoctin®, Optivate®, Fanhdi®, and Octanate® are not indicated for use in von Willebrand’s disease
Note Preparation of recombinant human coagulation factor VIII (octocog alfa) available from CSL Behring (Helixate® NexGen), Baxter (Advate®), Bayer (Kogenate® Bayer); preparation of recombinant human coagulation factor VIII (moroctocog alfa) available from Wyeth (ReFacto AF®); octocog alfa and moroctocog alfa are not indicated for use in von Willebrand's disease
|
02.11 |
Factor VIII Inhibitor Bypassing Fraction FEIBA® |
Non-pharmacy item. Please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines.
|
02.11 |
Factor XIII Fraction, Dried Fibrogammin® P |
Non-pharmacy item. Please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines.
|
05.06 |
Faecal Microbiota Transplant |
RBCH & PHT: Approved as a treatment option for patients with recurrent C. difficile infections that have failed to respond to antibiotics and other treatments on recommendation of Consultant Microbiologist and Gastroenterologist. |
05.03.02.01 |
Famciclovir Famvir® |
RBCH: GUM only.
DCHFT: Consultant only. |
10.01.04 |
Febuxostat Adenuric® |
For the management of hyperuricaemia in people with gout, in accordance with NICE TA 164 as a secondline treatment to allopurinol |
02.06.02 |
Felodipine |
Fourth Line Choice.
Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate.
Modified release tablets.
Alternative prescribing option.
|
06.04.01.01 |
Femoston® |
|
06.04.01.01 |
FemSeven Conti ® |
Patches, self-adhesive |
06.04.01.01 |
FemSeven Sequi® |
Combination pack, self-adhesive patches |
06.04.01.01 |
FemSeven® |
Patches, self-adhesive |
02.12 |
Fenofibrate |
Capsules / Tablets
|
15.01.04.03 |
Fentanyl |
Injection. |
04.07.02 |
Fentanyl Injection/Infusion |
Red status does not apply to palliative care settings. |
04.07.02 |
Fentanyl matrix patches Matrifen® |
Please ensure all prescribing is by brand to ensure matrix patches are issued to patients. Currently, the most cost-effective matrix patch is: Matrifen.
Pain team/palliative care initiation, where morphine is contra-indicated or not tolerated or where there is specific need for a non-oral route. For non-cancer pain, 75mcg/hour should be the maximum dose, if ineffective other causes for lack of response should be considered.
Green for use in palliative care (see chapter 21)
NB: fentanyl reservoir patches are non-formulary due to increased risk of abuse and diversion. |
21 |
Fentanyl patches |
|
04.07.02 |
Fentanyl sublingual tablets Abstral® |
Palliative care only, as a second line option for management of breakthrough pain in adults using opioid therapy for chronic cancer pain
Recivit® - this has now been withdrawn from the UK market
|
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Choice according to local specialist policy Not at PGH
RBCH: Only where allergic reaction with Cosmofer - consultant prescription only. DCHFT: 3rd line for renal use only. |
09.01.01.01 |
Ferric Maltol Feraccru® |
Approved as Red for acute trusts ahead of DMAG meeting in March 2021. |
09.01.01.01 |
Ferrous Fumarate |
Syrup and Tablets |
09.01.01.01 |
Ferrous Gluconate |
|
09.01.01.01 |
Ferrous Sulphate Tablets |
|
07.04.02 |
Fesoterodine fumarate |
Choice should be based on selecting the most cost-effective option. |
03.04.01 |
Fexofenadine |
Tablets.
Dermatology use only.
DCHFT: 3rd line after cetirizine and loratadine. |
02.11 |
Fibrinogen Riastap® |
Non-pharmacy item. Please contact blood bank for details and availability.
Commissioned by NHS England as per BCSH Guidelines.
|
05.01.07 |
Fidaxomicin Dificlir® |
DCHFT & Poole ONLY: On advice of Consultant Microbiologist ONLY for the treatment of recurrent Clostridium difficile infection. |
09.01.06 |
Filgrastim e.g. Zarzio® |
Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost.
Commissioned by NHS England for Barth Syndrome at specialist centres only.
|
13.06.01 |
Finacea® |
Gel, azelaic acid 15%
Excipients include disodium edetate, polysorbate 80, propylene glycol |
06.04.02 |
Finasteride |
|
08.02.04 |
Fingolimod Gilenya® |
Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA254. |
23.09 |
Fixation Devices |
Company |
Product Code |
Price Per Unit |
Comments |
Optium Ugo Gentle |
Code: 3004-Box of 5 |
2.48 |
Really gentle and moveable and re-sticks well |
Clinimed
Clinifix
|
Code: 40-310 Box of 10 (110mmx25mm) 40-410 Box of 10 (140mm x 40mm) |
1.78 small
£1.95 large
|
Good size variety. Kind to skin and suitable for fragile skin |
Bard Stat Loc
|
Code FOLO102DT Box of 5 |
2.51 |
Sticks well but can be tough on skin |
|
13.10.01.01 |
Flamazine® |
Cream, silver sulfadiazine 1% Excipients include cetyl alcohol, polysorbates, propylene glycol
|
A5.03 |
Flaminal Forte Gel |
alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds, |
A5.03 |
Flaminal Hydro Gel |
alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds |
02.03.02 |
Flecainide Tambocor® |
Tablets, (Injection - secondary care only). Hospital initiation. |
01.06.05 |
Fleet Phospho-soda® |
Oral solution.
Choice to be determined by Trust. |
13.02.01 |
Flexitol® |
Heel balm, urea 25% Excipients include benzyl alcohol, cetostearyl alcohol, fragrance, lanolin. Not RBCH.
Self Care Medicine for primary care.
|
12.02.01 |
Flixonase Nasule® |
Fluticasone propionate 400micrograms/unit doses |
12.02.01 |
Flixonase® |
Fluticasone propionate 50micrograms/dose nasal spray |
05.01.01.02 |
Flucloxacillin IV |
|
05.01.01.02 |
Flucloxacillin oral |
|
07.02.02 |
Fluconazole |
Oral treatment |
05.02.01 |
Fluconazole IV |
Excellent oral bioavailability: use oral route where possible |
05.02.01 |
Fluconazole oral |
|
05.02.05 |
Flucytosine Ancotil® |
For use on microbiology advice only. |
08.01.03 |
Fludarabine Phosphate |
|
06.03.01 |
Fludrocortisone Florinef® |
|
15.01.07 |
Flumazenil Anexate® |
Injection. |
18 |
Flumazenil |
For reversal of benzodiazepines. |
11.04.01 |
Fluocinolone acetonide intravitreal implant Iluvien® |
Commissioned for the indications within NICE TA301 and NICE TA590
NOT commissioned (therefore Non-Formulary) for the indications within NICE TA613 (see below). |
11.08.02 |
Fluorescein sodium injection |
Unlicensed
For hospital use during surgical procedures
DCHFT: 20% injection stocked. |
11.04.01 |
Fluorometholone FML® |
|
08.01.03 |
Fluorouracil |
|
13.08.01 |
Fluorouracil 5& cream Efudix® |
Cream, fluorouracil 5% Excipients include hydroxybenzoates (parabens), polysorbate 60, propylene glycol, stearyl alcohol |
04.03.03 |
Fluoxetine |
|
04.02.01 |
Flupentixol Depixol®, fluanxol® |
Hospital or specialist initiation. Option based on NICE guidance and licence.
Note, Amber for pyshosis, non formulary for depression |
04.02.02 |
Flupentixol Decanoate |
Depot injection
Hospital initiation
Option based on NICE guidance and licence
200mg/ml low volume injection is more expensive so reserve for higher dose prescriptions (>250mg)
|
04.02.02 |
Fluphenazine Decanoate |
Hospital initiation Option based on NICE guidance and licence
Discontinued in March 2018. Not to be prescribed for new patients |
08.03.04.02 |
Flutamide |
|
03.02.01 |
Fluticasone Flixotide® |
Inhaler.
Single agent - For combinations with Long-Acting Beta Agonists see separate entries |
03.02.03 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
Inhaler.
For both licensed indications, asthma and COPD.
|
03.02.03 |
Fluticasone Furoate / Vilanterol / Umeclidinum Trelegy® |
For use within its licensed indication for COPD |
03.02.03 |
Fluticasone/Salmeterol Seretide® |
Inhalers.
*prescribe by brand to ensure the patient receives the same inhaler at each dispensing*
Seretide 250 Evohaler is now Non-Formulary for new initiations as per DMAG March 2018
Seretide 250 and 500 Accuhaler are now Non-Formulary for new initiations as per DMAG March 2018 |
02.12 |
Fluvastatin Lescol® |
Capsules.
Existing patients only should not be newly initiated.
DCHFT: Held on formulary for renal patients only. |
09.01.02 |
Folic Acid |
|
06.05.01 |
Follitropin Alfa Gonal-F® |
|
06.05.01 |
Follitropin Beta Puregon® |
|
18 |
Fomepizole |
Unlicensed. Treatment of choice for methanol (methyl alcohol) and polyethylene glycol (antifreeze) poisoning. PbR excluded: Commissioned by CCG.
There is an agreement that DCH, RBCH and PHT will keep initial doses of fomepizole to allow time for additional doses to be sourced from other trusts - contact Pharmacy to arrange supplies
DCH: Available in Emergency Drugs Fridge.
RBCH: Kept on ITU |
02.08.01 |
Fondaparinux Arixtra® |
Injection.
Treatment of unstable angina or non-ST-segment elevation myocardial infarction (i.e. Acute Coronary Syndrome.
RBCH: Treatment option for Muslim patients not wishing to be treated with LMWH (porcine derived) for VTE treatment or prevention. |
A2.02.02.03 |
Foodlink® Complete |
The calories are based on a sachet made up with 200ml of full cream milk and contain approx. 385 kcals.
If your patient likes milky drinks prescribe as a supplement to diet 1-2 servings/day.
Not suitable for patient with cow’s milk intolerance or galactosaemia.
Not nutritionally complete.
If your patient dislikes milky drinks choose from the juice style supplements instead. |
03.01.01.01 |
Formoterol |
Inhalers.
Long-acting beta2 agonist. |
A2.02.02.03 |
Forticreme® Complete |
NICE CG32 Nutrition support in adults
For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds |
A2.02.01.02 |
Fortijuce® |
Nutritionally complete juice type sip feed.
Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.
These are not suitable for those with an allergy to cow's milk.
Adult patients
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Paediatric patients
For use in children over 1 year of age.
|
A2.02.02.03 |
Fortini Compact Multifibre® |
For use in children over 1 year of age. |
A2.01.03.03 |
Fortini® |
Nutritionally complete.
For use in children over 1 year of age. |
A2.01.03.03 |
Fortini®Multifibre |
Includes Smoothie Multifibre.
Nutritionally complete.
For use in children over 1 year of age. |
A2.02.02.03 |
Fortisip® Compact |
This has a smaller volume and more than 2kcals /ml these can very useful in those who struggle with a larger volume
Adult patients
NICE CG32 (Feb 2006) Nutrition support in adults
Paediatric patients
Paediatric patients: do not use in patients < 1 year of age, use with caution in children 1-5 years of age. |
A2.02.02.03 |
Fortisip® Compact Fibre |
125ml volume with same nutritional value as 200ml bottle so useful for those who cannot manage a large volume
Adult patients
NICE CG32 Nutrition support in adults
Paediatric patients
Paediatric patients: do not use in patients < 1 year of age, use with caution in children 1-5 years of age. |
A2.02.02.01 |
Fortisip® Yoghurt Style |
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Useful for patients with taste changes e.g. as a side effect to cancer treatments |
A2.02.02.01 |
Fortisip® Bottle |
Adult patients
NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds
Paediatric patients
Do not use in patients < 1 year of age, use with caution in children 1-5 years of age.
|
A2.02.02.03 |
Fortisip® 2kcal |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency.
|
A2.02.02.03 |
Fortisip® Compact Protein |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency. |
05.03.01 |
Fosamprenavir Telzir® |
Commissioned by NHS England for HIV in combination with other anti-retroviral drugs, as per BHIVA Guidelines.
|
11.03.03 |
Foscarnet intravitreal injection |
Unlicensed DCHFT: Not routinely stocked.
|
05.03.02.02 |
Foscarnet Sodium Foscavir® |
Commissioned by NHS England (for cytomegalovirus) as per agreed Trust Guidelines. Hospital trusts are responsible for making the necessary arrangemenets for patients to receive intravenous treatment. |
05.01.07 |
Fosfomycin Intravenous Fomicyt® |
RBCH only: On microbiology advice only.
DCHFT: Not stocked.
|
05.01.13 |
Fosfomycin oral |
On microbiology advice only for resistant urinary tract infection.
Prescribe as the licensed product, Monuril™. This is available from all major wholesalers so community pharmacies can order directly and there should be no undue delay in the patient receiving the drug (pharmacies are unlikely to keep this as stock).
Generic prescribing may lead to the dispensing of expensive specials.
|
06.01.06 |
FreeStyle Libre® Sensors |
From April 1st 2019 Freestyle Libre sensors are classified as Amber on the Dorset Formulary.
Following assessment and initiation GPs will be contacted by the diabetes specialist in secondary care to request a continuation of the prescription of sensors until the patient is reviewed by the specialist at 6 months.
In order to ensure that patients with Type 1 diabetes are engaged with specialist care then initiation must be by the diabetes specialists for the people that meet the NHSE criteria only, as outlined in the commissioning statement below.
There should be no initiation of Freestyle Libre in primary care. |
04.07.04.02 |
Fremanezumab Ajovy® |
In line with NICE TA631 for preventing migraine |
02.11 |
Fresh Frozen Plasma |
Available from Regional Blood Transfusion Services
Note: A preparation of solvent/detergent treated human plasma (frozen) from pooled donors is available from Octapharma (OctaplasLG®)
|
A2.02.02.03 |
Fresubin® 2 kcal Drink |
NICE CG32 Nutrition support in adults |
A2.02.02.03 |
Fresubin® 2 kcal Fibre Drink |
NICE CG32 Nutrition support in adults 125ml volume with same nutritional value as 200ml bottle so useful for those who cannot manage a large volume |
A2.04.01.01 |
Fresubin® 5 kcal Shot |
NICE CG32 Nutrition support in adults
(Modular energy supplements to be used under direction of Dietitian only) |
A2.02.02.01 |
Fresubin® Energy |
|
A2.02.02.01 |
Fresubin® Energy Fibre |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with bowel problems as slightly more expensive than 1.5kcal.ml sips without fibre. |
A2.02.02.03 |
Fresubin® YOcreme |
NICE CG32 Nutrition support in adults
For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds |
A2.02.02.03 |
Fresubin® 2kcal Crème |
NICE CG32 Nutrition support in adults
For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds |
A2.02.01.02 |
Fresubin® Jucy |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Useful for those patients with preference to juice /dislike to milk. However note these are less cost effective in terms of calorie and protein content than milk based sips.
These are not suitable for those with an allergy to cow’s milk. |
A2.02.02.01 |
Fresubin® Protein Energy Drink |
NICE CG32 Nutrition support in adults
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Restrict use to those patients with increased protein requirement. Use only under direction of dietitian. Not to be used for those with renal insufficiency. |
A2.02.02.01 |
Fresubin® Thickened Level 2 |
Previously "stage 1"
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
A2.02.02.01 |
Fresubin® Thickened Level 3 |
Previously "stage 2"
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
04.07.04.01 |
Frovatriptan |
|
09.06.07 |
Fruitivits® |
Vitamin, mineral, and trace element supplement in children 3 - 10 years with restrictive therapeutic diets |
13.04 |
Fucibet® |
Cream, betamethasone (as valerate) 0.1%, fusidic acid 2%
Potency: potent
Excipients include cetostearyl alcohol, chlorocresol |
13.04 |
Fucidin H® |
Cream, hydrocortisone acetate 1%, fusidic acid 2%
Potency: mild
Excipients include butylated hydroxyanisole, cetyl alcohol, polysorbate 60, potassium sorbate |
08.03.04.01 |
Fulvestrant Faslodex® |
Commissioned by CDF in combination with abemaciclib for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy in line with CDF criteria and NICE TA579.
Note: Fulvestrant is not recommended for treating locally advanced or metastatic oestrogen-receptor positive breast cancer as per NICE TA239 and TA503. |
02.02.02 |
Furosemide |
Tablets, Liquid, (Injection - secondary care only).
DCHFT: The 50mg/5mL and the 5mg/5mL ( unlicensed) oral solution is restricted to paediatrics only. |
21 |
Furosemide |
|
13.10.01.02 |
Fusidic acid Fucidin® |
Cream, fusidic acid 2% Excipients include butylated hydroxyanisole, cetyl alcohol Ointment, sodium fusidate 2% Excipients include cetyl alcohol, wool fat |
11.03.01 |
Fusidic Acid m/r drops 1% |
|
04.07.03 |
Gabapentin |
Capsules. |
04.08.01 |
Gabapentin |
Capsules. Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
16.01 |
Gadoteric Acid Dotarem® |
|
16.01 |
Gadoxetic Acid Primovist® |
|
04.11 |
Galantamine |
Tablet, modified release capsule, oral solution. Alternative prescribing option. Use in accordance with NICE recommendations TA217. Refer to local shared care guideline.
|
04.07.04.02 |
Galcanezumab Emgality® |
In Line with NICE TA659 for preventing chronic or episodic migraine. |
09.08.01 |
Galsulfase |
Commissioned by NHS England for mucopolysaccharidosis. as per NHS England Service Specification.
For initiation by specialist centres only
|
05.03.02.02 |
Ganciclovir Cymevene® |
Commissioned by NHS England (for Cytomegalovirus) as per agreed Trust Guidelines. Hospital trusts are responsible for making the necessary arrangements for patients to receive intravenous treatment. |
11.03.03 |
Ganciclovir gel 0.15% |
As a alternative to Aciclovir as Aciclovir now discontinued. |
11.03.03 |
Ganciclovir intravitreal injection |
unlicensed
DCHFT: Not routinely stocked. |
01.01.02 |
Gaviscon® Infant |
Paediatrics.
Self Care Medicine for primary care.
|
01.01.02 |
Gaviscon®Advance |
Tablets on formulary at DCHFT. RBCH:
- ENT use only for severe gastro-pharyngeal reflux causing ENT symptoms.
- Mr Byrom using as an alternative to sucralfate (long-term shortage)to prevent reflux in patients who have had stomach and oesophageal resections
Self Care Medicine for primary care.
|
08.01.05 |
Gefitinib Iressa® |
Commissioned by NHS England in line with TA192. |
09.02.02.02 |
Gelaspan® Gelatin |
DCHFT only. |
09.02.02.02 |
Gelatin Gelofusine® |
PHFT - for use by endocopy only |
12.03.01 |
Gelclair® |
Oncology.
Only at PHFT and RBCH: Haematology and Oncology.
DCHFT: Oncology patients only. Can be used for palliative care patients at Joseph Weld Hospice. |
08.01.03 |
Gemcitabine |
Only when used in accordance with NHS England criteria |
07.01.01 |
Gemeprost |
|
08.01.05 |
Gemtuzumab ozogamicin MYLOTARG® |
Commissioned by NHSE in line with NICE TA545. |
13.10.01.02 |
Gentamicin 0.1% cream |
Unlicensed medicine. Restricted use: Renal service for application to PD exit sites. |
11.03.01 |
Gentamicin drops 0.3% |
|
12.01.01 |
Gentamicin drops 0.3% Genticin® |
|
11.03.01 |
Gentamicin drops 1.5% |
Preservative free
unlicensed: Available as a manufactured special
DCHFT: Both preservative free and with preservative available. |
05.01.04 |
Gentamicin Injection |
DCHFT: Adult gentamicin prescribing guidelines - see link below. |
12.01.01 |
Gentisone® HC |
Hydrocortisone acetate drops 1% with gentamicin 0.3% |
08.01.05 |
Gilteritinib Xospata® |
Commissioned by NHSE in line with NICE TA642 as monotherapy for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults.
Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant. |
08.02.04 |
Glatiramer Acetate Copaxone® |
Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA32. |
05.03.03.02 |
Glecaprevir with Pibrentasvir Maviret® |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
06.01.02.01 |
Gliclazide |
|
06.01.02.01 |
Gliclazide MR |
|
19.09 |
Glide Odour Neutralising Pouch Lubricant |
Respond Healthcare LTD Product reference code TCB6 Approved pack size 300ml Amber only after a trial of baby oil or alternative simple measures |
06.01.02.01 |
Glimepiride |
DCHFT: Consultant diabetologist only. |
06.01.02.01 |
Glipizide |
DCHFT: Consultant diabetologist only. |
06.01.04 |
Glucagon GlucaGen® HypoKit |
|
18 |
Glucagon injection GlucaGen® Hypokit |
For treatment of hypoglycaemia due to insulin overdose and supportive off-label (unlicensed) treatment of beta-blocker overdose. Other indications e.g. calcium channel blockers, seek NPIS advice.
Beta-blocker overdose requires large amounts of glucagon - contact Pharmacy to arrange supplies ASAP. |
08.01 |
Glucarpidase |
Orphan drug High Cost Medicine: Commissioned by NHS England for urgent treatment of methotrexate-induced renal dysfunction in accordance with policy. Due to the cost of this antidote for methotrexate toxicity, it is not stocked at any hospital in the area. If a supply is needed it can be obtained on a named-patient basis from Clinigen Group 24 hours a day 7 days a week. Within office hours: Tel: 01283 494 340 Fax: 01283 494 341 Out of hours: Email: outofhours@clinigengroup.com Phone number: 07741 242858 |
18 |
Glucarpidase |
Orphan drug
High Cost Medicine: Commissioned by NHS England for urgent treatment of methotrexate-induced renal dysfunction in accordance with policy.
Due to the cost of this antidote for methotrexate toxicity, it is not stocked at any hospital in the area. If a supply is needed it can be obtained on a named-patient basis from Clinigen Group 24 hours a day 7 days a week. Within office hours: Tel: 01283 494 340 Fax: 01283 494 341 Out of hours: Email: outofhours@clinigengroup.com Phone number: 07741 242858 |
22.01 |
Gluco Rx FinePoint |
Size: 4mm/31g Size: 5mm/31g Size: 6mm/31g |
06.01.06 |
Gluco Rx Nexus® |
|
09.02.01 |
Glucodrate® |
For short bowel syndrome. ’Food for Special Medical Purpose’ Approved for use at RBCH. |
06.01.04 |
GlucoGel® |
|
06.01.01.03 |
Glucoject® Lancets PLUS |
|
06.01.06 |
GlucoMen® Areo Sensor Test Strips |
|
13.02.01 |
GlucoRx Allpresan® diabetic foam cream |
Allpresan diabetic foam cream Basic (5% urea) is a medical device for the specific treatment of dry and sensitive foot skin in patients with diabetes mellitus. Allpresan diabetic foam cream Basic reduces roughness, counteracts pressure marks and smoothes the skin. Allpresan diabetic foam cream Intensive (10% urea) is a medical device for the specific treatment for very dry to chapped foot skin in patients with diabetes mellitus. Allpresan diabetic foam cream Intensive counteracts pressure marks and helps prevent callouses
Both Allpresan diabetic foam creams can be used on the entire foot, from heel to toe, including between the toes and around wound edges. |
06.01.01.03 |
GlucoRx Lancets |
|
06.01.01.03 |
GlucoRx Safety Lancets |
|
09.02.02.01 |
Glucose Intravenous |
5%, 10%, 20% and 50% IV infusions
RBCH: 50% not available - use 20% to treat hyperkalaemia - see policy
DCHFT: 5%, 10%, 15%, 20% and 50% available |
13.07 |
Glutarol® |
Solution (= application), glutaraldehyde 10% DCHFT: Not routinely stocked.
Used at RBH
Self Care Medicine for primary care.
|
01.06.02 |
Glycerol (Glycerin) |
Suppositories.
- Alternative prescribing option.
Self Care Medicine for primary care.
|
02.06.01 |
Glyceryl Trinitrate |
Available as Tablet (S/L & Buccal), PUMP Spray, Patches, (Injection/infusion - secondary care only). |
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
Ointment. |
07.04.04 |
Glycine Irrigation Solution |
Hospital only |
03.01.04 |
Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler® |
|
03.01.02 |
Glycopyrronium Seebri breezhaler® |
Inhaler.
Long-acting option. |
15.01.03 |
Glycopyrronium |
Injection. |
21 |
Glycopyrronium |
|
13.12 |
Glycopyrronium 0.5% in 70%IMS Lotion |
Unlicensed |
13.12 |
Glycopyrronium 0.5% Lotion |
Unlicensed |
15.01.03 |
Glycopyrronium Bromide Sialanar® & Colonis Pharma Ltd |
Licensed for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3-years and older with chronic neurological disorders
Also approved for patients with Parkinsons Disease for the management of sialorrhoea (DMAG Nov 2020) |
01.05.03 |
Golimumab Simponi® |
|
10.01.03 |
Golimumab Simponi® |
Commissioned by NHS England for paediatric indications.
- For psoriatic arthritis in accordance with NICE TAs and local pathway.
- For Rheumatoid arthritis in accordance with NICE TAs and local pathway.
- For ankylosing spondylitis in accordance with NICE TAs and local pathway.
|
06.05.01 |
Gonadorelin |
|
06.07.02 |
Goserelin Zoladex®, Zoladex® LA |
DCHFT: 3.6mg implant only. |
08.03.04.02 |
Goserelin Zoladex®, Zoladex® LA |
DCHFT: 3.6mg implant only. |
02.05.03 |
Guanethidine Monosulphate |
Injection.
DCHFT: Restricted to Consultant use only. |
04.04 |
Guanfacine Intuniv® |
in line with NICE NG87 diagnosis and local shared care guidance |
19.03 |
Guard no sting barrier film sachets |
OstoMart Ltd Product reference code RMC3 Approved pack size 30 |
13.05.03 |
Guselkumab Tremfya® 100 mg solution for injection |
In accordance with NICE guidance |
07.03.03 |
Gygel® |
Gel, nonoxinol ‘9’ 2% Excipients include hydroxybenzoates (parabens), propylene glycol, sorbic acid
No evidence of harm to latex condoms and diaphragms Pregnancy toxicity in animal studies Breast-feeding present in milk in animal studies
DCHFT: Not routinely stocked. |
13.04 |
Haelan® tape |
Tape, polythene adhesive film impregnated with fludroxycortide 4 micrograms /cm2 |
09.08.02 |
Haem Arginate Normasang® |
Commissioned by NHS England (for hepatic porphyria) according to NHS England Service Specification. For highly specialised criteria only. |
14.04 |
Haemophilus influenzae type B Menitorix® |
|
14.04 |
Haemophilus influenzae type B Combined Vaccine |
|
03.01.05 |
Haleraid Haleraid® |
Cannot be prescribed on FP10 |
04.02.01 |
Haloperidol |
Hospital or specialist initiation.
Baseline ECG is recommended prior to treatment in all patients.
Option based on NICE guidance and licence.
Maximum licensed daily dose is 20mg oral administration or 12mg by IM injection. |
04.02.02 |
Haloperidol |
Hospital initiation
Option based on NICE guidance and licence |
04.06 |
Haloperidol |
Capsules, tablets, liquid.
Palliative care. |
21 |
Haloperidol |
|
04.06 |
Haloperidol Injection |
|
13.10.04 |
Hedrin® |
Lotion, dimeticone 4% Note Patients should be told to keep hair away from fire and flames during treatment
Self Care Medicine for primary care.
|
02.08.01 |
Heparin |
Injection.
RBCH: 5000unit in 0.2mL for SC use; 20 000unit in 20mL for IV infusion.DCHFT:
Heparin calcium 5000 units in 0.2mL.
Heparin sodium 200 units in 2mL - Renal use only.
Heparin sodium 5000 units in 5mL - Renal use only.
Heparin sodium 25000 units in 5mL - Renal use only.
Heparin sodium (for syringe pump) 1000 units per mL (10mL vial).
Heparin sodium (for syringe pump) 1000 units per mL (20mL vial).
Heparin sodium 1000 units per mL (1mL vial).
Heparin sodium 5000 units per mL (1mL vial).
Heparin sodium 10 units per mL (5mL vial). Heparin flush restricted for CVP lines only. |
02.08.01 |
Heparinised saline flush |
Heparin sodium 10 units per mL (5mL vial). Specialist initiation.
- DCHFT:
Heparin flush restricted for CVP lines only.
|
14.04 |
Hepatitis A & B vaccines Twinrix Adult |
This vaccine is not available at NHS expense in Dorset for Overseas Travel : See Dorset Guidance on Prescribing for Overseas Travel |
14.04 |
Hepatitis A & B vaccines Twinrix Paediatric |
This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel |
14.04 |
Hepatitis A vaccine Havrix Junior Monodose |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine Single Component Avaxim® |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine Single Component Epaxal® |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine Single Component Havrix Monodose® |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine Single Component VAQTA® Paediatric |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
|
14.04 |
Hepatitis A vaccine with typhoid vaccine Hepatyrix® |
DCHFT: Not routinely stocked. |
14.04 |
Hepatitis A vaccine with typhoid vaccine ViATIM® |
DCHFT: Not routinely stocked. |
14.05.02 |
Hepatitis B immunoglobulin |
Microbiology request only |
14.04 |
Hepatitis B vaccine Single Component Engerix B® |
This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel
Recategorised as for Renal
Only to be considered as on specialist advice for exceptional circumstances |
14.04 |
Hepatitis B vaccine Single Component Fendrix® |
DCHFT: Not routinely stocked. This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
Recategorised as for Renal
Only to be considered as on specialist advice for exceptional circumstances |
14.04 |
Hepatitis B vaccine Single Component HBvaxPRO® |
DCHFT: 10mcg/mL and 40mcg/mL stocked. This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance on Prescribing for Overseas Travel
Recategorised as for Renal
Only to be considered as on specialist advice for exceptional cercumstances |
07.04.04 |
Hexaminolevulinate 85mg for intravesical solution Hexvix® |
RBCH approved: Diagnostic agent for patients undergoing blue light cystoscopy for investigation of the bladder to detect cancerous tumours.
|
11.99.99.99 |
Histacryl Blue® Tissue Adhesive |
|
11.99.99.99 |
Holoclar® Viable autologous human corneal epithelial cells |
Only for use at Specialist Centres (University of Southampton and Oxford) in accordance with NICE TA 467. |
09.02.02.02 |
Human Albumin Solution |
4.5% and 20% infusions
DCHFT: Not stocked in Pharmacy - contact blood bank. |
14.05.03 |
Human Anti-D (Rh0) Immunoglobulin |
For routine antenatal anti-D prophylaxis for RhD-negative women in accordance with NICE TA156.
DCHFT: Not pharmacy. |
14.05.01 |
Human normal immunoglobulin |
Commissioned by NHS England in line with 'Updated Commissioning Criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England (January 2019)'. For indications not covered by these commissioning criteria, commissioning is in line with the 'DoH Clinical Guidelines for Immunoglobulin Use (second edition update, July 2011)'.
Note: Guidance from NHS England (October 2017) states that the recommended dose of IVIg for the treatment of ITP is a single dose of 1g/kg. A repeat dose of 1g/kg should only be considered at day 7 if there is a failure to achieve a haemostatically adequate platelet count (approval from the local immunoglobulin approval panel is required if earlier use is contemplated in cases of exceptional clinical circumstances such as active mucosal bleeding or the need for emergency surgery). |
14.04 |
Human papilloma virus vaccine Gardasil® |
|
06.01.01.01 |
Human soluble insulin Actrapid® |
For inpatient use - only available in 10ml vials |
06.01.01.01 |
Human soluble insulin Humulin® S |
Alternative prescribing option |
14.05.02 |
Human Tetanus immunoglobulin |
|
11.99.99.99 |
Hyaluronidase Hyalase® |
|
02.05.01 |
Hydralazine IV |
Injection - secondary care only.
DCHFT: Tablets stocked and listed as Amber Shared Care Guidelines. |
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
13.04 |
Hydrocortisone cream |
Cream, hydrocortisone 0.5%, 1%, 2.5% Potency: mild
Self Care Medicine for primary care for hydrocortisone cream 1% 15g pack size.
|
01.05.02 |
Hydrocortisone foam enema Colifoam® |
Jan 18 (reviewed Sept 19): There is a shortage of this product due to a change of manufacturer and there is currently no date for when this is expected to be available again. Budesonide foam enema can be used as an alternative for adults in the interim at a dose of 1 application daily ( Note this product is not licensed in under 18s). |
06.03 |
Hydrocortisone granules Alkindi® granules in capsules for opening |
0.5mg, 1mg, 2mg & 5mg capsules.
Restricted for use at Poole hospital for paediatric adrenal insufficiency only. |
12.03.01 |
Hydrocortisone mucoadhesive buccal tablets 2.5mg |
Self Care Medicine for primary care.
|
13.04 |
Hydrocortisone ointment |
Ointment, hydrocortisone 0.5%, 1%, 2.5% Potency: mild
Self Care Medicine for primary care for hydrocortisone ointment 1% 15g pack size.
|
06.03.02 |
Hydrocortisone sodium phosphate Efcortesol® |
Amber for patients with Hypoadrenalism e.g. Addison's Disease
Red for all other indications
|
11.04.01 |
Hydrocortisone sodium phosphate 3.35mg/mL single dose eye drops Softacort® |
As an alternative to Prednisolone 0.5% PF eye drops if they are unavailable, where a preservative free option is required |
06.03.02 |
Hydrocortisone sodium succinate Solu-Cortef® |
Amber for patients with Hypoadrenalism e.g. Addison's Disease
for all other indications
Patients should be encouraged to register as a steroid-dependant patient with their local ambulance service as patient consent is required (see SWASFT form below)
Please see the addisons.org.uk website for videos explaining how to give an emergency injection of hydrocortisone sodium succinate in the event of an adrenal crisis. |
06.03.02 |
Hydrocortisone tablets |
|
13.11.06 |
Hydrogen Peroxide Crystacide® |
Cream.
In accordance with the recommendations within NICE NG153 Not at DCHFT. |
12.03.04 |
Hydrogen peroxide mouthwash 3% and 6% |
DCHFT: 3% only.
Self Care Medicine for primary care.
|
13.11.06 |
Hydrogen Peroxide Solution BP |
For Procedural Use |
13.02.01 |
Hydromol® |
Cream, sodium pidolate 2.5%, liquid paraffin 13.8% Excipients include cetostearyl alcohol, hydroxybenzoates (parabens) Ointment, yellow soft paraffin 30%, emulsifying wax 30%, liquid paraffin 40% Excipients include cetostearyl alcohol
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.Â
|
13.02.01 |
Hydrous ointment (oily cream) |
Ointment, (oily cream), dried magnesium sulfate 0.5%, phenoxyethanol 1%, wool alcohols ointment 50%, in freshly boiled and cooled purified water. Not DCHFT and RBCH.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.Â
|
09.01.02 |
Hydroxocobalamin |
|
18 |
Hydroxocobalamin Cyanokit® |
Can be considered for use in victims of smoke inhalation who show signs of significant cyanide poisoning.
RBCH: 1 kept in ED; obtain further supplies from PHT |
08.01.05 |
Hydroxycarbamide |
Hospital initiation. Use in accordance with local shared care guideline. |
09.01.03 |
Hydroxycarbamide |
In essential thrombocythaemia |
10.01.03 |
Hydroxychloroquine |
|
13.05.03 |
Hydroxychloroquine |
For rheumatoid arthritis in accordance with NICE CG79 recommendations. |
03.04.01 |
Hydroxyzine |
Tablets. Sedating option. Alternative prescribing option to first line. A European review of the safety and efficacy of hydroxyzine has been undertaken following concerns of heart rhythm abnormalities associated with this medicine. The review concluded that hydroxyzine is associated with a small risk of QT interval prolongation and Torsade de Pointes, the link to the Drug Safety Update provides more information, click here |
01.02 |
Hyoscine butylbromide Buscopan® |
Tablets, injection.
Self Care Medicine for primary care for tablets
|
21 |
Hyoscine butylbromide Buscopan ® |
|
04.06 |
Hyoscine Hydrobromide |
Patches, tablets. For hypersalivation.
Green: patches in palliative care (see chapter 21) |
15.01.03 |
Hyoscine Hydrobromide |
Injection.
Green for use in palliative care (see chapter 21) |
21 |
Hyoscine Hydrobromide |
Injection, patches |
04.06 |
Hyoscine Hydrobromide Injection |
Green for use in palliative care (see chapter 21) |
A5.07.03 |
Hypafix® Surgical Adhesive Tape |
Dressing retention in particular of large post-operative wound dressings, gauze and absorbent compresses.
- Skin friendly
- Split liner for easy removal of release paper.
- Large range of sizes fits: a large amount of uses.
- Square frame printing on the release paper: guideline for cutting.
|
03.07 |
Hypertonic sodium chloride MucoClear®3% |
Nebuliser solution. DCHFT only: Consultant paediatrician only.
RBH: Not stocked for in-patients (risk avoidance measure) |
03.07 |
Hypertonic sodium chloride 7% |
Nebuliser solution. |
11.08.01 |
Hypromellose drops 0.3% |
Preserved or Preservative-free. Preservative-free - NOT RBCH- if admitted on this convert to alternative lubricant Other strengths of Hypromellose are considered non-formulary
Self Care Medicine for primary care.
|
06.06.02 |
Ibandronate 50mg Tablets |
Locally approved for use in post menopausal women with breast cancer in accordance with the local Shared Care Guideline and Pathway. |
06.06.02 |
Ibandronic Acid |
150mg strength for use in osteoporosis
DCHFT: Injection is 3rd line, used in rheumatology patients intolerant of oral bisphosphonates. |
08.01.05 |
Ibrutinib Imbruvica® |
In accordance with CDF policy and NICE TA429, TA491 and TA502. |
10.01.01 |
Ibuprofen |
Self Care Medicine for primary care.
|
10.03.02 |
Ibuprofen 5 % gel |
DCHFT: 5% and 10% stocked.
Self Care Medicine for primary care.
|
03.04.03 |
Icatibant Firazyr® |
Commissioned by NHS England for Hereditary Angioedema and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy: B09/P/b.
May only be initiated by (or on advice of) Specialist Centres where:
C1inh is unsuitable due to adverse effects or administration difficulties
the specialist clinician determines that Icatibant is the most suitable or cost-effective preparation for the patient
Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
|
08.01.02 |
Idarubicin Hydrochloride Zavedos® |
|
02.08.03 |
Idarucizumab Praxbind® |
When rapid reversal of dabigatran is require for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
On Consultant Haematologist advice only.
UHD hospitals: Stored in Haematology/Blood Transfusion departments.
Commissioned by CCG. |
08.01.05 |
Idelalisib Zydelig® |
Commissioned in accordance with NICE TA359.
|
09.08.01 |
Idursulfase |
Commissioned by NHS England (for mucopolysaccharidosis) according to NHS England Service Specification, for highly specialised criteria only.
For initiation by specialist centres only
|
08.01.01 |
Ifosfamide |
|
02.05.01 |
Iloprost injection |
Restricted for peripheral vascular and rheumatology use.
- DCHFT:
Specialist use only.
|
02.05.01 |
Iloprost nebules Ventavis® |
Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension.
|
08.01.05 |
Imatinib Generic, Glivec® |
For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec® brand. |
09.08.01 |
Imiglucerase Cerezyme® |
Commissioned by NHS England (for Gaucher's disease), according to the NHS England Service Specification for highly specialised criteria only. For initiation by specialist centres only |
05.01.02.02 |
Imipenem |
On microbiology advice only.
DCHFT: Consultant only. |
04.03.01 |
Imipramine |
Third line choice in line with the primary care protocol for depression
Anxiety - second line recommended by NICE for Panic Disorder and within Primary Care Protocol |
07.04.02 |
Imipramine |
|
A5.03.02 |
Inadine |
Knitted viscose primary dressing impregnated with povidone–iodine ointment 10% |
03.01.01.01 |
Indacaterol Onbrez® |
Inhalers.
Long-acting beta 2 agonist for COPD. |
02.02.01 |
Indapamide |
Standard release formulation - tablet 2.5mg.
(MR tablet 1.5mg - non formulary) |
16.01 |
INDIGO CARMINE Injection 0.8 % |
Unlicensed
To aid with detection of colonic polyps/surveillance of ulcerative colitis |
05.03.01 |
Indinavir Crixivan® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs). See BHIVA Guidelines. |
11.08.02 |
Indocyanine green 25mg injection |
unlicensed
DCHFT: Not routinely stocked. |
07.01.03 |
Indometacin |
Not at RBCH |
10.01.04 |
Indometacin |
|
13.11.01 |
Industrial Methylated Spirit BP |
|
14.04 |
Infanrix hexa |
Powder and suspension for suspension for injection.
Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. |
A2.03.01 |
Infatrini Peptisorb® |
200ml bottle.
Nutritionally complete.
For use from birth to 8kg weight. |
A2.01.03.02 |
Infatrini® |
ACBS indication: disease related malnutrition and malabsorption, or growth failure. For use from birth to 18 months. |
01.05.03 |
Infliximab Remsima®, Inflectra®, Remicade®, Flixabi® |
All products should be prescribed by brand. Biosimilars should be used where possible. RBCH: Preferred brand is Flixabi |
10.01.03 |
Infliximab Flixabi®, Remsima®, Inflectra®,Remicade® |
All products should be prescribed by brand. Biosimilars should be used where possible.

- For rheumatoid arthritis in accordance with NICE recommendations TA130 and TA195 and local pathway.
- For ankylosing spondylitis in accordance with NICE TA145 and TA140 and local pathway.
- For psoriatic arthritis in accordance with NICE TA199 and local pathway.
- For psoriasis in accordance with NICE TA134.
Commissioned by NHS England for paediatric indications (where adult TA available). According to adult TAs (TA130, TA134, TA140, TA143, TA163, TA199) for the range of arthritis-related indications. Also Crohn's disease in children (TA187). Not routinely commissioned by NHS England for: connective tissue disease - interstitial lung disease, graft versus host disease, renal indications, sarcoidosis, progressive pulmonary sarcoidosis, uveitis or hidradenitis suppurativa. As per IFR approval.
|
13.05.03 |
Infliximab Remsima®, Inflectra®, Remicade® |
All products should be prescribed by brand. All products should be prescribed by brand. Biosimilars should be used where possible. RBCH: Preferred brand is Remsima |
14.04 |
Influenza vaccine |
|
14.04 |
Influenza vaccine (NASAL) Fluenz |
DCHFT: Not routinely stocked.
Primary Care Only : Please note that flu vaccines for children should be ordered via IMMFORM and should NOT be reclaimed via NHS prescription services (PPA). |
08.01.05 |
Inotuzumab ozogamicin BESPONSA® |
Commissioned by NHSE in line with NICE TA541. |
06.01.01 |
Insulin (continuous subcutaneous infusion) |
Use in accordance with NICE recommendations for insulin pump therapy (TA151). |
06.01.01.01 |
Insulin 500 units in 1mL Humulin R® |
Unlicensed - RBCH & PHT: See policy. Only to be initiated by Diabetes Specialists. Patients should be initiated on the Humulin R Kwikpen.
DCHFT: only to be initiated by a Consultant Endocrinologist HUMULIN R IS 5 TIMES THE STRENGTH OF OTHER INSULINS - TAKE GREAT CARE WHEN PRESCRIBING OR ADMINISTERING! |
06.01.01.01 |
Insulin Aspart Fiasp® |
For patients where Novorapid has been tried and proven to be ineffective and where patients are getting post meal hyperglycaemia.
"The safety and efficacy of Fiasp in children and adolescents below 18 years of age has not been established" SPC |
06.01.01.01 |
Insulin Aspart NovoRapid® |
|
06.01.01.02 |
Insulin degludec Tresiba® |
Type 1 patients as second line for adults and children.
Type 2 patients as third line for adults.
Initiation would be for:
- Recurrent ketosis / ketoacidosis - use of insulin degludec in patients, particularly those with suspected poor compliance.
- Adolescent / young adult type 1 diabetes population where there is a history of irregular administration of long-acting insulin.
- Paediatric patient population already established on insulin degludec treatment reaching adulthood to continue on degludec treatment.
- Type 1 diabetes population with reduced hypoglycaemia awareness and at risk of severe hypoglycaemic events, including those experiencing nocturnal hypoglycaemia.
- For frail patients with type 1 or type 2 diabetes at risk of hypoglucaemia and the housebound population requiring administration of insulin from healthcare providers, where timing of insulin administration may vary on a day to day basis.
|
06.01.01 |
Insulin Degludec with Liraglutide Xultophy® |
|
06.01.01.02 |
Insulin Detemir Levemir® |
Alternative prescribing option.
Recommended option where a basal analogue is required, see NG17, 18 and NG28 |
06.01.01.02 |
Insulin Glargine Lantus® |
|
06.01.01.02 |
Insulin Glargine (biosimilar) Semglee® |
Formulary choice for new patients needing a basal analogue insulin. Only available as pre-filled 3 mL pen |
06.01.01.02 |
Insulin glargine (biosimilar) Abasaglar® |
Formulary choice for new patients needing a basal analogue insulin. |
06.01.01.02 |
Insulin Glargine 300 UNITS/ML SOLUTION Toujeo® Solostar® or DoubleStar® pens |
Amber, initiated by Diabetes Specialists only. For use in patients requiring greater than 100 units. Formulations of insulin glargine are not bioequivalent and require dosing changes. It is recommended prescriptions should state the brand name Toujeo® where prescribed. Advice on changing from glargine 100units/ml or other basal insulin to Toujeo see Drug Safety Update from April 2015 (link)
- With Toujeo SoloStar pre-filled pen, a dose of 1-80 units per single injection, in steps of 1 unit, can be injected.
- With Toujeo DoubleStar pre-filled pen a dose of 2-160 units per single injection, in steps of 2 units, can be injected.
|
06.01.01.01 |
Insulin Glulisine Apidra® |
|
06.01.01.01 |
Insulin Lispro Humalog® |
|
06.01.01.01 |
Insulin Lispro Humalog® |
|
08.02.04 |
Interferon Alfa IntronA® |
Commissioned by NHS England for hepatitis B (TA96) and C (TA75). |
08.02.04 |
Interferon Beta-1a & Interferon Beta 1-b Avonex®, Rebif®, Extavia® |
Commissioned by NHS England (for Multiple sclerosis) in accordance with NICE TA527 and Department of Health guidance contained in health service circular 2002/004. See NHS England Policy: D04/P/b
Note: Betaferon® is not recommended as per NICE TA527. |
09.03 |
Intralipid 20% |
For severe local anaesthetic toxicity |
A5.03.02 |
Iodoflex |
Paste, iodine 0.9% as cadexomer–iodine in a paste basis with gauze backing |
A5.03.02 |
Iodosorb |
Ointment, iodine 0.9% as cadexomer–iodine in an ointment basis,
Powder, iodine 0.9% as cadexomer–iodine microbeads
|
16.01 |
Iohexol Omnipaque® |
|
16.01 |
Iopamidol Niopam® |
|
08.01.05 |
Ipilimumab YERVOY ® |
Commissioned by NHSE in line with NICE TA268, TA319 and TA400 recommendations.
Commissioned by CDF in combination with nivolumab in line wth CDF criteria.
|
03.01.02 |
Ipratropium Atrovent |
Inhaler, nebuliser solution. Short-acting muscarinic agonist
It is recommended that if patients are on a "triple therapy inhaler" and they are requiring ipratropium or similar medications including Combivent via a nebuliser for an acute episode that they should cease use of the triple inhaler short term due to the possible cardiac side effects (in particular arrhythmias).
Amber categorisation only applies to adult patients, for paediatric patients, this should be considered "green" |
03.01.04 |
Ipratropium bromide with salbutamol nebules Combivent® |
NB - less suitable for prescribing. Licensed for bronchospasm in patients with COPD. BNF states flexibility of dosing is lost with a compound bronchodilator but it may be appropriate for patients stabilised on the individual components in the same proportion.
Amber categorisation only applies to adult patients, for paediatric patients, this should be considered "green"
It is recommended that if patients are on a "triple therapy inhaler" and they are requiring ipratropium or similar medications including Combivent via a nebuliser for an acute episode that they should cease use of the triple inhaler short term due to the possible cardiac side effects (in particular arrhythmias).
|
08.01.05 |
Irinotecan Hydrochloride |
|
09.01.01.02 |
Iron Dextran CosmoFer® |
Choice according to local specialist policy |
09.01.01.02 |
Iron Isomaltoside 1000 Monofer® / Diafer® |
Choice according to local specialist policy Poole - as per Poole Policy
Bournemouth - as per Poole policy until 1st October 2021. DCHFT: 2nd line in patients intolerant of iron dextran. In dialysis patients Diafer® is 1st line. |
09.01.01.02 |
Iron Sucrose Venofer® |
Choice according to local specialist policy |
08.01.05 |
Isatuximab Sarclisa® |
Commissioned within the CDF in combination with pomalidomide and dexamethasone as a 4th line option for treating relapsed and refractory multiple myeloma as per NICE TA 658. |
05.02.01 |
Isavuconazole CRESEMBA® |
Commissioned by NHS England (for the treatment of fungal infections), as per agreed Trust Guidelines.
For use on microbiology/specialist mycology advice only.
prior approval required.
|
04.03.02 |
Isocarboxazid |
Initiated on specialist advice only as per shared care |
15.01.02 |
Isoflurane |
Anaesthetic. |
05.01.09 |
Isoniazid |
|
06.01.01.02 |
Isophane Insulin Insulatard® |
|
06.01.01.02 |
Isophane Insulin Humulin® I |
|
06.01.01.02 |
Isophane Insulin Insuman® Basal |
DCHFT: Not stocked. |
02.07.01 |
Isoprenaline |
Injection.
Unlicensed.
Available from special order manufacturers or specialist importing companies. |
13.02.01 |
Isopropyl Myristate 15% w/w, Liquid Paraffin 15% w/w Isomol Gel® |
Prescribe by brand name A highly moisturising gel for regular and frequent use in eczema, psoriasis and other dry skin conditions.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
02.06.01 |
Isosorbide Mononitrate |
Tablets - standard release or MR 60mg.
Short acting preparations should be prescribed asymmetrically to reduce the risk of nitrate tolerance.
MR tablet 40mg and MR capsules non-formulary.
|
13.06.02 |
Isotretinoin |
Capsules.
Hospital or specialist use only
Side effects require specialist supervision |
13.06.01 |
Isotrexin® |
Gel, isotretinoin 0.05%, erythromycin 2% in ethanolic basis
Excipients include butylated hydroxytoluene
DCHFT: Not routinely stocked. |
01.06.01 |
Ispaghula Husk |
Granules.
Self Care Medicine for primary care.
|
05.02.01 |
Itraconazole |
Suspension is significantly more expensive than the capsules |
02.06.03 |
Ivabradine Procoralan® |
Tablets.
|
03.12 |
Ivacaftor 150mg tablets Kalydeco® |
Indicated for:
- the treatment of Cystic Fibrosis in patients aged 6 years or older and weighing at least 25kg with a gating mutation of the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R
- the treatment of adults and children (aged 6 months and older who are at least 5Kg in weight) with cystic fibrosis (CF) who have an R117H mutation in the CFTR gene.
- use in a combination regimen with tezacaftor 100 mg/ivacaftor 150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.
|
03.12 |
Ivacaftor/Tezacaftor/Elexacaftor Kaftrio® |
Commissioned via NHSE for for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are: • homozygous for the F508del mutation in the CFTR gene or • heterozygous for the F508del mutation combined with a minimal function gene mutation (MF) corresponding to either no production of a CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor in vitro
Commissioned by NHSE "off-label" for all CF patients with an F508DEL mutation plus another mutation, where there aren't any suitable licensed medicines that meet the patient's needs.
Restricted to initiation in specialist cystic fibrosis centres
|
13.06.03 |
Ivermectin Soolantra® |
|
08.01.05 |
Ixazomib Ninlaro® |
Commissioned by CDF in accordance with CDF policy and NICE TA505 for use in combination with lenalidomide and dexamethasone if the conditions of the managed access agreement are followed. |
13.05.03 |
Ixekizumab Taltz® |
In accordance with NICE guidance |
A5.08.08 |
K- Lite |
- For the treatment of Venous Leg Ulcers (2nd layer of K-Four multilayer bandage system)
- Light support for sprains and strains
- Can be used for retention bandaging
|
A5.08.08 |
K- Lite Long |
Provides no compression 2nd layer of multi-layer compression bandaging
- For the treatment of Venous Leg Ulcers (2nd layer of K-Four multilayer bandage system)
- Light support for sprains and strains
- Can be used for retention bandaging
|
A5.02.06 |
Kaltostat® Calcium-Sodium Alginate fibre dressings |
Sizes: 5cmx5cm, 7.5cmx12cm, 10cmx20cm, 15cmx25cm
|
A5.08.08 |
K-Band® |
Knitted Polyamide and Cellulose Contour Bandage, BP 1988 4 m stretched 10cm and 15cm |
A5.02.04 |
KerraCel® Gelling Fiber Dressing |
All sizes
100% caboxmethyl celluose primary dressing for use on a variety of exuding wounds. Soft and conformable with high absorbency, and retains its integrity when removed from the wound/cavity.
KerraCel dressings are designed to:
Lock in exudate to protect peri-wound skin from maceration
Form a soothing gel when wet
Contour to the wound bed to minimise dead space where bacteria can live
Sequester harmful components found in exudate (bacteria and MMPs)
Help maintain a moist healing environment
Be removed from the wound bed in one piece
|
A5.03.03 |
KerraContact AG® |
Silver wound dressing that is fast and powerful at killing bacteria, destroys biofilms and prevents reformation.
Contains silver in its most active state |
A5.02.01 |
Kerralite Cool Border® (Adhesive) |
|
A5.02.01 |
KerraLite Cool Dressings |
KerraLite Cool is a soothing, debriding and moisturising dressing that provides the ideal environment for treating dry to lightly exuding sloughy wounds. It contains a strong, transparent hydrogel that is impermeable to bacteria but permeable to moisture, giving it the capacity to absorb or donate water, according to the needs of the wound. |
A5.02.01 |
Kerralite Cool® |
|
A5.01.02 |
Kerramax Care ® |
Rationale for use should be based on clinical assessment
- Highly absorbent for fewer dressing changes
- Unique horizontal wicking layer increases capacity by distributing exudate
- Retains exudate to help prevent maceration
- Stackable to increase absorption for very wet wounds
- Works under pressure with all forms of compression
- Maintains integrity, even when fully soaked in exudate
- Cost-effective compared with similar dressings
- Locks away exudate so that outer layers remain dry
|
15.01.01 |
Ketamine Ketalar® |
|
15.01.04.02 |
Ketorolac Toradol® |
Injection. |
11.08.02 |
Ketorolac trometamol drops 0.5% Acular® |
|
06.01.06 |
Ketostix® |
|
11.04.02 |
Ketotifen 0.25mg/ml Preservative-Free Eye Drops Ketofall® |
|
01.06.05 |
Klean-Prep® |
Oral powder.
Choice to be determined by Trust. |
06.04.01.01 |
Kliofem® |
|
06.04.01.01 |
Kliovance® |
|
A5.08.08 |
Knit-Band® |
Knitted Polyamide and Cellulose Contour Bandage, BP 1988
For dressing retention Secondary care supply subject to NHS supply chain derivatives
All sizes |
A5.08.08 |
Ko-Flex and Ko-Flex Long |
4th layer of multi-layer compression bandaging 10cm x 6m 10cm x 7m |
A5.08.08 |
K-Plus Long |
3rd layer of multi-layer compression bandaging.
10cm x 10.25m Stretched |
A5.08.08 |
K-Plus® |
3rd layer of multi-layer compression bandaging 10cm x 8.7m stretched |
A5.08.07 |
K-Soft® and K-Soft Long |
Padding, absorbent, 10cm x 3.5 m unstretched, 10 cm x 4.5 m unstretched, |
07.03.02.03 |
Kyleena® |
|
02.04 |
Labetalol |
Tablets, (Injection - secondary care only).
Specialist initiation.
|
02.06.02 |
Lacidipine Motens® |
3rd Line Choice
Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate. |
04.08.01 |
Lacosamide |
Tablets, syrup.
As adjunct therapy (not monotherapy)
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
01.06.04 |
Lactulose |
Solution.
- Note: Lactulose may also be used for alternative indications e.g. hepatic encephalopathy.
Self Care Medicine for primary care.
|
05.03.01 |
Lamivudine Generic, Epivir® |
Commissioned by NHS England (for HIV in combination with other anti-retrovirals). |
05.03.03.01 |
Lamivudine Zeffix® |
Commissioned by NHS England (for Hepatitis B). See NICE CG165. |
05.03.03.01 |
Lamivudine Generic, Zeffix® |
|
04.02.03 |
Lamotrigine |
second line for mood stabilisation See NICE CG185 Bipolar Disorder |
04.08.01 |
Lamotrigine |
Tablets, dispersible tablets.
Options based on licence.
When given for epilepsy: Category 2: base the need for continued supply of a particular manufacturer's product on clinical judgement and consultation with the patient and/or carer, taking into account factors such as seizure frequency and treatment history.
|
03.04.03 |
Lanadelumab Takhzyro® |
For prevention of recurrent attacks of hereditary angioedema in accordance with NICE TA606.
May only be prescribe by specialist centres (locally this is Southampton) in accordance with NHS England arrangements. |
08.03.04.03 |
Lanreotide Somatuline® Autogel®, Somatuline® LA |
Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.
- Neuroendocrine tumors (carcinoid syndrome).
RBCH only: Third line treatment for acromegaly (second line if patient is unfit for surgery).
Specialist centres only: congenital hyperinsulinism - in line with highly specialised criteria.
|
01.03.05 |
Lansoprazole |
- Capsules first line.
- Orodispersible tablets (i.e. Lansoprazole FasTabs) are restricted for use in adult patients with swallowing difficulties or with a feeding tube only.
GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.
Such patients should be referred for specialist advice as per CKD NICE guidance i.e.
- eGFR less than 30 ml/min/1.73m2
- sustained decrease in eGFR of 25% or more within 12 months
- sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months
Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours. |
09.05.02.02 |
Lanthanum Fosrenol® |
Commissioned by NHS England via specialist renal centres for renal patients undergoing dialysis whilst waiting for renal transplantation or parathyroidectomy.
In accordance with the phosphate binders shared care guideline for the management of Hyperphosphataemia in patients with chronic kidney disease.
|
09.08.01 |
Laronidase Aldurazyme® |
Commissioned by NHS England (for mucopolysaccharidosis)as per NHS England Service Specification, for highly specialised criteria only.
For initiation by specialist centres only.
|
08.01.05 |
Larotrectinib Vitrakvi® |
Commissioned in line with CDF criteria and conditions of the managed access agreement in accordance with the recommendations in NICE TA630 for treating NTRK fusion-positive solid tumours. |
11.06 |
Latanoprost 50micrograms/ml Single Use Drops Monopost® |
Preservative-free.
RBCH: 1st line prostaglandin analogue for patients with preservative allergy.
DCHFT: Consultant use only. 1st line prostaglandin analogue for patients with proven intolerance to preserved eye drops. |
11.06 |
Latanoprost 50micrograms/mL with timolol 5mg/mL Fixapost® |
Preservative free.
Cost effective alternative to existing formulary entries, for glucoma where a preservative free option is needed. |
11.06 |
Latanoprost drops 50micrograms with timolol 5mg/ml Xalacom® |
|
11.06 |
Latanoprost drops 50micrograms/ml |
|
19.03 |
LBF Sterile no sting barrier film wipes |
CliniMed Ltd® Product reference code 3820 Approved pack size 30 |
10.01.03 |
Leflunomide |
For third-line use in patients with active RA when treatment with sulphasalazine and methotrexate is contra-indicated or has been found to be ineffective or not tolerated. Treatment to be initiated by a consultant rheumatologist. In accordance with NICE recommendations (CG79) and local shared care guideline. DCHFT: Consultant Rheumatologist only. |
23.14 |
Leg Bag Support Straps |
Company |
Product Codes |
Price per unit |
Comments |
Unomedical |
45-85-Ex |
£1.42 |
Box of 10 (straps last a week) |
Qufora |
21100301 |
£2.05 |
Box of 10 |
Gret Bear |
10622C |
£1.38 |
Box of 10 |
CliniSupplies |
P10LS |
£1.27 |
Box of 10 |
|
08.02.04 |
Lenalidomide Revlimid® |
Commissioned by NHS England in line with NICE TA171, TA322, TA586, TA587 and TA627.
Commissioned by CDF/NHSE in line with NICE TA680 for maintenance therapy post autologous stem cell transplanation in adults with multiple myeloma. • This indication is funded by the CDF until 1/6/2021
May 2019: all new patients require prior authorisation. |
09.01.06 |
Lenograstim Granocyte® |
Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost.
Commissioned by NHS England for Barth Syndrome according to highly specialised criteria only. |
08.01.05 |
Lenvatinib Kisplyx®, Lenvima® |
Kisplyx®:
- Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.
Lenvima®:
- Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.
- Commissioned by NHSE in accordance with NICE TA551 for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.
|
02.06.02 |
Lercanidipine |
2nd Line Choice
Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate. |
05.03.02.02 |
Letermovir Prevymis® |
For use in accrodance with NICE TA591
Commissioned by NHS England for prevention of CMV after stem cell transplant as per NHS England Service Specification by specialist centres only. |
08.03.04.01 |
Letrozole |
Use in accordance with NICE TA112 and local shared care guideline. Local criteria for use include for advanced disease in postmenopausal women (including those in whom other anti-oestrogen therapy has failed) and those women at high risk of early distant relapse.
|
06.07.02 |
Leuprorelin acetate Prostap® SR DCS, Prostap® 3 DCS |
Acute trusts only stock the 3.75mg (monthly) implant.
|
08.03.04.02 |
Leuprorelin Acetate Prostap® SR DCS, Prostap® 3 DCS, |
Lutrate® has been discontinued (Jun 19)
|
04.08.01 |
Levetiracetam |
Tablets, oral solution.
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.
|
04.08.01 |
Levetiracetam IV |
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.
|
11.06 |
Levobunolol drops 0.5% and polyvinyl alcohol 1.4% Betagan® |
|
15.02 |
Levobupivacaine Chirocaine® |
0.25% and 0.5% injections, 0.125% epidural infusion
|
15.02 |
Levobupivacaine with Fentanyl |
Fentanyl 2 micrograms per mL & levobupivacaine 0.1% Epidural infusions.
|
09.08.01 |
Levocarnitine Carnitor® |
Commissioned by NHS England for carnitine deficiency when supplied in secondary care, as per NHS England service specification. For initiation by specialist centres only.
May be supplied in primary care when adequate shared care with specialist centre is in place.
Specialist centre to provide appropriate shared care agreement. |
11.03.01 |
Levofloxacin 5mg/ml Eye Drops |
Unit dose vials are preservative-free. Preserved formulations contain benzalkonium chloride 0.05 mg in 1 ml
RBCH only: Acute microbial keratitis and corneal conditions where benzlkonium chloride is contra-indicated. Where avoidance of preservative is not necessary (e.g. in patients without pre-existing corneal epitheliopathy or small corneal ulcers [<1mm]) preserved G.ofloxacin / G.levofloxacin will be the agent of choice.
For patients who might require treatment up to 6 months. Hospital consultant should advise GP of course length and stopping date. |
05.01.12 |
Levofloxacin IV |
Initial treatment for severe community acquired penumonia. |
05.01.12 |
Levofloxacin oral |
For severe community acquired pneumonia (after initial IV treatment). DCH only - see guidelines for place in therapy.
|
13.03 |
Levomenthol cream Dermacool® |
Restrict to pruritic conditions where moderate to severe skin condition requires it
Dermacool® 0.5%, Dermacool® 1%, Dermacool® 2% Aqua, White Soft Paraffin, Emulsifying Wax, Paraffinum Liquidum, Menthol (1%), Phenoxyethanol.
Self Care Medicine
|
04.02.01 |
Levomepromazine Nozinan® |
Oncology/palliative care use. |
21 |
Levomepromazine |
|
04.06 |
LEVOMEPROMAZINE (METHOTRIMEPRAZINE) |
Used in palliative care. |
07.03.05 |
Levonelle® 1500 |
Levonorgestrel 1.5 mg. Emergency contraception up to 72 hours after UPSI/contraceptive failure
Not RBCH |
07.03.02.03 |
Levonorgestrel 13.5mg intrauterine delivery system Jaydess® |
Jaydess® should only be used if other alternatives have been considered but none is suitable, eg:
For those who wish to use IUS and plan pregnancies for less than 5
years.
Previous failed fit with IUS because of malposition.
IUS required and uterine cavity on sounding is between 5-7cm
Amenorrhea associated with Mirena ® is unacceptable to patient
Previous ovarian cysts
Hormonal adverse effects with Mirena®; but IUS required (reduced dose of LNG in Jaydess® less likely to cause AE). |
06.02.01 |
Levothyroxine |
|
02.03.02 |
Lidocaine |
Injection.
Minijet 2% (Not DCHFT).
Lidocaine infusion in 5% glucose (Not DCHFT).
DCHFT: 1% and 2% injections (which can be used to prepare 0.1% or 0.2% in glucose 5% intravenous infusions).
|
15.02 |
Lidocaine 10% spray Xylocaine® |
|
15.02 |
Lidocaine 2% with Chlorhexidine 0.25% Instillagel® |
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine 4% cream LMX 4® |
DCHFT - Paediatrics only. Cannulation in/for theatres. |
15.02 |
Lidocaine 40mg/ml solution Laryngojet® |
|
15.02 |
Lidocaine 5% and Phenylephrine 0.5% |
Pump spray. |
15.02 |
Lidocaine 5% Ointment |
For perianal use only
NB: Sensitisation may occur with ongoing use |
15.02 |
Lidocaine 700mg plasters (5%) |
Only within licensed indication (post herpetic neuralgia) by chronic pain specialists.
It remains non-formulary for other indications apart from restrictions listed below
Additional Acute Trust restricted indications (off-label): RBH, PH, DCH: Rib Fracture Pain: - Max 5 days supply. Patients must be informed that this treatment is short-term before commencing therapy.
RBH only: Post-amputation pain: Acute Pain Consultant only:where other analgesics or anaesthetic techniques are contra-indicated or have limited benefit - Maximum 30 days supply. Patients must be informed that this treatment is short-term before commencing therapy.
|
15.02 |
Lidocaine Injection |
Injection - various strengths.
- DCHFT: 0.5%, 1% and 2% available.
Primary Care: for use in minor surgery and soft tissue injections |
15.02 |
Lidocaine with Adrenaline Injection |
- DCHFT: Lidocaine 1% and 2% with adrenaline (various strengths). Dental cartridges.
Primary Care: for use in minor surgery and soft tissue injections |
13.02.01 |
Light Liquid Paraffin 63.4% Oilatum® Cream |
Prescribe by Brand Oilatum Cream is indicated in the treatment of contact dermatitis, atopic dermatitis, senile pruritus, ichthyosis and related dry skin conditions.
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
01.06.07 |
Linaclotide Constella▼® |
Within local pathway for chronic constipation, and commissioning statement |
06.01.02.03 |
Linagliptin Trajenta® |
- No dosing adjustment required in renal impairment
- Use in accordance with NICE NG28 i.e. if metformin is not tolerated, or in combination for first and second treatment intensification
- If patients and their clinicians consider one of the gliptins to be a suitable treatment then the least expensive should be chosen, all other things being equal
|
05.01.07 |
Linezolid |
On microbiology advice only |
06.02.01 |
Liothyronine Injection |
For emergency treatment of hypothyroid coma, OR in patients exhibiting signs and symptoms of hypothyroidism following failure to administer/absorb usual oral replacement therapy (typically after 5-7 days). |
06.02.01 |
Liothyronine Tablets |
 (NOT RECOMMENDED) for new patients
 Amber SCG for existing patients (pending review with endocrinologist)
 When prescribed by oncologists in management of thyroid cancer.
For treatment resistant depression, following updated RMOC guidance. |
08.01.05 |
Liposomal Cytarabine-Daunorubicin Vyxeos® |
Commissioned by NHSE in line with NICE TA552 for untreated, high risk, acute myeloid leukaemia. |
13.10.05 |
LiquiBand® Tissue Adhesive |
|
13.02.01 |
Liquid and White Soft Paraffin Ointment |
Ointment, liquid paraffin 50%, white soft paraffin 50%
Self Care Medicine - to be purchased when part of routine skin care in the absence of a moderate to severe skin condition.
|
11.08.01 |
Liquid Paraffin ointment |
VitA-POS®/Hylo Night® or Xailin Night®
31/3/20 - VitA-POS is being re-branded as Hylo Night (product is identical)
For night time use.
Self Care Medicine for primary care.
|
A2.04.01.02 |
Liquigen® |
Liquigen is an emulsion consisting of approximately 50% MCT oil and 50% water.
Liquigen may be used in conditions requiring high energy where fat absorption is impaired and where a high MCT intake is indicated.
Liquigen can be used as part of the MCT ketogenic diet.
Liquigen can be used to fortify a wide variety of drinks and foods and is also useful as an energy enhancer in tube and sip feeds.
Liquigen is suitable from birth. |
04.05.02 |
Liraglutide Saxenda® |
In line with NICE TA664 for weight management and should only be used within Dorset as part of a tier 3 weight management service provided at the Spire Hospital in Southampton, and only for those patients meeting the criteria defined by the NICE guidance. |
06.01.02.03 |
Liraglutide Victoza® |
Use in accordance with NICE TA 203 and local shared care guideline. For GLP-1 agonists use in accordance with NICE NG28.
 : When used with oral anti diabetic agents in patients with Type 2 Diabetes
 : When used with insulin in patients with Type 2 Diabetes
Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, within the criteria outlined in NICE TA664. |
04.04 |
Lisdexamfetamine Elvanse® |
Second/third line option for adults, younger patients and those unable to swallow tablets as part of a comprehensive treatment in line with NICE NG87.
Refer to shared care guidance. DCHFT: Consultant psychiatrist only. |
02.05.05.01 |
Lisinopril |
Tablets. |
04.02.03 |
Lithium Carbonate |
Hospital initiation. Prescribers should be aware of the brand and form of lithium each patient is taking and ensure all prescribing is branded. Local practice, prescribing guidance, formulary restrictions and shared care guideline should be considered when initiating lithium.
***The Priadel discontinuation planned for April 2021 has been suspended***
Do not start any new patients on Priadel.
PLEASE TAKE EXTRA CARE WITH DOSE CONVERSIONS.
Lithium citrate tetrahydrate 520 mg is equivalent to lithium carbonate 204 mg. This means that:
5mL Li-Liquid 509mg/5mL oral syrup (509mg) is approximately equivalent to 200mg lithium carbonate
5mL Li-Liquid 1018mg/5mL oral syrup (1018mg) is approximately equivalent to 400mg lithium carbonate
5mL Priadel 520mg/5mL liquid (520mg) is approximately equivalent to 204mg lithium carbonate.
All lithium preparations vary widely in bioavailability. Prescriptions should specify brand and formulation; changing the preparation requires the same precautions as initiation of treatment. As most lithium tablets are modified-release, when lithium is given as a liquid the total daily dose of lithium will need to be given in divided doses.
Please refer to document from SPS (linked below) for more conversion information, and/or consult a local specialist mental health pharmacist if considering changing formulation. |
04.02.03 |
Lithium Citrate liquid |
Hospital initiation. Prescribers should be aware of the brand and form of lithium each patient is taking and ensure all prescribing is branded. Local practice, prescribing guidance, formulary restrictions and shared care guideline should be considered when initiating lithium.
The Preferred Brand for DHC is Priadel.
PLEASE TAKE EXTRA CARE WITH DOSE CONVERSIONS.
Lithium citrate tetrahydrate 520 mg is equivalent to lithium carbonate 204 mg. This means that:
5mL Li-Liquid 509mg/5mL oral syrup (509mg) is approximately equivalent to 200mg lithium carbonate
5mL Li-Liquid 1018mg/5mL oral syrup (1018mg) is approximately equivalent to 400mg lithium carbonate
5mL Priadel 520mg/5mL liquid (520mg) is approximately equivalent to 204mg lithium carbonate.
All lithium preparations vary widely in bioavailability. Prescriptions should specify brand and formulation; changing the preparation requires the same precautions as initiation of treatment. As most lithium tablets are modified-release, when lithium is given as a liquid the total daily dose of lithium will need to be given in divided doses.
Please refer to document from SPS (linked below) for more conversion information, and/or consult a local specialist mental health pharmacist if considering changing formulation. |
06.01.02.03 |
Lixisenatide Lyxumia® |
As an option alongside exenatide and liraglutide. When initiating a GLP-1 agonist choice should be on clinical indication and consideration to use the most cost effective product, first line. Refer to shared care guideline.
 : When used with oral hypoglycaemics in patients with Type 2 Diabetes
 : When used with insulin in patients with Type 2 Diabetes |
13.04 |
Locoid® |
Cream, hydrocortisone butyrate 0.1%
Potency: potent
Excipients include cetostearyl alcohol, hydroxybenzoates (parabens)
Ointment, hydrocortisone butyrate 0.1%
Potency: potent |
12.01.01 |
Locorten-Vioform® |
Flumetasone pivalate drops 0.02% and clioquinol 1% |
11.04.02 |
Lodoxamide drops 0.1% |
Second choice for
Adults
Seasonal allergies
Not at DCHFT. |
04.03.01 |
Lofepramine |
|
04.10.03 |
Lofexidine BritLofex® |
For Specialist Use only |
01.04.02 |
Loperamide |
Capsules, syrup.
Self Care Medicine for primary care.
|
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines. |
03.04.01 |
Loratadine |
Tablets, syrup.
Self Care Medicine for primary care.
|
04.01.02 |
Lorazepam |
See Primary care protocol for anxiety disorders. |
04.01.02 |
Lorazepam injection 4mg/ml |
For status epilepticus or rapid tranquilisation. By intramuscular or slow intravenous injection (into a large vein) Note: Only use intramuscular route when oral and intravenous routes not possible For intramuscular injection it should be diluted with an equal volume of water for injections or physiological saline (but only use when oral and intravenous routes not possible)
See NICE NG10: Violence and Aggression: Short Term Management in Mental Health, Health and Community Settings |
04.08.02 |
Lorazepam IV 4mg/ml |
By slow intravenous injection (into large vein) |
21 |
Lorazepam Tablets Genus® |
Can be used sublingually |
08.01.05 |
Lorlatinib Lorviqua® |
Commissioned by NHSE in accordance with NICE TA628. |
02.05.05.02 |
Losartan |
Tablets |
11.04.01 |
Loteprednol |
Not at DCHFT. |
13.04 |
Lotriderm® |
Cream, betamethasone dipropionate 0.064% (≡ betamethasone 0.05%), clotrimazole 1%
Potency: potent
Excipients include benzyl alcohol, cetostearyl alcohol, propylene glyco |
03.12 |
lumacaftor/ivacaftor Orkambi® |
100/125 lumacaftor/ivacaftor tablets
200/125 lumacaftor/ivacaftor tablets
Indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene. |
04.02.01 |
Lurasidone Latuda® |
Consultant Psychiatrist Initiation only
For Schizophrenia
Aripiprazole must have been considered first |
09.01.04 |
Lusutrombopag Mulpleo® |
tablets 3mg
For treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures, in accordance with NICE TA617 |
08.01.05 |
Lutetium (177Lu) oxodotreotide Lutathera® |
Commissioned by CDF in line with CDF criteria and NICE TA539. |
05.01.03 |
Lymecycline Tetralysal® 300 |
For dermatology use only. |
13.06.02 |
Lymecycline |
DCHFT: Dermatology use only. |
01.06.04 |
Macrogols |
Oral powder.
Alternative prescribing option.
Available as various brands including Laxido®, Movicol®.
DCHFT: Consultant use only and, restricted indications (i) one-off use in faecal impaction or (ii) patients intolerant or unresponsive to lactulose and magnesium hydroxide suspension. It is envisaged that very few patients will be discharged from hospital on this medication. |
18 |
Macrogols Klean-Prep® or similar |
For gut decontamination of agents not bound by activated charcoal (e.g. iron & lithium). |
01.06.04 |
Macrogols Paediatric |
Oral Powder
First line in paediatric patients.
To avoid confusion this should be prescribed by brand and prescribers are asked to use the most cost effective option. Brands available (DM&D 21/11/16) include:
• CosmoCol® Paediatric
• Laxido® Paediatric plain
• Macilax® Paediatric
• Molative® Paediatric
• Movicol® Paediatric Chocolate
• Movicol® Paediatric Plain |
09.05.01.03 |
Magnesium Aspartate Magnaspartate® |
|
09.05.01.03 |
Magnesium citrate |
Not at RBCH
Not at DCHFT
See primary care Magnesium guidelines |
09.05.01.03 |
Magnesium Glycerophosphate |
Oral
See primary care magnesium guidelines |
09.05.01.03 |
Magnesium Glycerophosphate NeoMag® |
Second line: for patients who cannot tolerate magnesium aspartate |
01.06.04 |
Magnesium Hydroxide Mixture |
Self Care Medicine for primary care.
Dec 19: Manufacturing issue - alternative laxatives will need to be used. Earliest anticipated date for return is Feb 2020. |
09.05.01.03 |
Magnesium Sulfate |
Injection / Infusion |
01.01.01 |
Magnesium Trisilicate Mixture BP |
Self Care Medicine for primary care.
|
23.06 |
Male drainage pouch |
Company |
Code |
Price |
Comment |
Hollister
|
Urinary pouch Code: 9873
|
£2.96
|
Specialist Item. Retractable penis– area would need to be shaved.
|
|
23.05 |
Male urinals |
Company |
Code |
Price |
Comment |
Beambridge Medical
|
Male Funnel (6–35)
Male Mini Funnel (6–35 M)
|
£13.55
£13.55
|
For men who Spray when passing urine. Mini will fit in pocket. One Supplied.
|
|
02.02.05 |
Mannitol |
Infusions. |
03.07 |
Mannitol Bronchitol ® |
Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA266.
Adult patients: specialist centre only (University Hospital Southampton)
Paediatric patients: PHFT use in line with network arrangements with UHS.
Not at DCH or RBCH. |
05.03.01 |
Maraviroc Celsentri® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.
|
A2.04.01.01 |
Maxijul® Super Soluble |
(Modular energy supplements to be used under direction of Dietitian only)
Adult patients
NICE CG32 Nutrition support in adults
Paediatric patients
Flavoured carbohydrate supplements are not suitable for children under 1 year of age, dilute liquid supplements forfore use in children under the age of 5. |
11.04.01 |
Maxitrol® |
Eye drops, dexamethasone 0.1%, neomycin sulfate 3500 units /g, polymyxin B sulfate 6000 units/mL
Eye ointment, dexamethasone 0.1%, neomycin sulfate 3500 units/g, polymyxin B sulfate 6000 units/g |
14.04 |
Measles, mumps and rubella vaccine MMRVAXPRO |
|
05.05.01 |
Mebendazole |
Self Care Medicine for primary care.
|
01.02 |
Mebeverine Hydrochloride |
Tablets, liquid.
Self Care Medicine for primary care
|
06.07.04 |
Mecasermin Increlex® |
Commissioned by NHS England (for growth failure) as per NHS England Policy: E03/P/a. |
A5.03.01 |
Medihoney Antibacterial Apinate Dressings |
creates a micro-environment that supports healing and provides an antibacterial barrier.
INDICATIONS
- Acute and chronic wounds
- Infected and malodorous wounds
- Necrotic and sloughy wounds
- Pressure sores
- Surgical, post op wounds, donor sites and recipient graft sites
- Leg ulcers (venous, arterial and mixed aetiology ulcers) and diabetic foot ulcers
- 1st and 2nd degree burns
|
A5.03.01 |
Medihoney Antibacterial Wound Gel |
Medihoney Antibacterial Wound Gel is formulated from 100%. Medical Grade Manuka Honey combined with 20% natural plant waxes in a single patient sealable, reusable tube.
INDICATIONS
- Acute and chronic wounds
- Infected and malodorous wounds
- Necrotic and sloughy wounds
- Pressure sores
- Surgical, post op wounds, donor sites and recipient graft sites
- Leg ulcers (venous, arterial and mixed aetiology ulcers) and
- diabetic foot ulcers
- 1st and 2nd degree burns
|
A5.03.01 |
Medihoney Tulle |
Medihoney® Antibacterial Honey Tulle Dressing protects the wound by creating a barrier against wound pathogens, including antibiotic resistant strains, and therefore reducing the risk of infection. The osmotic action produces an outflow of body fluid which assists the removal of wound bacteria, endotoxins, debris and slough, providing a cleaner wound, rapidly removing malodour and helping to reduce the inflammatory response, oedema and exudate levels. Granulation and epithelialisation are enhanced through provision of the optimal healing environment.
INDICATIONS
- Leg/foot ulcers
- Pressure ulcers
- Infected wounds
- Sloughy wounds
- Necrotic wounds
- Malodorous wounds
- Donor and recipient graft sites
- Burns
- Surgical wounds
- Diabetic wounds
- Abrasions
|
13.02.02 |
Medihoney® Barrier Cream |
Medihoney barrier cream contains only natural products with the addition of 30% active 100% Pure Medical Grade Manuka Honey.
INDICATIONS
• Protects at risk skin from breakdown associated with incontinence. Can be used under incontinence pads
• Can be used around wound edges to protect skin from irritation and breakdown caused by wound exudate
• Suitable for injured skin or areas that are inflamed or excoriated
• Suitable for all ages including paediatrics and neonates |
A5.03.01 |
Medihoney® Gel Sheet Dressing |
Medihoney Gel Sheet is a sterile, non-adherent wound dressing made from Medihoney Antibacterial Honey (80%w/w) and Sodium Alginate for wound care (20%w/w).
The gel sheet is helpful in treating a wide variety of mild to moderately exudating wounds
Indications:
- Leg and foot ulcers.
- Pressure ulcers.
- Infected wounds.
- Burns.
- Sloughy wounds.
- Malodorous wounds.
- Donor and recipient graft sites.
|
A5.03.01 |
Medihoney® HCS |
Medihoney® HCS is an all in one dressing combining the unique properties of medical grade Manuka honey with a hydrogel sheet containing superabsorbent polymers.
INDICATIONS
- Diabetic Foot Ulcers
- Leg Ulcers (venous, arterial and mixed aetiology ulcers)
- Pressure Ulcers 1st and 2nd degree burns
- Donor sites
- Traumatic Wounds
- Surgical and post op wounds
- Skin tears
- Suitable for neonatal and paediatric patients
|
06.01.06 |
Medi-Test® Glucose Test Strips |
|
06.04.01.02 |
Medroxyprogesterone Acetate Provera® Climanor® |
|
07.03.02.02 |
Medroxyprogesterone acetate as Sayana Press® |
|
08.03.02 |
Medroxyprogesterone Acetate Provera® |
|
10.01.01 |
Mefenamic Acid |
|
05.04.01 |
Mefloquine Lariam® |
BNF caution: mefloquine and driving - dizziness or a disturbed sense of balance may affect performance of skilled tasks e.g. driving; effects may occur and persist upto several months after stopping mefloquine. DCHFT: Not stocked.
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel†|
08.03.02 |
Megestrol Acetate Megace® |
|
04.01.01 |
Melatonin SR Circadin ® |
When used for licensed indication only: for short-term treatment of insomnia in adults over 55 years, for up to 13 weeks. |
A5.01.01 |
Melolin |
A low-adherent absorbent dressing used for the management of a wide variety of light to moderately exuding wounds including clean sutured wounds, abrasions, lacerations and minor burns. |
A5.01.01 |
Melolite |
Only available to secondary care via NHS supply chain and not available on FP10 |
10.01.01 |
Meloxicam |
Orodispersible formulation is Non-Formulary. |
08.01.01 |
Melphalan Alkeran® |
|
04.11 |
Memantine |
Tablets, oral solution. For moderate to severe Alzheimer's disease. In accordance with NICE recommendations (TA217). Refer to local shared care guideline. |
09.06.06 |
Menadiol Sodium Phosphate |
For malabsorption syndrome |
14.04 |
Meningococcal A, C, W135, and Y conjugate vaccine Menveo® |
Menveo powder and solution for solution for injection
Meningococcal Group A, C, W135 and Y conjugate vaccine
DCHFT: Not routinely stocked.
This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel |
14.04 |
Meningococcal group B Vaccine Bexsero® |
Meningococcal group B Vaccine (rDNA, component, adsorbed) |
14.04 |
Meningococcal group C conjugate vaccine Menjugate Kit® |
|
14.04 |
Meningococcal Group C conjugate vaccine NeisVac-C |
|
14.04 |
Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax® |
DCHFT: Not routinely stocked.
This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
|
14.04 |
Meningococcal Quadrivalent A, C, W135 & Y conjugate vaccine Nimenrix ® |
DCHFT: Not routinely stocked.
This vaccine is not available at NHS expense in Dorset for Overseas Travel : see Dorset Guidance for Prescribing for Overseas Travel
|
06.05.01 |
Menotrophin Menopur ®, Merional®, |
Human Menopausal Gonadotrophin |
A5.02.03 |
Mepitel |
Soft silicone, semi-transparent/transparent wound contact dressing
All Sizes
For the management of life threatening acute skin disorders such as toxic epidermal necrolysis (TEN), bullous pemphigoid and vasculitis. |
15.02 |
Mepivacaine Scandonest Plain® |
Injection. |
03.04.02 |
Mepolizumab Nucala® |
Commissioned by NHS England in accordance with NICE TA431 at specialist centres only. |
09.08.01 |
Mercaptamine Cystagon® |
Commissioned by NHS England (for nephropathic cystinosis) as per NHS England Service Specification according to highly specialised criteria.
For initiation by specialist centres only |
01.05.03 |
Mercaptopurine |
Unlicensed special - see entry above |
01.05.03 |
Mercaptopurine |
Tablets only. Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults Unlicensed for these indications but in line with national guidelines. See also Chapter 8 section 8.1.3
Unlicensed 10mg capsules may be available as a special. At RBCH, the capsules are Consultant Gastroenterologist for Crohn's disease in conjunction with allopurinol only.
|
08.01.03 |
Mercaptopurine |
Also see BNF chapter 1 section 1.5.3. |
01.05.03 |
Mercaptopurine 20mg in 1mL Suspension |
Unlicensed RBCH: Consultant Gastroenterologist for Crohn’s disease where patients are unable to swallow capsules
|
05.01.02.02 |
Meropenem Meronem® |
On microbiology advice only.
RBCH:On microbiology advice or in accordance with neutropenic sepsis policy.
DCHFT: Consultant only or as per local guidelines. |
01.05.01 |
Mesalazine |
Tablets, m/r tablets, sachets.
- There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary. It is recommended that mesalazine is prescribed by brand name (Asacol®, Asacol® MR, Ipocol®, Mezavant® XL, Octasa®, Pentasa®, or Salofalk®).
- If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.
- Initiate all non-oral mesalazine products in secondary care.
- Give Octasa® for all newly initiated patients. Patients on Asacol® can safely be switched to Octasa®. Routine switching of brands is not expected.
- Patients prescribed mesalazine require 6 monthly or annual blood tests for renal function when treatment is stable.
Crohns patients prescribed mesalazine should undergo a specialist review given the updated guidance from the Gastroenterology working group: "There is almost no convincing evidence of any therapeutic benefit for the use of any form of mesalazine in Crohns. All patients with Crohns currently receiving mesalazine should be reviewed with consideration of the aim of stopping this treatment." |
01.05.01 |
Mesalazine |
Retention enema, foam enema, suppositories.
- To be initiated in secondary care.
- Only Asacol® foam enemas are licensed for 2g doses to treat disease in the descending colon.
Crohns patients prescribed mesalazine should undergo a specialist review given the updated guidance from the Gastroenterology working group: "There is almost no convincing evidence of any therapeutic benefit for the use of any form of mesalazine in Crohns. All patients with Crohns currently receiving mesalazine should be reviewed with consideration of the aim of stopping this treatment.
|
01.05.01 |
Mesalazine Octasa® |
All new initiations should be for the Octasa® brand |
08.01 |
Mesna |
DCHFT: Injection and tablets available. |
18 |
Mesna |
For cyclophosphamide toxicity.
RBCH: IV kept in Pharmacy Aseptic Unit |
13.02.02 |
Metanium® |
Ointment, titanium dioxide 20%, titanium peroxide 5%, titanium salicylate 3% in a basis containing dimeticone, light liquid paraffin, white soft paraffin, and benzoin tincture
This product is indicated for use in Paediatrics and is not included in the Moisture Pathway.
Self Care Medicine for primary care.
|
02.07.02 |
Metaraminol |
Injection. |
06.01.02.02 |
Metformin |
|
06.01.02.02 |
Metformin modified release |
DCHFT: In accordance with NICE guidelines - for patients in whom gastrointestinal tolerability prevents patients continuing with standard release metformin. |
04.10.03 |
Methadone hydrochloride |
Now categorised as a "red drug" for substance misuse. DMAG March 2018 |
03.09.01 |
Methadone linctus 2mg/5ml |
Oral solution for palliative care only (not substance misuse). |
05.01.13 |
Methenamine Hippurate Hiprex® |
May be used as a third-line prophylactic agent if no renal or hepatic impairment. For prophylaxis of UTIs only in line with the SCAN Guidelines |
01.05.03 |
Methotrexate |
Tablets.
2.5mg tablets preferred as per Dorset CCG policy.
There are a number of different indications for methotrexate. Please see
here for other indications.
Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults Unlicensed for these indications but in line with national guidelines. |
08.01.03 |
Methotrexate |
|
10.01.03 |
Methotrexate |
Hospital initiation for rheumatoid arthritis in accordance with shared care guidelines, NICE recommendations CG79 and NPSA patient safety alert. Do not prescribe 10mg tablets. See the Policy for Prescribing Methotrexate for further information. Where using a Pre-Filled Syringe, patients should be maintained on the product they were initiated / trained on. Brands available include Nordimet® and Metoject® |
13.05.03 |
Methotrexate |
For severe psoriasis unresponsive to conventional therapy. DCHFT: Consultant use only. |
09.01.03 |
Methoxy Polyethylene Glycol-Epoetin Beta Mircera® |
|
15.01.02 |
Methoxyflurane Penthrox® |
UHD: Approved for use within Emergency Departments for joint reduction/fracture manipulation.
Dorset County: Not yet assessed/approved |
13.05.02 |
Methoxypsoralen Gel/Bath Lotion |
Not DCHFT. |
13.08.01 |
Methyl-5-Aminolevulinate Metvix® |
Poole: Treatment of Bowen's Disease - Used in photodyamic therapy
|
01.06.01 |
Methylcellulose 450 0.5% liquid |
Liquid.
Radiology use for MRI enteroclysis.
RBCH UL medicines risk assessment: LOW risk
|
02.05.02 |
Methyldopa |
Tablets.
For use during pregnancy. |
04.04 |
Methylphenidate |
Tablets, modified release capsules and tablets. Use as per NICE NG87 and local shared care guidelines - children and adults. All modified release preparations can be prescribed under shared care agreement.
Branded generics bioequivalent to Concerta are now available. These include Delmosart, Matoride, Xaggitin and Xenidate. Prescribers are asked to consider the most cost effective option taking into consideration the strengths and release profiles available. Prescribers should specify the specific name of the preparation and these should not be switched.
Relative costs of bioequivalent MR generics:
Methylphenidate brand
|
Cost per 30 tablets
|
|
18mg
|
27mg
|
36mg
|
54mg
|
Concerta XL tab
|
£31.19
|
36.81
|
42.45
|
73.62
|
Matoride XL tablets, Xenidate XL tablets, Delmosart XL tablets and Xaggitin XL tablets have all been granted marketing authorisation on the bioequivalence to Concerta XL tablets as the licensed reference product as opposed to clinical studies.
Matoride XL tablets and Xenidate XL are presented as biconvex round tablets whereas Concerta XL, Delmosart XL and Xaggitin XL are capsule shaped tablets of a similar size to the bioequivalent products.
|
Delmosart tab
|
£15.57
|
18.39
|
21.21
|
36.79
|
Xaggitin XL tab
|
£15.58
|
18.40
|
21.22
|
36.80
|
Xenidate XL tab
|
£18.39
|
18.39
|
21.21
|
36.79
|
Matoride XL tab
|
£15.58
|
-
|
21.22
|
36.80
|
Prices from Shared Care guideline, July 2019 DCHFT: Modified release formulations are second line when compliance with standard release form is a significant problem. |
06.03.02 |
Methylprednisolone |
|
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone®, |
|
10.01.02.02 |
Methylprednisolone Acetate with Lidocaine Depo-Medrone® with Lidocaine |
DCHFT: Not routinely stocked. |
18 |
Methylthioninium chloride injection methylene blue |
Unlicensed. For treatment of methaemoglobinaemia and as a diagnostic aid for fistula detection.
RBCH: kept in ITU and Theatres |
04.06 |
Metoclopramide |
Tablets, syrup.
MHRA/CSM advice Aug 13:
In adults over 18 years, metoclopramide should only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics
Metoclopramide should only be prescribed for short-term use (up to 5 days)
Usual dose is 10 mg, repeated up to 3 times daily; max. daily dose is 500 micrograms/kg
Note This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care)
|
04.06 |
Metoclopramide Injection |
Green for use in palliative care (see chapter 21) MHRA/CSM advice Aug 13:
- In adults over 18 years, metoclopramide should only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics
- Metoclopramide should only be prescribed for short-term use (up to 5 days)
- Usual dose is 10 mg, repeated up to 3 times daily; max. daily dose is 500 micrograms/kg
Note This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care)
|
21 |
Metoclopramide injection |
|
02.02.01 |
Metolazone |
Tablets.
For refractory heart failure.
Unlicensed, available from special order manufacturers or specialist importing companies.
|
02.04 |
Metoprolol |
Tablets, (Injection - secondary care only).
- Modified release tablet is non formulary.
- Alternative prescribing option to first line agents.
|
13.04 |
Metosyn® |
FAPG cream, fluocinonide 0.05%
Potency: potent
Excipients include propylene glycol
Ointment, fluocinonide 0.05%
Potency: potent
Excipients include propylene glycol, wool fat
Not RBCH
Not DCHFT |
13.10.01.02 |
Metrogel® |
Gel, metronidazole 0.75%
Excipients include hydroxybenzoates (parabens), propylene glycol
For rosacea |
05.04.02 |
Metronidazole |
|
05.04.03 |
Metronidazole |
|
05.04.04 |
Metronidazole |
|
07.02.02 |
Metronidazole 0.75% Vaginal Gel |
1st line treatment for bacterial vaginosis. |
05.01.11 |
Metronidazole IV |
|
05.01.11 |
Metronidazole oral/rectal |
|
06.07.03 |
Metyrapone Metopirone® |
Hospital initiation |
02.03.02 |
Mexiletine |
Capsules, injections.
Unlicensed: Available from special order manufacturers or specialist importing companies for treatment of arrhythmias provided consultant provides a letter of clinical need to justify use of unlicensed formulation over the licensed product ( indicated for non-dystrophic myotonia).
Restricted to specialist use only.
|
04.09.03 |
Mexiletine NaMuscla® |
Commissioned by NHSE for the treatment of non-dystrophic myotonic disorders at specialised neurosciences centres only. |
05.02.04 |
Micafungin Mycamine® |
Commissioned by NHS England (for fungal infection treatment). Use as per Trust Guidelines. DCHFT: Not routinely stocked. |
07.02.02 |
Miconazole Gyno-Daktarin® |
|
11.03.02 |
Miconazole drops 1% |
Preservative free
unlicensed
DCHFT: On formulary but not stocked. |
05.02.02 |
Miconazole oral gel Daktarin® |
|
12.03.02 |
Miconazole oral gel 20mg/g Daktarin® |
Not at RBCH
Self Care Medicine for primary care.
|
22.02 |
Microdot Safety Pen Needles NB: formerly Verifine |
Size: 5mm/30g |
15.01.04.01 |
Midazolam Hypnovel® |
Injection.
DCHFT: Higher strength products (2mg/mL or 5mg/mL) are restricted to critical care areas only. |
21 |
Midazolam |
|
04.08.02 |
Midazolam buccal liquid Buccolam® and Epistasus® |
For use in status epilepticus in accordance with local shared care guidelines for use in children and adults. Buccolam® is licensed for use in status epilepticus in children (3months up to 18 years). Epistasus® is licensed for ages 10-18years. DCHFT: Buccolam® 2.5mg in 0.5mL, 5mg in 1mL, 7.5mg in 1.5mL stocked. For adult patients (> 18 years of age) there is no licensed version of buccal midazolam for this age group. DCHFT: Epistatus 10mg in 1mL stocked. unlicensed.
Green for use of Buccolam in palliative care (see chapter 21) |
21 |
Midazolam buccal liquid Buccolam® |
Use 5mg in 1ml for 5mg dose as per COVID-19 palliative guidelines |
04.08.02 |
Midazolam IV |
|
02.07.02 |
Midodrine |
Tablets.
- DCHFT: 2.5mg and 5mg tablets stocked.
|
08.01.05 |
Midostaurin Rydapt® |
Commissioned by NHSE in line with NICE TA523 recommendations. |
08.02.04 |
Mifamurtide Mepact ® |
|
07.01.02 |
Mifepristone |
DCHFT: CD. Medical termination of pregnancy in accordance with local protocol. |
09.08.01 |
Miglustat Zavesca® |
Commissioned by NHS England (for Gaucher's disease/Niemann-Pick) as per NHS England Service Specification according to highly specialised criteria only.
For initiation by specialist centres only. |
02.01.02 |
Milrinone Primacor® |
Injection.
Secondary care only. Specialist use for severe heart failure. |
11.05 |
Minims® Atropine Sulfate drops 1% |
Preservative-free |
11.05 |
Minims® Cyclopentolate Hydrochloride drops 0.5% |
Preservative-free
RBCH only: For in-patient/clinic use.
DCHFT: On local formulary and stocked. |
11.05 |
Minims® Cyclopentolate Hydrochloride drops 1% |
Preservative-free |
11.05 |
Minims® Phenylephrine Hydrochloride drops 10% |
Preservative-free |
11.05 |
Minims® Phenylephrine Hydrochloride drops 2.5% |
Preservative-free |
11.06 |
Minims® Pilocarpine 2% |
Preservative-free |
11.05 |
Minims® Tropicamide drops 0.5% |
Preservative-free |
11.05 |
Minims® Tropicamide drops 1% |
Preservative-free |
11.03.01 |
Minims®Chloramphenicol drops 0.5% |
Preservative free |
11.08.02 |
Minims®Fluorescein Sodium drops 1% |
DCHFT: 2% on local formulary.
|
11.07 |
Minims®Lidocaine Hydrochloride 4% with Fluorescein 0.25% |
Preservative free |
11.07 |
Minims®Oxybuprocaine Hydrochloride 0.4% |
|
11.04.01 |
Minims®Prednisolone drops 0.5% |
Preservative free |
11.07 |
Minims®Proxymetacaine Hydrochloride 0.5% |
|
11.07 |
Minims®Tetracaine Hydrochloride(Amethocaine hydrochloride 0.5% and 1% |
|
03.01.05 |
Mini-Wright® |
Available as low range peak flow meter and standard range peak flow meter. |
13.06.02 |
Minocycline |
To give the option of using minocycline for patients who suffer with mood problems when using isotretinoin for acne
Minocycline should not be used routinely for acne as there are safety risks and it is an expensive treatment.
Minocycline can cause gastrointestinal and dermatological adverse reactions. Minocycline has also been associated with hyperpigmentation and systemic lupus erythematosus (SLE) and autoimmune hepatitis. The BNF advises that if treatment continues beyond six months, GPs should monitor patients every three months for hepatotoxicity, pigmentatiion and SLE. |
02.05.01 |
Minoxidil Loniten® |
Tablets.
Restriction: For renal use only. |
07.04.02 |
Mirabegron |
Choice should be based on selecting the most cost-effective option. Use within NICE TA 290 and local commissioning statement. |
07.03.02.03 |
Mirena® |
Intra-uterine system, T-shaped plastic frame (impregnated with barium sulfate and with threads attached to base) with polydimethylsiloxane reservoir releasing levonorgestrel 20 micrograms/24 hours
Mirena and HRT
The 52mg LNG-IUS Mirena offers protection against the stimulatory effects of oestrogen as part of hormone replacement therapy. Mirena is licensed in the UK for protection from endometrial hyperplasia when combined with oestrogen. Unfortunately, when the application was made for a licence 4 years was requested, rather than 5 years. However, the Faculty of Sexual and Reproductive Healthcare supports use of up to 5 years for this purpose off label. To guarantee endometrial protection, the device must be changed every 5 years irrespective of age at the time of insertion
Levosert, Jaydess and Kliofem are not licensed for this indication and so should not be used for endometrial protection in the HRT regimen. |
04.03.04 |
Mirtazapine |
Second choice after SSRIs |
01.03.04 |
Misoprostol Cytotec® |
Tablets. |
07.01.01 |
Misoprostol |
RBCH use licensed oral tablets for vaginal administration (off-label) |
08.01.02 |
Mitomycin Mitomycin C Kyowa® |
|
11.99.99.99 |
Mitomycin C Eye Drops 0.02% and 0.04% |
Unlicensed.
For ocular surface neoplasms.
DCHFT: Not routinely stocked. |
08.01.05 |
Mitotane Lysodren® |
|
08.01.02 |
Mitoxantrone |
|
15.01.05 |
Mivacurium Chloride Mivacron® |
Injection. |
04.03.02 |
Moclobemide |
|
04.04 |
Modafinil Provigil® |
Tertiary care initiation only |
A2.03.01 |
Modjul® Flavour System Nutricia |
If patient dislikes or does not tolerate Modulen IBD then trial of Elemental 028 extra can be considered
Available in 2 flavours or the unflavoured one can be made more palatable using the flavour modjuls
Use liquid E028 for patients who need to take product away from home or who dislike the taste of powdered E028
Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae. |
A2.03.02 |
Modulen IBD® |
Paediatric and adult patients.
Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae. |
03.03.02 |
Montelukast |
Tablets, chewable tablets, granules.
For use in asthma in accordance with British Thoracic Society Guidelines |
04.07.02 |
Morphine |
Solution, concentrated solution, immediate release tablets, modified release tablets and capsules.
For non-cancer pain, strong opioids should be considered only when they are used as part of a programme of supported rehabilitation, with the goal of helping patients to manage pain-related disability. There is no evidence of superior clinical analgesic effect of other opioids over morphine.
|
04.07.02 |
Morphine Injection/Infusion |
There is no evidence of superior clinical analgesic effect of other opioids over morphine.
Green for use in palliative care (see chapter 21) |
21 |
Morphine sulphate injection |
|
21 |
Morphine sulphate oral solution 10mg/5ml Oramorph® |
|
12.03.04 |
Mouthwash solution tablets |
Not stocked at RBCH
Self Care Medicine for primary care.
|
01.06.05 |
Moviprep® |
Oral powder.
Choice to be determined by Trust.
DCHFT: For patients with co-morbidities only. |
05.01.12 |
Moxifloxacin |
Restricted indications:
PGH respiratory
DCH GUM only
Osteomyelitis in patients with diabetes, on advice of consultant microbiologist ONLY |
11.03.01 |
Moxifloxacin 0.5% Eye Drops |
Contans boric acid as a preservative
RBCH only: Acute microbial keratitis and corneal conditions where benzlkonium chloride is contra-indicated. Based on clinical review of eye this may be more cost effective than preservative free G.levofloxacin. Boric acid is less toxic to the cornea than benzalkonium chloride, and is more suitable for short- to medium-term use.
For patients who might require treatment up to 6 months. Hospital consultant should advise GP of course length and stopping date. |
02.05.02 |
Moxonidine |
Tablets.
For renal use only. |
13.10.01.01 |
Mupirocin 2% Cream / Ointment Bactroban® |
Cream; mupirocin (as mupirocin calcium) 2%
Excipients include benzyl alcohol, cetyl alcohol, stearyl alcohol DCHFT: Cream, indicated for the topical treatment of secondary infected traumatic lesions such as small lacerations, sutured wounds or abrasions [up to 10cm in length or 100cm square in area], due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Treatment should not exceed 10 days. Ointment; mupirocin 2% no excipients DCHFT: Ointment, indicated for the treatment of skin infections by susceptible organisms, e.g. impetigo, folliculitis and furunculosis. Treatment should not exceed 10 days. |
12.02.03 |
Mupirocin nasal ointment 2% Bactroban® |
Nasal ointment; mupirocin 2% (as calcium salt) in white soft paraffin basis |
08.02.01 |
Mycophenolate mofetil |

- Commissioned by NHS England (for transplant immunosuppression only).
Renal transplant under the care of Dorset County Hospital or Portsmouth Hospitals Trust – RED (where GPs are still prescribing immunosuppressants, in these cases please inform the CCG Medicines Management team)
- Renal or other organ transplant by tertiary centre other than Dorset County Hospital or Portsmouth Hospitals Trust – AMBER drug with shared care guideline (Trust specific). GPs are expected to continue supplies for existing patients only until repatriation occurs, no dates yet confirmed by NHS England.
|
13.05.03 |
Mycophenolate mofetil |
Hospital use only - unlicensed |
08.02.01 |
Mycophenolic acid (as Mycophenolate sodium) Myfortic® |

- Commissioned by NHS England (for transplant immunosuppression only). Renal transplant under the care of Dorset County Hospital or Portsmouth Hospitals Trust – RED (where GPs are still prescribing immunosuppressants in these cases please inform the CCG Medicines Management team)

- Renal or other organ transplant by tertiary centre other than Dorset County Hospital or Portsmouth Hospitals Trust – AMBER drug with shared care guideline (Trust specific). GPs are expected to continue supplies for existing patients only until repatriation occurs, no dates yet confirmed by NHS England.
|
11.05 |
Mydricaine No. 2 injection |
Compound preparation containing procaine, atropine and adrenaline.
Unlicensed special.
DCHFT: Consultant only. |
22.02 |
Mylife Clickfine AutoProtect |
Size: 5mm/31g
|
06.01.01.03 |
Mylife lancets |
|
22.01 |
Mylife Penfine Classic |
Size: 4mm/32g Size: 6mm/32g |
06.01.01.03 |
Mylife Safety Lancets |
|
06.01.06 |
MyLife® Pura Test Strips |
|
06.01.06 |
MyLife® Unio Test Strips |
|
02.04 |
Nadolol Corgard® |
For long QT syndrome |
06.07.02 |
Nafarelin Synarel® |
Hospital only, for in vitro fertilisation. |
02.06.04 |
Naftidrofuryl Oxalate |
Capsules.
- For use in accordance with NICE TA223.
|
01.06.07 |
Naldemedine Rizmoic® |
In accordance with NICE TA651 for treating opioid -induced constipation and locally agreed pathway for the management of constipation |
04.10.01 |
Nalmefene |
Tablets
It is very important that both the services who will be providing the psychosocial support and the GP who will be prescribing communicate closely to ensure that the drug is used in accordance with its licence and the NICE guidance (TA 325). A patient should not continue to receive the drug if they drop out of the support structure. Whilst the drug is categorised as “amber” all prescribing including the initial supply will be the responsibility of the GP and the shared care is in place as the prescribing and support will be coming from different providers who need to communicate closely. Providers of psychosocial support are listed in the shared care guidance and accompanying flow diagram. Patients should be encouraged to self-refer to these services following their initial discussion with their GP. GPs should not initiate prescriptions until they have received communications from the support service. |
01.06.07 |
Naloxegol |
As per nice TA 345 |
18 |
Naloxone injection |
For emergency treatment of opioid overdose. |
04.10.01 |
Naltrexone |
|
04.10.03 |
Naltrexone Liquid 5mg/ml |
RBCH & PHFT: Consultant dermatologist use for treatment of Hailey-Hailey disease only. |
04.10.03 |
Naltrexone Tablets |
As an adjunct to prevent relapse in detoxified, formerly opioid-dependent patients, in accordance with NICE TA115, shared care guideline and where supporting infrastructure is available to primary care. |
10.01.01 |
Naproxen |
|
10.01.04 |
Naproxen |
or alternative NSAID |
12.02.01 |
Nasacort® |
Triamcinolone acetonide 55micrograms/dose nasal spray
Self Care Medicine for primary care.
|
12.02.03 |
Naseptin® |
Chlorhexidine hydrochloride drops 0.1% and neomycin sulfate 0.5%
Contains arachis oil: avoid in peanut or soya allergy |
12.02.01 |
Nasonex® |
Mometasone furoate 50micrograms/dose nasal spray |
08.02.04 |
Natalizumab Tysabri® |
Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA127. |
11.03.02 |
Natamycin drops 5% |
unlicensed
DCHFT: On formulary but not stocked.
|
02.04 |
Nebivolol |
Tablets.
Specialist initiation. Usually restricted to patients intolerant of other beta-blockers, bisoprolol usual first line choice. Note for patients requiring a 2.5mg dose, halve 5mg tablets where possible.
DCHFT: Restricted for heart failure patients intolerant of other beta-blockers. Must be initiated by consultant cardiologist or heart failure specialists (including Nurse Prescribers).
|
04.07.01 |
Nefopam |
RBCH only: For in-patient post arthroplasty and for discharge post arthroplasty in patients unable to have NSAIDs in accordance with pathways. 6 months funding agreed from May 2019 |
08.01.03 |
Nelarabine Atriance® |
Commissioned by CDF (for cancer) as per CDF policy. |
A2.03.01 |
Neocate Junior® |
Neocate Junior is a rarely used product. It is for use in children with severe ongoing allergies who have difficulty maintaining adequate nutritional intake and are usually prescribed for children with a complex clinical picture. |
A2.03.01 |
Neocate LCP® |
On advice of dietitian or hospital specialist, for cow's milk protein allergy and other ACBS indications |
A2.03.01 |
Neocate Spoon® |
Neocate Spoon is a weaning aid suitable for short term use by infants who are unable to take adequate amounts of specialised infant formula to meet their nutritional requirements for calcium. Its ongoing use should be closely monitored. |
05.01.04 |
Neomycin Sulphate |
|
15.01.06 |
Neostigmine |
Injection. |
15.01.06 |
Neostigmine with Glycopyrronium |
Injection. |
08.01.05 |
Neratinib Nerlynx® |
Commissioned by NHSE in line with the recommendations in NICE TA612. |
04.06 |
Netupitant / Palonosetron Akynzeo® |
Single dose for the following indications:
- Prophylactic use in all chemotherapy regimens containing initial doses of cisplatin ≥ 70mg/m2 (highly emetogenic). E.g Pemetrexed+Cisplatin and Vinorelbine+Cisplatin for lung cancer.
- Prophylactic use in all chemotherapy regimens that are deemed moderately emetogenic (FEC 100)
- Replacing aprepitant or palonosetron as secondary prophylaxis of chemotherapy induced nausea and vomiting.
|
19.13 |
Neutralise Respond Healthcare Ltd |
(Formerly OstoMart ostoMist odour Neutralising Spray)
Approved size: 50ml
Products available
Apple
Blackberry
Cinnamon & Sandalwood
Grapefruit
Mint |
05.03.01 |
Nevirapine |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs) as per BHIVA Guidelines.
Generic products should be used where available. |
07.03.02.02 |
Nexplanon® |
Implant, containing etonogestrel 68 mg in radiopaque flexible rod
For use by doctors with appropriate training and up-to-date documentary evidence of competency from the Faculty of Family Planning
DCHFT: Family planning only. |
02.06.03 |
Nicorandil |
Tablets. |
04.10.02 |
Nicotine |
Poole: Nicorette Quick Mist SmartApp is available only via the Maternity Smoking Cessation programme. |
07.01.03 |
Nifedipine |
Not at RBCH |
02.06.02 |
Nifedipine capsules |
Capsules. For Raynaud's phenomenon only.
Generic brand now available from Relonchem |
02.06.02 |
Nifedipine Modified-Release |
Once daily long acting preparations:
- Adalat® LA 20mg (DCHFT: 30mg also on formulary/stocked).
Twice daily sustained release:
- Coracten SR® (except maternity - Nifedipress MR & Adipine MR
|
08.01.05 |
Nilotinib Tasigna® |
Commissioned by NHS England in line with NICE TA241 and TA251. |
02.06.02 |
Nimodipine Nimotop® |
Tablets, Injection. |
03.11 |
Nintedanib Ofev® |
Commissioned by NHS England for idiopathic pulmonary fibrosis as per TA379 via specialist centres only. |
08.01.05 |
Nintedanib Vargatef®, Ofev® |
Vargatef®:
- Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.
Ofev®:
- Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.
|
08.01.05 |
Niraparib Zejula® |
Commissioned by CDF in line with CDF criteria and NICE TA528.
Commissioned by the CDF in line with NICE TA673 for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. |
09.08.01 |
Nitisinone Orfadin® |
Commissioned by NHS England (for alkaptonuria and tyrosinaemia), as per NHS England Service Specification for highly specialised criteria only.
For initiation by specialist centres only. |
02.05.01 |
Nitric oxide (inhaled) |
Commissioned by NHS England (for Pulmonary Arterial Hypertension of the newborn mostly) as per agreed Trust Guidelines. |
05.01.13 |
Nitrofurantoin |
|
15.01.02 |
Nitrous oxide |
Anaesthetic. |
08.01.05 |
Nivolumab Opdivo® |
Commissioned by NHSE for: - Melanoma, in line with NICE TA384 and TA400 - Renal Cell Carcinoma, in line with NICE TA417 - Hodgkin's Lymphoma, in line with NICE TA462
Commissioned by the CDF for: - Melanoma, in line with NICE TA684 (NOTE: switching to NHSE commissioning on 15th June 2021) - Renal Cell Carcinoma, in line with NICE TA581 - Lung Cancer, in line with NICE TA484 or TA655 - Head & Neck Cancer, in line with NICE TA490
Via Early Access to Medicines Scheme (EAMS) for: - Mesothelioma: previously untreated, unresectable malignant disease of pleural origin, in combination with Ipilimumab |
13.09 |
Nizoral® |
Restrict to where moderate to severe skin condition requires it
Shampoo, ketoconazole 2%
Self Care Medicine
|
13.10.02 |
Nizoral® |
Cream, ketoconazole 2%
Excipients include cetyl alcohol, polysorbates, propylene glycol, stearyl alcohol |
02.07.02 |
Noradrenaline / Norepinephrine |
Injection, pre-filled syringe.
- RBCH: 4mg/8mg/16mg in 50mL prefilled syringes for Critical Care
Unlicensed.
- DCHFT: 4mg/4mL injection. 8mg in 50mL vial for Critical Care .
|
06.04.01.02 |
Norethisterone |
|
08.03.02 |
Norethisterone |
|
05.01.12 |
Norfloxacin |
For microbiology use only. Not at DCH. |
07.03.02.01 |
Norgeston® |
Levonorgestrel 30 micrograms
|
07.03.02.01 |
Noriday® |
Norethisterone 350 micrograms
|
06.01.01.01 |
NovoRapid® PumpCart® |
For patients using Accu-Chek Insight insulin pump only. |
04.09.03 |
Nusinersen Spinraza® |
Local trusts not commissioned to prescribe. Commissioned specialist centres can prescribe in accordance with NICE TA588. |
A2.05.02 |
Nutilis® Clear |
Should only be started under SLT guidance (dysphagia assessment needed). These tend to be better tolerated
For a syrup thick consistency per 200ml costs are as follows:
- Nutilis = 15-23p
- Nutilis Clear = 14.5p
- Thick & easy Clear = 14.5p
- Resource Thicken up clear = 16p
|
A2.02.02.03 |
Nutilis® Complete Drink Level 3 |
Previously "stage 1"
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
A2.05.02 |
Nutilis® Powder |
For adult and paediatric patients.
Should only be started under speech and language therapist guidance (dysphagia assessment needed). Not stocked at RBCH - use Nutilis Clear |
A2.02.02.03 |
Nutilis® Complete Creme Level 3 |
Previously "stage 2"
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
A2.02.02.03 |
Nutilis® Fruit Dessert Level 4 |
Previously "stage 3"
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
A2.03.01 |
Nutramigen 1 with LGG ® |
For cow's milk protein allergy in infants under 6 months of age |
A2.03.01 |
Nutramigen 2 with LGG ® |
For cow's milk protein allergy in infants over 6 months of age |
A2.03.01 |
Nutramigen PURAMINO® |
On advice of dietitian or hospital specialist, for cow’s milk protein allergy and other ACBS indications |
A2.01.01.01 |
Nutricomp® Standard |
NICE CG32 (Feb 2006) Nutrition support in adults www.nice.org.uk/page.aspx?o=cg032niceguideline
Should be prescribed only after nutrition screening has taken place using a validated tool e.g. MUST (Malnutrition Universal Screening Tool)
Adult sip feeds containing 1kcal/ml (Fresubin Original, Ensure, Fortimel, Clinutren ISO) should not be prescribed as they are less cost effective compared to 1.5kcal/ml sip feeds |
A2.02.02.02 |
Nutricrem® |
NICE CG32 Nutrition support in adults
For use predominantly with patients with swallowing problems/dysphagia although can be useful for those with taste fatigue with sip feeds |
A2.01.03.01 |
Nutriprem 2 |
For promoting catch up growth in pre-term and small for gestational age infants. Use up to 6 months corrected age. |
09.03 |
Nutryelt ® |
|
07.03.01 |
NuvaRing® |
To be initiated under specialist advice
Vaginal ring, releasing ethinylestradiol approx. 15 micrograms/24 hours and etonogestrel approx. 120 micrograms/24 hours, |
05.02.03 |
Nystatin Nystan® |
|
12.03.02 |
Nystatin 100,000 units/ml oral suspension |
Use Nystin brand (£1.80) compared with generic (£20) |
07.02.02 |
Nystatin Pessaries |
unlicensed
|
01.09.01 |
Obeticholic acid Ocaliva® |
Commissioned by NHS England in accordance with NICE TA443 at specialist hepatobiliary centres only. Commissioned specialist centres in South region:
- University Hospital Southampton NHS Foundation Trust
- Portsmouth Hospitals NHS Trust
- Oxford University Hospitals NHS Foundation Trust
- University Hospitals Bristol NHS Foundation Trust
- Royal Surrey County Hospital NHS Foundation Trust
|
08.02.03 |
Obinutuzumab Gazyvaro® |
In accordance with NICE TA343 in combination with chlorambucil for untreated chronic lymphocytic leukaemia.
In accordance with NICE TA513 for untreated advanced follicular lymphoma.
Commissioned by NHSE in accordance with NICE TA629 in combination with bendamustine for treating follicular lymphoma after failure of rituximab treatment. |
13.07 |
Occlusal® |
Cutaneous solution, salicylic acid 26% in polyacrylic solution
Used by DCH
Self Care Medicine for primary care.
|
08.02.04 |
Ocrelizumab OCREVUS® |
Commissioned by NHS England for the treatment of relapsing–remitting MS in adults at approved centres in accordance with NICE TA533 and TA585. |
11.08.02 |
Ocriplasmin |
PbR excluded: Commissioned by CCG - See commissioning statement and NICE TA297. |
13.11 |
Octenisan® |
For MRSA decolonisation
2nd line at PHT & those with sensitivity to chlorhexidine. |
08.03.04.03 |
Octreotide |
For the short term management of high output stomas and fistulas and in palliative care. |
08.03.04.03 |
Octreotide Sandostatin® LAR® |
Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.
- Neuroendocrine tumors (carcinoid syndrome).
RBCH only: Third line treatment for acromegaly (second line if patient is unfit for surgery).
Specialist centres only: congenital hyperinsulinism - in line with highly specialised criteria.
|
18 |
Octreotide injection |
For sulphonylurea overdose. |
06.04.01.01 |
Oestrogel® |
|
08.02.03 |
Ofatumumab Arzerra® |
In accordance with NICE TA344 in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
05.01.12 |
Ofloxacin |
 For pelvic inflammatory disease (PID), on advice from local sexual health specialists and in-line with the SCAN guidelines (wherever possible, patients should be referred to GUM for follow-up and partner notification.
All other indications  
For microbiology use only.
Not at PGH. RBCH: GUM DCHFT: In accordance with PID guidelines only and second line for chronic prostatitis. Urology or Microbiology consultant only, or on Urology or Microbiologist advice in patients with chronic prostatitis who haven't responded to ciprofloxacin. |
11.03.01 |
Ofloxacin drops 0.3% |
DCHFT: Consultant use only. |
13.02.01.01 |
Oilatum® Emollient |
Reserved for patients with severe eczema and infants under the age of 1 year.
Emollient bath additive Light liquid paraffin 63.4% Excipients include acetylated lanolin alcohols, isopropyl palmitate, fragrance DCHFT: Scalp application also on local formulary.
Do not use soap or bubble baths etc when you wash as they can dry out the skin and make it more prone to irritation.
Use a leave-on emollient as a soap substitute and continue with standard eczema management, including regular leave-on emollients and topical corticosteroids when required
Self Care Medicine for primary care.
|
01.07.03 |
Oily Phenol Injection BP |
5% injection.
|
04.02.01 |
Olanzapine (oral) |
In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline. In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of biolar disorder NICE CG185 To be initiated on specialist advice only for schizophrenia, mania and preventing recurrence in bipolar disorders. DCHFT: Orodispersible tablets (Velotabs) limited to use when compliance is a problem. |
04.02.02 |
Olanzapine Embonate ZypAdhera® |
Hospital use only
See olanzapine LAI guidelines
Can be considered as a treatment option for psychoses with appropriate risk management arrangements |
04.02.01 |
Olanzapine injection |
UNLICENSED Can be considered as a short term treatment option for psychoses with appropriate risk management arrangements. |
08.01.05 |
Olaparib Lynparza® |
Commissioned by CDF in accordance with NICE TA598 for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Commissioned by CDF in accordance with NICE TA620 for 2nd line maintenance therapy following relapse. - NOTE: Under CDF review imminently
Commissoned by NHS England from 28/02/2020 in accordance with NICE TA620 for 3rd line maintenance therapy following relapse (IFA in place until this date) |
03.01.01.01 |
Olodaterol Striverdi Respimat® |
|
11.04.02 |
Olopatadine drops 1mg/ml |
Children
Antihistamine and mast cell stabiliser combined and has advantage of twice daily application
Second choice for
Adults
Seasonal allergies |
03.04.02 |
Omalizumab Xolair® |
Commissioned by NHS England (for uncontrolled asthma) in accordance with NICE TA278. Patients must be assessed and approved for a 16 weeks trial by MDT decision at the Wessex Severe Asthma Centre. Trial outcome to be assessed at regional MDT to decide if ongoing treatment is appropriate. Blueteq registration and approval is necessary for all new initiations and continuations. |
13.05.03 |
Omalizumab Xolair® |
Commissioned by CCG (for chronic spontaneous urticaria) in accordance with NICE TA339 and local commissioning statement. |
05.03.03.02 |
Ombitasvir with Paritaprevir and Ritonavir Viekirax® |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
01.03.05 |
Omeprazole |
- Omeprazole MUPS: Restricted use Paediatrics only
- Omeprazole liquid: Restricted use - 2mg/ml and 4mg/ml liquid (75ml bottle) for use by for infants/children with enteral feeding tubes only.
- Update from the Cardiology Working Group July 2020: The interaction of omeprazole on the antiplatelet efficacy of clopidogrel is no longer considered clinically significant.
GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.
Such patients should be referred for specialist advice as per CKD NICE guidance i.e.
- eGFR less than 30 ml/min/1.73m2
- sustained decrease in eGFR of 25% or more within 12 months
- sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months
Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours. |
01.03.05 |
Omeprazole IV |
DCHFT:IV infusion ( Unlicensed) used only in accordance with local protocol.Not available at RBCH.1st line PHT |
04.06 |
Ondansetron |
Tablets, sublingual tablets, injections.
Hospital use only.
DCHFT information: Ondansetron is licensed for moderately emetogenic chemotherapy for up to 5 days duration. It is also used for post-operative nausea and vomiting for just three doses. Long term treatment is rarely justified or necessary. |
06.01.01.03 |
OneTouch® Delica® Plus |
|
06.01.06 |
OneTouch® Select Plus Test Strips |
For existing patients only - please select an alternative option for new patients |
04.09.01 |
Opicapone |
Second line use in patients for whom entacapone is not tolerated or ineffective but a COMT inhibitor is still the favoured option
|
19.05 |
Orabase Paste® |
ConvaTec Ltd Product reference code S103 Approved pack size 30g AMBER -For protective paste for Peristomal or Mucosal Ulceration or Mucocutaneous Separation . Should only be a recurring item for patients with prolapsed stoma.
Self Care Medicine for primary care.
|
19.10 |
Orahesive powder® |
ConvaTec Ltd Product reference code S106 Approved pack size 25g
AMBER – only to be initiated by stoma nurse; Protective powder for broken skin or Mucocutaneous Separation. |
09.02.01.02 |
Oral Rehydration Salts |
For oral rehydration therapy (ORT)
Self Care Medicine for primary care.
|
12.03.05 |
Oralieve® oral gel |
Carbomer, hydroxyethylcellulose, lactoferrin, lactoperoxidase, glucose oxidase, sorbitol, xylitol and other ingredients. |
04.05.01 |
Orlistat Xenical® |
Capsules.
For use in accordance with NICE CG43. |
05.03.04 |
Oseltamivir Tamiflu® |
For influenza prophylaxis in accordance with NICE TA158 and NICE TA168.
(19/05/2020 - Flu season has ended - use FLUOOS) For the treatment of influenza out of flu season, please search the term "fluoos" in the search bar and follow the guidance provided.
For the treatment of influenza in adults and children if all the following circumstances apply: •national surveillance schemes indicate that influenza virus A or B is circulating •the person is in an 'at-risk' group as defined in the guidance •the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms as per licensed indications. Vaccination, particularly targeting "high risk" patients, remains the mainstay of influenza management. |
08.01.05 |
Osimertinib Tagrisso® |
Commissioned by NHSE for treating EGFR T790M mutation-positive advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA653, only if their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor.
Commissioned by NHSE for untreated EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in accordance with NICE TA654. |
07.02.01 |
Ospemifene tablets Senshio® |
Poole - Initial 1 year period.
Restricted to Gynaecology consultants prescribing treatment for moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy due to the following reasons:
- Physical limitations: arthritis, hemiparesis (e.g. after non-thrombotic stroke), Parkinson’s Disease, extreme obesity or lack of dexterity
- Contraindications, such as history of breast or endometrial cancer
- Unwillingness to be treated with local oestrogens (due to issues such as a lack of efficacy, intolerable side effects, unacceptable route of administration, dislike of oestrogen therapy and cross contamination with partner).
|
19.11 |
OstoSorb gel 3g sachets |
OstoMart Ltd Product reference code PFW. Approved pack size 30 Product reference code PFW6. Approved pack size 150
AMBER – only to be initiated by stoma nurse
Thickens liquid output to aid management. |
12.01.01 |
Otomize® |
Dexamethasone ear spray 0.1% with neomycin sulfate 3250 units/ml and glacial acetic acid 2% |
11.08.02 |
Otrivine® |
Xylometazoline paediatric nasal drops For hospital use during surgical procedures |
08.01.05 |
Oxaliplatin |
|
04.08.01 |
Oxcarbazepine Trileptal® |
|
07.04.02 |
Oxybutynin hydrochloride |
NICE NG 123: Do not offer oxybutynin (immediate release) to older women who may be at higher risk of a sudden deterioration in their physical or mental health |
07.04.02 |
Oxybutynin hydrochloride patch |
Not for frail older women (NICE NG123). For those unable to take oral medicines. |
04.07.02 |
Oxycodone (oral) |
Solution, concentrated solution, capsules, 12 hourly modified release tablets. Pain team/palliative care initiation. Oxycodone is included only for patients where morphine is contra-indicated or not tolerated. Available data does not provide any evidence of oxycodone's superiority to morphine.
DCHFT: Used in post-operative pain in patients with eGFR <60mL/min. RBCH: 1st line modified release opioid for Derwent patients for in-patient use only.
For Primary Care Only –Oxycodone MR tablets- branded prescribing required via EPS, recommended brands are Longtec® and Oxylan® |
21 |
Oxycodone injection |
|
04.07.02 |
Oxycodone Injection/Infusion |
Oxycodone is included only for patients where morphine is contra-indicated or not tolerated. Available data does not provide any evidence of oxycodone's superiority to morphine.
Green for use in palliative care (see chapter 21) |
09.01.03 |
Oxymetholone |
 RBCH only: Consultant Haematologist prescription |
13.06.02 |
Oxytetracycline |
|
07.01.01 |
Oxytocin |
|
09.06.02 |
Pabrinex® |
IV high potency injection
IM high potency injection
|
08.01.05 |
Paclitaxel |
|
08.01.05 |
Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) Abraxane® |
Commissioned by NHS England in line with NICE TA476 in combination with gemcitabine for untreated metastatic pancreatic cancer. |
A2.01.03.03 |
Paediasure Peptide® |
For use from age 1 - 10 years and 8-30 kg body weight. |
A2.02.01.02 |
Paediasure Plus Juce® |
Nutrionally complete.
For children 1-10 years of age, and 8-30kg in weight. |
09.06.07 |
Paediatric Seravit® |
|
08.01.05 |
Palbociclib IBRANCE® |
Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.
Commissioned by CDF in line with NICE TA619 for treating hormone receptor-positive, HER2-negative, advanced breast cancer in combination with Fulvestrant. |
04.02.02 |
Paliperidone 3 monthly -prolonged release suspension for injection Trevicta ® |
3 monthly injections for patients on a stable dose of paliperidone LAI for a minimum of 6 months.
New requests for Trevicta must be approved by Dorset Healthcare Medicines Management Team |
04.02.02 |
Paliperidone prolonged release suspension for injection Xeplion® |
Hospital Use only
See paliperidone long-acting injection prescribing guidelines. |
05.03.05 |
Palivizumab Synagis® |
Commissioned by NHS England (for RSV prophylaxis) as per JCVI Guidelines and PHE specification. See Green Book Chapter 27a. |
04.06 |
Palonosetron Aloxi® |
Injection.
Hospital use only.
In accordance with locally agreed protocol for the prevention of nausea and vomiting induced by moderately and severely emetogenic chemotherapy. |
01.09.04 |
Pancreatin |
Capsules, granules, tablets, powder.
- Brand choice to be determined by Trust.
- Brands include; Creon®, Pancrex®, Pancrex V®, Nutrizym®, Pancrease HL®.
- DCHFT: Only Creon® routinely kept in stock.
- RBCH: Creon® for licensed indications; Pancrex V® powder for unblocking enteral tubes (in-patient use only)
As of June 2019, Creon 40,000® will be discontinued due to continued supply constraints. Please see the patient leaflet from Myla here. Dosing recommendations can be found here . Please note that 2 x 25,000 capsules are recommended to replace 40,000 (rather than 4 x 10,000 capsules).
|
08.01.05 |
Panitumumab Vectibix® |
Commissioned by NHSE in line with NICE TA439. |
08.01.05 |
Panobinostat Farydak® |
Commissioned by NHSE for treating multiple myeloma after at least 2 previous treatments in accordance with NICE TA380 |
01.03.05 |
Pantoprazole |
Tablets.
GPs should consider discontinuing PPIs in patient with unexplained eGFR decline or substituting them with ranitidine if indicated.
Such patients should be referred for specialist advice as per CKD NICE guidance i.e.
- eGFR less than 30 ml/min/1.73m2
- sustained decrease in eGFR of 25% or more within 12 months
- sustained decrease in eGFR of 15 ml/min/1.73m2 or more within 12 months
Alternatively, patients with AKI as defined in the AKI NICE guidance should be discussed with a nephrologist if interstitial nephritis is suspected, as soon as it is possible i.e. within 24 hours. |
01.03.05 |
Pantoprazole IV Protium® |
Approved at RBCH whilst supply issue with IV esomeprazole (Sept 2020) |
02.06.04 |
Papaverine injection |
Poole: For topical application in free-flap surgery to prevent vasospasm of blood vessels during anstomosis. [Unlicensed drug/indication]
|
04.07.01 |
Paracetamol |
Tablets, suspensions (various strengths), suppositories.
Soluble tablets are considered 2nd Line.
Self Care Medicine for primary care.
Adult patients with a body weight under 50kg and additional risk factors may have an increased risk of toxicity at therapeutic doses. For child doses please see BNFc.
Guidance on adult oral dosing below. Clinical judgement should be used to adjust dosing:
Patient weight
|
Dose
|
Frequency
|
Maximum daily dose
|
> 50kg with additional risk factors* for hepatotoxicity
|
1g
|
8 hourly
|
3g
|
>33 kg to ≤ 50 kg
|
15mg/kg
|
6 hourly
|
60mg/Kg not exceeding 3g
|
Under 33kg
|
15mg/Kg
|
6 hourly
|
60mg/kg not exceeding 2g
|
Please note, doses should be rounded to the nearest 250mg
Risk factors are: alcohol dependence, cirrhosis, increasing age, frail patients, hepatitis B & C, malnutrition, liver impairment, p450 enzyme inducers e.g. carbamazepine, isoniazid, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, St John's Wort. |
04.07.01 |
Paracetamol IV Perfalgan® |
|
04.08.02 |
Paraldehyde enema |
|
06.06.01 |
Parathyroid Hormone Preotact® |
Commissioned by NHS England (for specialist endocrinology conditions), as per agreed Trust Guidelines. |
09.06.07 |
Paravit-CF |
Fat-soluble vitamin supplements for use when recommended by specialist in patients with cystic fibrosis. Specialists to ensure preferred formulation and dose is clearly communicated to primary care prescribers |
04.03.03 |
Paroxetine |
For use in line with the Primary Care Protocol for Anxiety
|
09.02.01.01 |
Patiromer Sorbitex Calcium Veltassa |
For use only in accordance with recommendations in NICE TA623 |
08.01.05 |
Pazopanib Votrient® |
Commissioned by NHS England as per NICE TA215. |
14.04 |
Pediacel® |
Suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
|
19.01 |
Peel Adhesive Remover Spray Respond Healthcare Ltd |
(Formerly Remove, OstoMart OstoPEEL No Sting Medical Adhesive Remover Spray)
Approved pack size: 50ml
Product reference codes:
OPA50 (Apple)
OPB50 (Blackberry)
OPM50 (Mint)
OPN50 (No fragrance)
|
08.01.05 |
Pegaspargase Oncaspar® |
In accordance with NICE guidance. |
08.02.04 |
Peginterferon Alfa Pegasys® ; ViraferonPeg® |
HCD Commissioned by NHS England (for Hepatitis B and C), as per NICE TA75, TA96, TA106, TA200, TA300 and CG165.
RBCH: Approved for patients with Philadelphia chromosome negative myeloproliferative neoplasms (includes polycythaemia vera, essential thrombocythaemia, primary, post-polycythaemia vera and post-essential thrombocythaemia myelofibrosis. Second-line for patients intolerant or unresponsive to hydroxycarbamide. First-line for patients <40, 40-60 years of age and pregnant patients ( in-tarriff). |
08.02.04 |
Peginterferon beta-1a Plegridy® |
Commissioned by NHS England for Multiple Sclerosis as per SSC1534: Multiple Sclerosis: First line disease modifying agents and for relapsing-remitting MS as per NICE TA624. |
06.05.01 |
Pegvisomant Somavert® |
Commissioned by NHS England as third line treatment for acromegaly at specialist centres only in line with commissioning policy 16050/P |
08.01.05 |
Pembrolizumab Keytruda® |
Commissioned by NHSE for: - Melanoma, in line with NICE TA357, TA366 - Lung Cancer, in line with NICE TA428, TA531 - Head & Neck Cancer, in line with NICE TA661
Commissioned by the CDF for: - Melanoma, in line with NICE TA553 - Lung Cancer, in line with NICE TA600, TA683 (switching to NHSE on 14/4/21) - Urothelial Carcinoma, in line with NICE TA519 (decommissioning on 28/4/21), TA522 (decommissioning on 14/4/21) - Hodgkin's Lymphoma, in line with NICE TA540
All commissioned indications require a BlueTeq form |
08.01.03 |
Pemetrexed Alimta® |
Commissioned by NHS England as per NICE guidance.
prior approval required for use in line with NICE TA402 for the maintenance treatment of non-squamous NSCLC after pemetrexed and cisplatin.
|
08.01.05 |
Pemigatinib Pemazyre® |
Available under EAMS for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy |
10.01.03 |
Penicillamine |
For rheumatoid arthritis in accordance with NICE recommendations (NG100). |
18 |
Penicillamine Distamine® |
|
05.04.08 |
Pentamidine Isetionate |
Intravenous and nebulised |
07.04.03 |
Pentosan polysulfate sodium Elmiron® |
|
08.01.05 |
Pentostatin Nipent® |
|
02.06.04 |
Pentoxifylline |
Modified release tablet.
Gastroenterology use only Off label indication. |
01.02 |
Peppermint water |
Unlicensed.
For in-patient use in acute trusts.
Self Care Medicine for out-patients and primary care
|
01.01.02 |
Peptac® |
Note: Individual trusts may use a different alginate of choice.
Self Care Medicine for primary care.
|
A2.03.02 |
Peptamen® |
Short bowel syndrome, intractable malabsorption, inflammatory bowel disease, bowel fistulae. |
04.08.01 |
Perampanel Fycompa® |
|
02.05.05.01 |
Perindopril |
Tablets. Erbumine salt.
Alternative prescribing option to first line ACE inhibitors. |
01.05 |
Peristeen® |
Included on formulary as amber in conjunction with the locally agreed pathway. Patients need to be referred to the Dorset Bladder and Bowel continence service who will support the patient in the training and introduction of the product and review initially for benefit before passing prescribing responsibility to primary care. |
13.10.04 |
Permethrin |
Cream, permethrin 5%
Self Care Medicine for primary care.
|
08.01.05 |
Pertuzumab Perjeta® |
Commissioned by NHSE in line with NICE TA424, TA509 and TA569.
PHESGO® (Pertuzumab/Trastuzumab) subcutaneous injection NHSE have advised as of 10/2/21 that the combination subcutaneous PHESGO product may be used in place of the separate IV preparations for the existing commissioned indications (NICE TA424,509 and 569) |
04.07.02 |
Pethidine |
Hospital use only. |
04.03.02 |
Phenelzine Nardil® |
Initiated on Specialist Advice only as per shared care guidance
|
02.08.02 |
Phenindione |
Tablets.
Specialist initiation. |
04.08.01 |
Phenobarbital |
Tablets, elixir, alcohol-free & sugar free suspension.
Category 1: ensure patient is maintained on a specific manufacturer's product. |
04.08.02 |
Phenobarbital |
a second line/alternative option in status epilepticus |
02.05.04 |
Phenoxybenzamine Hydrochloride Dibenyline® |
Capsules.
- DCHFT:
Restricted to Consultant use only.
|
05.01.01.01 |
Phenoxymethylpenicillin |
|
02.05.04 |
Phentolamine |
Injection.
Unlicensed.
|
18 |
Phentolamine injection |
For digital ischemia due to accidental injection of epinephrine (adrenaline) and resistant hypertension related to sympathomimetic drugs of abuse, MAOIs and clonidine. |
10.01.01 |
Phenylbutazone |
Rheumatology |
02.07.02 |
Phenylephrine |
Injection. |
04.08.01 |
Phenytoin |
Capsules, suspension. Options based on licence. Category 1: ensure patient is maintained on a specific manufacturer's product.
|
04.08.02 |
Phenytoin IV |
|
09.05.02.01 |
Phosphate Polyfusor® |
|
01.06.04 |
Phosphates (Rectal) |
Enema.
Alternative prescribing option. |
09.05.02.01 |
Phosphate-Sandoz® |
|
02.08.03 |
Phytomenadione Vitamin K |
Injection may be used orally. |
09.06.06 |
Phytomenadione |
DCHFT: Various formulations available (inlcuding unlicensed 1mg capsules). Note:Paediatric injection may be given orally. |
18 |
Phytomenadione Vitamin K1 |
For reversal of warfarin and other coumarin anticoagulants (vitamin K1 antagonists). |
01.06.05 |
Picolax® Sodium picosulfate and magnesium citrate |
Oral powder.
- Choice to be determined by Trust.
- DCHFT: Used instead of CitraFleet®.
|
11.06 |
Pilocarpine |
Drops 1%, 2% and 4% |
12.03.05 |
Pilocarpine hydrochloride tablets 5mg Salagen® |
For patients with Sjogren's syndrome |
13.05.03 |
Pimecrolimus Elidel® |
Use in accordance with NICE recommendations for the use of tacrolimus and pimecrolimus for atopic eczema (TA82) and local shared care guideline.
Cream, pimecrolimus 1%
Excipients include benzyl alcohol, cetyl alcohol, propylene glycol, stearyl alcohol |
06.01.02.03 |
Pioglitazone Actos® |
Use in accordance with NICE NG28. |
05.01.01.04 |
Piperacillin and Tazobactam IV |
RBCH: On microbiology advice only unless for treatment of neutropenic sepsis |
03.11 |
Pirfenidone Esbriet® |
Commissioned by NHS England for idiopathic pulmonary fibrosis as per TA504 via specialist centres only. |
05.01.13 |
Pivmecillinam Selexid® |
Second line option for use in accordance with the SCAN Guidelines |
08.01.02 |
Pixantrone Pixuvri® |
|
04.07.04.02 |
Pizotifen |
Tablets only. |
09.02.02.02 |
Plasma-lyte 148 |
DCHFT only. |
01.06.05 |
Plenvu® |
Oral powder
- DCH
- Poole - Bowel Cancer Screening service - for re-appraisal March 2020
|
09.01.07 |
Plerixafor Mozobil® |
Commissioned by NHS England (for stem cell mobilisation), as per NHS England policy: B04/P/2. |
14.04 |
Pneumoccocal Polysaccharide Vaccine - 23 valent PPV |
Pneumococcal Polysaccharide Vaccine - PPV23 Contains the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F
Primary Care: at NHS expense for patients in accordance with the national immunisation programme. Adults over 65 years and at risk groups, as listed in the Green Book, chapter 25. Use practice stock and claim on FP34 appendix form. |
14.04 |
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13® |
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - PCV13
Primary Care: at NHS expense for infants as part of the routine childhood immunisation programme (order free of charge via Immform) |
08.01.05 |
Polatuzumab vedotin Polivy® |
Commissioned via NHSE in combination with rituximab and bendamustine as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant as per NICE TA649. |
11.03.01 |
Polihexanide Eye Drops |
Unlicensed
Preservative free
RBCH: 0.02%
Not DCHFT. |
A2.04.01.01 |
Polycal® |
NICE CG32 Nutrition support in adults
(Modular energy supplements to be used under direction of Dietitian only) |
A5.02.05 |
Polymem |
For specialist Prescribing.
PolyMem dressings are designed to facilitate healing, relieve pain and reduce inflammation in a unique way. Each PolyMem dressing includes a hydrophilic polyurethane matrix with a mild, tissue-friendly wound cleanser, a soothing moisturizer, a superabsorbent, and a semi-permeable film backing. This patented formulation of ingredients works synergistically to provide unrivaled benefits for clinicians and patients. |
14.04 |
Polysaccharide Typhoid Vaccine Typherix® |
DCHFT: Not routinely stocked.
|
14.04 |
Polysaccharide vaccine for injection Typhim Vi® |
DCHFT: Not routinely stocked.
|
09.02.01.01 |
Polystyrene Sulfonate Resins Calcium Resonium® |
For management of hyperkalaemia |
08.02.04 |
Pomalidomide Imnovid® |
Commissioned by NHS England in line with NICE TA427. |
08.01.05 |
Ponatinib Iclusig® |
Commissioned by NHS England in line with NICE TA451. |
03.05.02 |
Poractant Alfa Curosurf® |
Commissioned by NHS England (for Respiratory Distress Syndrome in neonates). Use product with lowest procurement cost in line with Trust guidelines. Hospital only. |
05.02.01 |
Posaconazole Noxafil® |
Commissioned by NHS England (for prophylaxis and treatment of fungal infections), as per agreed Trust Guidelines. For microbiology and haematology use only. |
11.08.02 |
Potassium ascorbate drops 10% |
Preservative free
Unlicensed |
09.02.01.01 |
Potassium Chloride Slow-K® |
Modified release tablets only to be prescribed if effervescent tablets or liquid preparations are inappropriate.
As branded product has been discontinued only specials are available to order - these my be expensive.
Additional Note:
Can cause oesophageal burning -Only suitable for patients who are able to sit upright and take a full glass of water after dose. |
09.02.01.01 |
Potassium Chloride Sando-K® |
Effervescent tablets |
09.02.02.01 |
Potassium Chloride and Glucose Intravenous Infusion |
Use ready-prepared solutions: consult local Trust policy |
09.02.02.01 |
Potassium Chloride and Sodium Chloride Intravenous Infusion |
Use ready-prepared solutions: consult local Trust policy |
09.02.02.01 |
Potassium Chloride Concentrate (Sterile) |
Use ready-prepared solutions: consult local Trust policy
RBCH: Critical Care only
DCHFT: Ordered as Controlled drug. Critical care only.
|
09.02.01.01 |
Potassium Chloride syrup Kay-Cee-L® |
Paediatric use 1mmol/mL each of K+ and Cl-
|
09.02.02.01 |
Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion |
Use ready-prepared solutions: consult local Trust policy |
07.04.03 |
Potassium Citrate Mixture BP |
Oral solution, potassium citrate 30%, citric acid monohydrate 5% in a suitable vehicle with a lemon flavour.
Self Care Medicine for primary care.
|
13.11.06 |
Potassium Permanganate Permitabs® and EN-Potab® |
Potassium permanganate is used in topical preparations for the care of wounds because of its antiseptic and antimicrobial properties. It is available as a tablet preparation, which is dissolved in water. It is for external use only and can be fatal if ingested orally. |
13.11.04 |
Povidone-Iodine Betadine® |
DCHFT: Variety of products and strength stocked. 10% alcoholic solution. 10% aqueous solution 2.5% spray powder.
Self Care Medicine for primary care.
|
18 |
Pralidoxime chloride |
|
18 |
Pralidoxime chloride Protopam® |
For use as an adjunct to atropine in the treatment of poisoning by organophosphorus insecticides or nerve agents. ‘NAAS pods’ containing pralidoxime chloride can be obtained through the Ambulance Service from the National Blood Service — see NPIS or TOXBASE for list of designated centres.
RBCH is a designated regional holding site - kept in ED Resus |
04.09.01 |
Pramipexole |
Tablets.
See shared care guideline for dopamine agonists
Use in accordance with local guidance on drug treatment of Parkinson's Disease and the shared care guideline for dopamine agonists used in Parkinson's Disease.
Includes modified release formulation |
04.09.04 |
Pramipexole |
Immediate release formulations only.
For use in line with the NICE CKS pathway on restless leg syndrome.
|
02.09 |
Prasugrel Efient ® |
Tablets.
Specialist initiation.Use in accordance with NICE TA 182. In patients with ST elevation and diabetes requiring a stent who are unable to receive treatment with ticagrelor.
|
02.12 |
Pravastatin |
Tablets.
Alternative to 2nd choice. |
05.05.05 |
Praziquantel |
If clinically appropriate a GP may prescribe on advice of a tertiary centre outside of Dorset. If local microbiologists wish to prescribe this must be via outpatients at their Trust and they should not ask primary care to prescribe
Unlicensed Medicine |
02.05.04 |
Prazosin |
Tablets. Alternative prescribing option to first line agent.
|
07.04.01 |
Prazosin |
1mg tablets out of stock until early December. 0.5mg still available but cannot uplift demand for the 1mg strength. New patients should not be started on prazosin and the use of the 0.5mg strength should be restricted to current users to avoid depletion of that stock. |
01.05.02 |
Prednisolone |
Tablets, soluble tablets (expensive), retention enema, foam enema (expensive), suppositories.
- Rectal formulations are active in different areas of the GI tract so may not be interchangeable - see BNF for details.
|
06.03.02 |
Prednisolone |
For swallowing difficulties or administration via feeding tubes
Soluble prednisolone tablets are a costly choice and their use should be reserved for only when absolutely necessary. The standard tablets can be dispersed in water in two to five minutes (enteric coated tablets are not suitable to be used in this way). Please note dispersing standard prednisolone tablets is considered an “off label “use.” |
06.03.02 |
Prednisolone |
|
10.01.02.01 |
Prednisolone |
For swallowing difficulties or administration via feeding tubes RBCH: Non-formulary - plain tablets disperse readily in water. Soluble tablets cost 35 x the price of plain tablets. Soluble prednisolone tablets are a costly choice and their use should be reserved for only when absolutely necessary. The standard tablets can be dispersed in water in two to five minutes (enteric coated tablets are not suitable to be used in this way). Please note dispersing standard prednisolone tablets is considered an “off label “use.”
Alternatively, tablets may be crushed and mixed with soft food (such as yogurt) and swallowed (straight away and without chewing). Please see the Medicine for Children guidance here. Enteric coated tablets are not suitable to be used in this way |
10.01.02.02 |
Prednisolone Acetate Deltastab® |
|
11.04.01 |
Prednisolone drops 0.1% |
Preservative free
unlicensed
Not RBCH
DCHFT: Both preservative free and 'with' preservative available. |
11.04.01 |
Prednisolone drops 0.5% Predsol® |
|
11.04.01 |
Prednisolone drops 1% Predforte® |
|
10.01.02.01 |
Prednisolone plain tablets |
|
12.01.01 |
Prednisolone sodium phosphate drops 0.5% Predsol® |
|
04.03.04 |
Pregabalin |
Licensed for Generalised Anxiety Disorder. See local guidance. |
04.07.03 |
Pregabalin |
Capsules. For neuropathic pain in accordance with local guidance. For 3rd line use in generalised anxiety in accordance with local guidance. Amber in epilepsy. |
04.08.01 |
Pregabalin |
Capsules. Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
06.04.01.01 |
Premarin® |
|
06.04.01.01 |
Premique Low Dose ® |
|
15.02 |
Prilocaine Hydrochloride Prilotekal® |
Injection.
DCHFT: Day case and enhanced recovery patients only in accordance with local guideline.
RBCH for short procedures in patients suitable for same day surgery by Consultant Anaesthetists only. |
15.02 |
Prilocaine Hydrochloride |
Injection.
0.5% is unlicensed. |
15.02 |
Prilocaine Hydrochloride Citanest® |
Injection. |
15.02 |
Prilocaine Hydrochloride with Felypressin Citanest with Octapressin® |
Dental cartridge. |
05.04.01 |
Primaquine |
Unlicensed Second line therapy for PCP infection (Pneumocystis jirovecii pneumonia)if patients intolerant of co-trimoxazole/constituents/ first line treatment failure.
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel |
04.08.01 |
Primidone |
Tablets.
Category 1: Ensure patient is maintained on a specific manufacturer's product. |
05.01.01.01 |
Procaine Penicillin G Injection |
For GUM |
A2.04.01.02 |
Procal MCT® |
MCT Procal is a medicine containing the active ingredient(s) triglycerides medium chain formula. |
A2.04.01.02 |
Pro-Cal® |
Energy supplement. To be used under direction of dietitian only.
Paediatric patiens: not suitable in children under the age of 3, use with caution in children aged 3-6 years. |
A2.04.01.02 |
Pro-Cal® Shot |
Energy supplement. To be used under direction of dietitian only.
Paediatric patients: not suitable in children under the age of 3, use with caution in children aged 3-6 years. |
08.01.05 |
Procarbazine |
|
04.06 |
Prochlorperazine |
Tablets, buccal tablets, suppositories, syrup. Phenothiazine option.
|
04.06 |
Prochlorperazine Injection |
Red status unless palliative care |
04.09.02 |
Procyclidine |
Tablets, syrup, injection. |
18 |
Procyclidine injection |
For dystonic reactions.
RBCH: kept in Emergency Drug Cupboard, ED resus and AMU |
06.04.01.02 |
Progesterone |
Crinone® (vaginal gel)
Cyclogest® (vaginal or rectal pessaries)
Gestone® (injection)
Lubion® (Injection)
Utrogestan® (Oral capsules,Vaginal capsule)
|
05.04.01 |
Proguanil Hydrochloride with Atovaquone |
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel |
03.04.01 |
Promethazine |
Tablets, elixir.
Sedating option.
Alternative prescribing option to first line. |
04.06 |
Promethazine |
Tablets, liquid. Antihistamine option.
Self Care Medicine for primary care.
|
04.01.01 |
Promethazine Hydrochloride |
Specialist mental health inpatients service use only for rapid tranquilisation. See NICE NG10 Violence and aggression: short-term management in mental health, health and community settings |
A5.03 |
Prontosan Wound Irrigation Solution |
Aqueous solution containing betaine surfactant and polihexanide |
A5.03 |
Prontosan X Wound Gel 50ml Previously named - Prontosan Wound Gel |
Hydrogel containing betaine surfactant and polihexanide |
02.03.02 |
Propafenone Arythmol® |
Tablets.
Hospital initiation. |
11.03.01 |
Propamidine Isetionate drops 0.1% Brolene® |
Acanthamoeba keratitis (unlicensed indication)
DCHFT: Consultant use only. Not routinely stocked. |
01.02 |
Propantheline bromide Pro-Banthine® |
Tablets.
Alternative prescribing option.
|
15.01.01 |
Propofol |
Injection.
RBCH: 1% onlyDCHFT: 1% only |
02.04 |
Propranolol |
Tablets, MR Capsule, Liquid, (Injection - secondary care only).
DCHFT: Injection is non formulary.
Alternative prescribing option to first line agents.
|
04.07.04.02 |
Propranolol |
Prescribing in accordance with NICE recommendations for prophylactic management of migraine. |
11.08.01 |
Propylene Glycol 0.6% and Hydroxypropyl Guar Systane Balance® |
Licensed for MGD only
Self Care Medicine for primary care.
|
11.08.01 |
Propylene Glycol and Polyethylene Glycol Drops Systane® |
Preserved or Preservative-Free
Self Care Medicine for primary care.
|
06.02.02 |
Propylthiouracil |
For use in pregnancy |
A2.04.01.02 |
ProSource® |
|
A2.04.01.02 |
Prosource® Jelly |
|
A2.04.01.02 |
Prosource® Plus |
|
02.08.03 |
Protamine Sulfate |
Injection. |
18 |
Protamine Sulphate |
For emergency reversal of heparin based anticoagulants. |
02.11 |
Protein C Concentrate Ceprotin® |
See commissioning and funding guidance from NHS England. |
02.11 |
Prothrombin complex Beriplex® P/N, Octaplex® |
Commissioned by NHS England as per BCSH Guidelines.
Blood-related product.
DCHFT: Held by Pharmacy (Nov 2014).
|
01.06.07 |
Prucalopride Resolor ® |
Tablets.
In accordance with the requirements of NICE TA211.
DCHFT: Gastroenterology consultant initiation only and in accordance with NICE TA211. |
13.05.02 |
Psoriderm® |
Bath emulsion, coal tar 40%
Excipients include polysorbate 20
DCHFT and RBCH: Not routinely stocked. |
13.05.02 |
Psoriderm® |
Cream, coal tar 6%, lecithin 0.4%
Excipients include isopropyl palmitate, propylene glycol
DCHFT: Not routinely stocked. |
13.09 |
Psoriderm® |
Scalp lotion (= shampoo), coal tar 2.5%, lecithin 0.3%
|
05.01.09 |
Pyrazinamide Zinamide® |
|
10.02.01 |
Pyridostigmine Bromide |
For Myasthenia gravis |
09.06.02 |
Pyridoxine Hydrochloride |
50mg tablets |
09.06.02 |
Pyridoxine Hydrochloride |
RBCH only: 10mg tablets to prevent isoniazid-related toxicity
DCHFT: 10mg tablets available. |
18 |
Pyridoxine injection |
For isoniazid toxicity. |
05.04.07 |
Pyrimethamine Daraprim® |
On recommendation by Consultants in Sexual Health, Ophthalmology or Microbiology for treatment of toxoplasmosis. |
05.04.01 |
Pyrimethamine with Sulfadoxine Fansidar® |
'Special order' manufacturers or specialist-importing companies.
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel |
04.02.01 |
Quetiapine |
Hospital or specialist initiation. In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline. Tablet formulation.
In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of bipolar disorder CG185 To be initiated on specialist advice only for: -schizophrenia. -treatment of mania and major depressive episodes associated with bipolar disorder. -preventing relapse in schizophrenia and preventing recurrence in bipolar disorder in patients whose have responded to quetiapine treatment. |
04.02.01 |
Quetiapine modified release |
N.B.Higher cost preparation
When Quetiapine is prescribed to patients under the care of the Dorset Perinatal Mental Health Service, the immediate release formulation should be used. If this causes sedation severe enough to interfere with parenting, Quetiapine modified release can be prescribed. The responsible prescriber in the perinatal mental health team should discontinue Quetiapine modified release before the patient is discharged or transferred to another service, if necessary replacing it with Quetiapine immediate releases or a different anti-psychotic drug. |
01.05 |
Qufora® |
Included on formulary as amber in conjunction with the locally agreed pathway. Patients need to be referred to the Dorset Bladder and Bowel continence service who will support the patient in the training and introduction of the product and review initially for benefit before passing prescribing responsibility to primary care. |
05.04.01 |
Quinine sulphate Malaria treatment |
Treatment for Malaria is available on the NHS (red traffic light status). Patients requiring Malaria prevention must acquire this on a private prescription as per the DCCG Guidance on prescribing for overseas travel |
10.02.02 |
Quinine sulphate |
Where cramps cause regular disruption to sleep - not for routine use. Reassess benefit regulary as per MHRA advice
200mg quinine sulphate is equivalent to 300mg quinine bisulphate |
14.05 |
Rabies immunoglobulin |
Human Rabies Immunoglobulin, not less than 150 IU/mL solution for injection
Microbiology request only.
Not routinely stocked - contact PHE. |
14.04 |
Rabies vaccine Rabipur®, Rabies Vaccine (Rab) |
Only on formulary for Rabies Post-Exposure treatment in accordance with PHE guidelines. |
06.02.02 |
Radioactive iodine-131 capsules |
Hospital only.
DCHFT: Consultant only. |
06.04.01.01 |
Raloxifene Hydrochloride Evista® |
For secondary prevention of osteoporosis in accordance with NICE TA161.
Not recommended by NICE for primary prevention of osteoporosis (TA160). |
05.03.01 |
Raltegravir Isentress ® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines. |
08.01.03 |
Raltitrexed Tomudex® |
NICE CG131: Consider raltitrexed only for patients with advanced colorectal cancer who are intolerant to 5-fluorouracil and folinic acid, or for whom these drugs are not suitable. |
02.05.05.01 |
Ramipril |
preferred formulation – Capsules (exception if vegetarian/vegan) |
11.08.02 |
Ranibizumab Lucentis® |
PbR excluded: Commissioned by CCG -In accordance with NICE TAs 155, 274, 283, 298.Ophthalmology consultant only.
- Macular degeneration
- Macular oedema(diabetic)
- Macular oedema(retinal vein occlusion)
- Choridal neovascularisation
Not Approved for treating diabetic retinopathy as per NICE TA637
|
01.03.01 |
Ranitidine |
Tablets, syrup, injection.
Self Care Medicine for primary care - 75mg tablets
During the shortage of ranitidine, you can supply cimetidine, nizatidine or famotidine as a last resort. |
02.06.03 |
Ranolazine Ranexa® |
Modified release tablets.
Specialist initiation.
For symptomatic stable angina pectoris in accordance with local shared care guidance. |
04.09.01 |
Rasagiline |
|
10.01.04 |
Rasburicase Fasturtec® |
Commissioned by NHS England (for hyperuricaemia) as per agreed Trust Guidelines.
DCHFT: Consultant use only. |
09.01.03 |
Recombinant human erythropoietins (all variants) |
Commissioned by NHS England (for dialysis-induced anaemia only including via outpatients and only as per NICE CG114) and Trust Guidelines.
Use product with lowest procurement cost.
Prescriber must specify which epoetin is required.
DCHFT:
Darbopoetin (Aranesp®) First line. Home delivery only.
Epoetin beta (NeoRecormon®) Second line if patient allergic to or intolerant of darbopoetin.
Methoxy polyethylene glycol-epoetin beta (Mircera®) Second line if patient allergic to or intolerant of darbopoetin. |
09.01.03 |
Recombinant human erythropoietins |
Prescriber must specify which epoetin is required.
For use in patients in accordance with NICE TA323 or local commissioning statement for patients with symptomatic anaemia due to low-risk MDS.
Choice of agent dependent on Trust and procurement costs.
RBCH: Epoetin alfa (Eprex®) for Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy
RBCH: Epoetin alfa (Eprex®) 40,000 units for pre-operative anaemia prior to elective orthopaedic surgery (1 year funding from June 2014) |
08.01.05 |
Regorafenib Stivarga® |
Commissioned by NHS England in line with NICE TA488 and TA555. |
05.03 |
Remdesivir Veklury (r) |
For hospital treatment of coronavirus disease 2019 (COVID-19) in patients ≥ 12 years of age and ≥ 40 kg, presenting with pneumonia requiring supplemental oxygen.
All patients must have:
- eGFR ≥ 30ml/min
- Alanine Aminotransferase (ALT) below 5 times the upper limit of normal at baseline
NOTE: In times of limited supply additional criteria will be necessary in order to allocate remdesivir to those with the greatest capacity to benefit (patients in the earlier stages of respiratory failure).
In this context the following criteria must also be met:
- At the time of decision to treat with remdesivir patients should not be receiving ongoing mechanical ventilation or ECMO. Patients who present with an initial rapid deterioration can, however, be considered for treatment with remdesivir.
- Multi-disciplinary team assessment should determine if patients not suitable for escalation would benefit from initiation of treatment with remdesivir.
- If patients on remdesivir require escalation, continuation of the drug should be considered by multi-disciplinary team assessment.
--------------------------------------------------------------------------------------------
Both the 'Solution for injection' & 'Powder for reconstitution for injection' are available.
---------------------------------------------------------------------------------------------
All initiated treatment must be documented via the Blueteq system. |
15.01.04.03 |
Remifentanil Ultiva® |
Injection. |
19.02 |
Remove Adhesive Remover Wipes Respond HealthCare Ltd |
(Formerly OstoMart OstoPEEL Blackberry No Sting Medical Adhesive Remover Wipes)
Approved pack size: 30
Product reference code: OPBW30 |
A2.03.02 |
Renapro Shot® |
For the dietary management of dialysis patients with biochemically proven hypoproteinaemia on the recommendation of a specialist dietician. |
14.04 |
Repevax® |
suspension for injection, in pre-filled syringe
Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
|
03.04.02 |
Reslizumab Cinqaero® |
Commissioned by NHS England in accordance with NICE TA479 at specialist centres only. |
A2.05.02 |
Resource® Thickened Drink |
Should only be started under SLT guidance (dysphagia assessment needed)
Useful for patients who have difficulty mixing powdered thickener into drinks or who are not compliant with thickened drinks made with powder.
Reduces risk of aspiration by removing potential for error |
A2.05.02 |
Resource® ThickenUp Clear |
Should only be started under SLT guidance (dysphagia assessment needed). These tend to be better tolerated
For a syrup thick consistency per 200ml costs are as follows:
- Nutilis = 15-23p
- Nutilis Clear = 14.5p
- Thick & easy Clear = 14.5p
- Resource Thicken up clear = 16p
|
23.11 |
Retaining Straps |
Company |
Product Codes and Sizes |
Price per unit |
Comments |
Great Bear
Fix It Strap
|
Short code: 10646A
Medium code: 10644A
Long code: 10645B
Adjustable code: 10647D
|
£2.86 Short/adult
£3.13 abdominal
£3.60 adjustable
|
Good variety of sizes |
Optimum
|
Ex-short - 35cm
Short - 45cm
Medium - 80cm
Long - 130cm
Ex-long - 180cm
|
£2.52 small / short
£2.78 med
£3.39 long
£3.78 Ex-long
|
Comes with good instructions and wash bag |
|
14.04 |
Revaxis® |
Suspension for injection in pre-filled syringe
Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
|
05.03.03.02 |
Ribavirin |
Treatment of hepatitis C commissioned in line with latest rate card from NHS England. |
05.03.05 |
Ribavirin |
|
08.01.05 |
Ribociclib Kisqali® |
Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Commissioned by the CDF in accordance with NICE TA687 for treating hormone receptor-positive, (HER2)-negative, locally advanced or metastatic breast cancer in adults - This indication will transition to NHSE on 29th June 2021 |
05.01.09 |
Rifampicin |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® |
|
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
|
05.01.07 |
Rifaximin Targaxan® |
DCHFT: Amber for NICE TA337 and RED Unlicensed indication as 3rd line agent for pouchitis. Consultant gastroenterologist only. |
05.03.01 |
Rilpivirine Edurant® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines. |
04.09.03 |
Riluzole Rilutek® |
Tablets.
For motor neurone disease. Use in accordance with NICE TA20. Refer to local shared care guideline. |
12.02.02 |
Rinatec® |
Ipratropium bromide 21micrograms/dose nasal spray |
09.02.02.01 |
Ringer's Solution for Injection |
Compound sodium chloride IV infusion |
02.05.01 |
Riociguat Adempas® |
Only to be initiated by approved Tertiary Centres in accordance with NHS England commissioning policies for Pulmonary Hypertension. |
13.05.03 |
Risankizumab Skyrizi® |
In accordance with CCG commissioning statement and NICE TA596. |
06.06.02 |
Risedronate |
For patients who do not tolerate Alendronic Acid
For Paget's disease and osteoporosis.
DCHFT: 2nd line, used in accordance with NICE TA160 & 161. |
04.02.01 |
Risperidone |
Red when used in children with neurodevelopmental disorders (oral preparation). Red - risperidone injection.
DCHFT: Orodispersible tablets restricted to paediatric use only. |
04.02.01 |
Risperidone |
In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of schizophrenia (CG178) and local shared care guideline. Tablet or liquid formulation.
In accordance with NICE recommendations for the use of atypical antipsychotic drugs for the treatment of bipolar disorder CG185 To be initiated on specialist advice only for:
- schizophrenia.
- treatment of manic episodes in bipolar disorder.
- short term use for persistent aggression in patients with moderate to severe Alzheimer’s dementia.
Refer to local dementia guidelines. Prescribing guidance to accompany request to prescribe. Generic risperidone remains one of the least expensive oral atypicals. Doses above 8-10mg daily may not increase therapeutic benefit but may result in extrapyramidal side effects.
|
04.02.02 |
Risperidone LAI Risperdal Consta® |
no new patients to intitiate risperidone long acting injection
see paliperidone LAI |
05.03.01 |
Ritonavir Norvir® |
Commissioned by NHS England (for HIV in combination with other anti-retroviral drugs), as per BHIVA Guidelines. |
08.02.03 |
Rituximab Truxima®, MabThera® |
All products should be prescribed by brand. Biosimilars should be used for new patients where possible.
NHS England states:
Where NICE has already recommended the originator biological medicine, the same guidance will normally apply to a biosimilar of the originator. Continuing development of biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, increased commercial competition and enhanced value propositions for individual medicines.
The decision to prescribe a biological medicine for an individual patient whether an originator or biosimilar medicine, rests with the responsible clinician in consultation with the patient. At the time of dispensing, a biosimilar medicine should not be automatically substituted for the originator by the pharmacist. In line with MHRA guidelines, biological medicines, including biosimilar medicines must be prescribed by brand name to support on-going pharmacovigilance of the individual products.
NHS England supports the appropriate use of biosimilars which will drive greater competition to release cost efficiencies to support the treatment of an increasing number of patients and the uptake of new and innovative medicines.
For splenic marginal zone lymphoma - not recommended for first-line use. May be considered on an individual patient basis in the second-line setting.
May be considered in autoimmune haematological disorders as a third-line option for patients who have failed steroids and splenectomy or as a second-line option where a splenectomy is not indicated.
|
10.01.03 |
Rituximab MabThera® ; Truxima® |
All products should be prescribed by brand. Biosimilars should be used where possible. In accordance with NHS England policies for:
- paediatric rheumatology indications where adult TA is available (TA195).
- ANCA-positive vasculitis as per NICE TA308 and NHS England Policy: A13/P/a.
- SLE in adults and post-pubescent children as per NHS England Policy (Updated 2020) [BlueTeq Required for Initiation and Continuation]
- Dermatomyositis and polymyositis.
- Neuromyelitis optica, as per specification.
- ABO-incompatible kidney transplants, as per specification.
- Myasthenia gravis as per NHSE policy 170084P (
specialist centres only, local centre is UHS). Not routinely commissioned by NHS England for: connective tissue disease - policy in progress, haemophilia, graft versus host disease and nephritis. As per IFR approval.
|
13.14 |
Rituximab MabThera®; Truxima® |
Must be prescribed by BRAND - these are biosimilar medicines!
In accordance with NHS England policies for
Immunobullous disease unlicensed
|
10.01.03 |
Rituximab biosimilar Truxima® |
Commissioned by NHS Dorset CCG and NHS England within SPC indications and as per the originator product above.
NHS England states:
Where NICE has already recommended the originator biological medicine, the same guidance will normally apply to a biosimilar of the originator. Continuing development of biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, increased commercial competition and enhanced value propositions for individual medicines.
The decision to prescribe a biological medicine for an individual patient whether an originator or biosimilar medicine, rests with the responsible clinician in consultation with the patient. At the time of dispensing, a biosimilar medicine should not be automatically substituted for the originator by the pharmacist. In line with MHRA guidelines, biological medicines, including biosimilar medicines must be prescribed by brand name to support on-going pharmacovigilance of the individual products.
NHS England supports the appropriate use of biosimilars which will drive greater competition to release cost efficiencies to support the treatment of an increasing number of patients and the uptake of new and innovative medicines. |
02.08.02 |
Rivaroxaban Xarelto® |

- Prophylaxis in Superficial Thrombosis - refer to Anticoagulation policy. 6 week course
Unlicensed
- In accordance with NICE TA for prevention of VTE in patients undergoing hip or knee replacement surgery, as per licensed indications.
- Note routine 1st line option at RBCH and DCH is LMWH
![]()
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. As per NICE TA335.
- For initiation by Consultant Cardiologist only. See shared care guideline for further details.
![]()

- For prevention of stroke or systemic embolism in patients with AF within NICE TA and local guidance, as per licensed indications.
- For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism in accordance with NICE TA.
- In Coronary artery disease or peripheral artery disease. In line with NICE TA607
|
02.08.02 |
Rivaroxaban Xarelto® |
RBCH: Prophylaxis in Superficial Thrombophlebitis - refer to Anticoagulation policy Unlicensed
6 week course. |
02.08.02 |
Rivaroxaban Xarelto® |
For the treatment of DVT/PE and long term secondary prevention of DVT/PE in accordance with NICE TAs 287, 261
Please note the commissioning statement is currently under review and will be updated shortly. |
02.08.02 |
Rivaroxaban Xarelto® |
N.B. NOTE INDICATION
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. As per NICE TA335.
For initiation by Consultant Cardiologist only. See shared care guideline for further details. |
02.08.02 |
Rivaroxaban Xarelto® |
Tablets.
FOR PREVENTION OF STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WITH AF in accordance with NICE TA256 and local guidance. As per licensed indications.
|
02.08.02 |
Rivaroxaban |
Tablets.
For prevention of VTE in patients undergoing hip or knee replacement surgery, in accordance with NICE TA170.
RBCH: 1st line option is dalteparin.
DCHFT: 1st line option is enoxaparin. |
04.11 |
Rivastigmine |
Capsules, oral solution and patches.
For mild to moderate Alzheimer's disease. In accordance with NICE recommendations (TA217). Refer to local shared care guideline.
|
04.07.04.01 |
Rizatriptan Maxalt® |
|
15.01.05 |
Rocuronium Bromide Esmeron® |
Injection. |
03.03.03 |
Roflumilast Daxas® |
|
09.01.04 |
Romiplostim Nplate® |
Commissioned by CCG: Use in accordance with NICE TA221 |
04.09.01 |
Ropinirole |
Tablets, modified release tablets. First line in accordance with local guidance on drug treatment of Parkinson's Disease and the shared care guideline for dopamine agonists used in Parkinson's Disease. |
04.09.04 |
Ropinirole |
Immediate release formulations only.
For use in line with the NICE CKS pathway on restless leg syndrome.
|
15.02 |
Ropivacaine Hydrochloride Naropin® |
Injection, infusion.
DCHFT: Non-formulary item. |
|